<SEC-DOCUMENT>0001047469-17-002937.txt : 20170426
<SEC-HEADER>0001047469-17-002937.hdr.sgml : 20170426
<ACCEPTANCE-DATETIME>20170426160624
ACCESSION NUMBER:		0001047469-17-002937
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20170607
FILED AS OF DATE:		20170426
DATE AS OF CHANGE:		20170426
EFFECTIVENESS DATE:		20170426

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CATABASIS PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001454789
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37467
		FILM NUMBER:		17784382

	BUSINESS ADDRESS:	
		STREET 1:		ONE KENDALL SQUARE
		STREET 2:		BLDG. 1400E, SUITE B14202
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		617-349-1971

	MAIL ADDRESS:	
		STREET 1:		ONE KENDALL SQUARE
		STREET 2:		BLDG. 1400E, SUITE B14202
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>a2231901zdef14a.htm
<DESCRIPTION>DEF 14A
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<P><FONT SIZE=3 >
Use these links to rapidly review the document<BR>
<A HREF="#bg74701_table_of_contents">  TABLE OF CONTENTS</A><BR></font>
</P>

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, D.C. 20549  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B> SCHEDULE 14A</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Proxy
Statement Pursuant to Section 14(a) of<BR>
the Securities Exchange Act of 1934 (Amendment No.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="17pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2> Filed by the Registrant <FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Filed by a Party other than the Registrant <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2><BR>
Check the appropriate box:</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Preliminary Proxy Statement</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><B> Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Definitive Proxy Statement</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Definitive Additional Materials</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Soliciting Material under &sect;240.14a-12<BR></FONT>
</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="17pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> CATABASIS PHARMACEUTICALS,&nbsp;INC.</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> (Name of Registrant as Specified In Its Charter)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> (Name of Person(s) Filing Proxy Statement, if other than the Registrant)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 style="font-family:times;"><FONT SIZE=2><BR>
Payment of Filing Fee (Check the appropriate box):</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>No fee required.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and&nbsp;0-11.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Title of each class of securities to which transaction applies:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Aggregate number of securities to which transaction applies:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Proposed maximum aggregate value of transaction:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(5)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Total fee paid:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Fee paid previously with preliminary materials.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Check box if any part of the fee is offset as provided by Exchange Act Rule&nbsp;0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration
statement number, or the Form or Schedule and the date of its filing.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><BR><FONT SIZE=2>Amount Previously Paid:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Form, Schedule or Registration Statement No.:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Filing Party:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Date Filed:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2231901",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=640369,FOLIO='blank',FILE='DISK104:[17ZAE1.17ZAE74701]BA74701A.;4',USER='HYUNG',CD='26-APR-2017;11:28' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>CATABASIS PHARMACEUTICALS,&nbsp;INC.<BR>  </B></FONT><FONT SIZE=2><B>One Kendall Square<BR>
Building 1400E, Suite B14202<BR>
Cambridge, MA 02139  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTICE OF&nbsp;2017 ANNUAL MEETING OF STOCKHOLDERS  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> To be held on June&nbsp;7, 2017  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You are cordially invited to attend the 2017 Annual Meeting of Stockholders (the "Annual Meeting") of Catabasis Pharmaceuticals,&nbsp;Inc., which is scheduled
to be held on Wednesday, June&nbsp;7, 2017 at 10:00&nbsp;a.m. Eastern Time, at the offices of WilmerHale located at 60 State Street, Boston, Massachusetts 02109. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
the Annual Meeting, the stockholders will consider and vote on the following matters: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Election
of two Class&nbsp;II Directors to our Board of Directors, to serve until the 2020 annual meeting of stockholders; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ratification
of the appointment of Ernst&nbsp;&amp; Young&nbsp;LLP as our independent registered public accounting firm for the fiscal year ending December&nbsp;31,
2017; and </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Transaction
of any other business properly brought before the Annual Meeting or any adjournment or postponement thereof. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
can find more information, including the nominees for directors, in the attached Proxy Statement. The Board of Directors recommends that you vote in favor of each of proposals one
and two as outlined in the attached Proxy Statement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are pleased to take advantage of the Securities and Exchange Commission rules that allow us to furnish proxy materials to our stockholders on the internet. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
invite all stockholders to attend the Annual Meeting in person. Stockholders of record at the close of business on April&nbsp;12, 2017, the record date for the Annual Meeting, are
entitled to notice of, and to vote at, the Annual Meeting or any adjournment or postponement of the Annual Meeting. Whether or not you expect to attend the Annual Meeting in person, please vote your
shares by proxy as promptly as possible to ensure your representation and the presence of a quorum at the Annual Meeting. In addition to returning your proxy card by mail, you may vote your shares on
the internet by visiting www.proxyvote.com or by telephone by calling 800-690-6903 and following the recorded instructions. Your vote is important regardless of the number of shares you own. If you
send in your proxy card or vote by telephone or the internet and then decide to attend the Annual Meeting to vote your shares in person, you may still do so. Your proxy is revocable in accordance with
the procedures set forth in the Proxy Statement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
your shares are held in "street name," that is, held for your account by a broker or other nominee, you will receive instructions from the holder of record that you must follow for
your shares to be voted. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>By order of the Board of Directors,</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><BR><FONT SIZE=2><B>
<IMG SRC="g102608.jpg" ALT="GRAPHIC" WIDTH="148" HEIGHT="67">
 </B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Jill C. Milne, Ph.D.<BR></FONT> <FONT SIZE=2><I>President and Chief Executive Officer</I></FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><BR><FONT SIZE=2> Cambridge, Massachusetts<BR>
April&nbsp;26, 2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=2,EFW="2231901",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=694232,FOLIO='blank',FILE='DISK104:[17ZAE1.17ZAE74701]BE74701A.;3',USER='HYUNG',CD='26-APR-2017;11:28' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A> </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><A
NAME="BG74701A_main_toc"></A> </FONT></P>

<A NAME="bg74701_table_of_contents"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="bg74701_catabasis_pharmaceuticals,_inc__cat02543"> </A>
<BR></FONT><FONT SIZE=2><B>  Catabasis Pharmaceuticals,&nbsp;Inc.<BR>  Proxy Statement<BR>  Table of Contents    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>
<A NAME="BG74701_TOC"></A> </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="17pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#Proxy_DA"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proxy Statement</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#Proxy_DA"><FONT SIZE=2>1</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da74701_important_information___da702385"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Important Information About the Annual Meeting and
Voting</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da74701_important_information___da702385"><FONT SIZE=2><BR>
2</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dc74701_proposal_no._1_#151;election_of_class_ii_directors"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proposal No.&nbsp;1&#151;Election of Class&nbsp;II
Directors</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dc74701_proposal_no._1_#151;election_of_class_ii_directors"><FONT SIZE=2><BR>
6</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#de74701_corporate_governance"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Corporate Governance</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#de74701_corporate_governance"><FONT SIZE=2><BR>
10</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dg74701_executive_officers"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Executive Officers</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dg74701_executive_officers"><FONT SIZE=2><BR>
19</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dg74701_executive_compensation"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Executive Compensation</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dg74701_executive_compensation"><FONT SIZE=2><BR>
20</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#di74701_certain_relationships___di702236"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Certain Relationships and Related Person Transactions</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#di74701_certain_relationships___di702236"><FONT SIZE=2><BR>
26</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#di74701_proposal_no._2_#151;ratificati__pro06344"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proposal No.&nbsp;2&#151;Ratification of the Appointment of
Ernst&nbsp;&amp; Young&nbsp;LLP as Catabasis' Independent Registered Public Accounting Firm for the Fiscal Year Ending December&nbsp;31, 2017</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#di74701_proposal_no._2_#151;ratificati__pro06344"><FONT SIZE=2><BR>
28</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dk74701_principal_stockholders"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Principal Stockholders</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dk74701_principal_stockholders"><FONT SIZE=2><BR>
30</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dk74701_section_16(a)_benefici__dk702033"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Section&nbsp;16(a) Beneficial Ownership Reporting
Compliance</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dk74701_section_16(a)_benefici__dk702033"><FONT SIZE=2><BR>
33</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dk74701_report_of_the_audit_committee"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Report of the Audit Committee</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dk74701_report_of_the_audit_committee"><FONT SIZE=2><BR>
34</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dk74701_householding"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Householding</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dk74701_householding"><FONT SIZE=2><BR>
35</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dk74701_stockholder_proposals"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stockholder Proposals</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dk74701_stockholder_proposals"><FONT SIZE=2><BR>
35</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dk74701_other_matters"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other Matters</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dk74701_other_matters"><FONT SIZE=2><BR>
36</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=3,EFW="2231901",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=553078,FOLIO='blank',FILE='DISK104:[17ZAE1.17ZAE74701]BG74701A.;5',USER='HYUNG',CD='26-APR-2017;11:28' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_da74701_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>CATABASIS PHARMACEUTICALS,&nbsp;INC.<BR>  </B></FONT><FONT SIZE=2><B>One Kendall Square<BR>
Building 1400E, Suite B14202<BR>
Cambridge, MA 02139<BR>
617-349-1971  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> <A NAME="Proxy_DA"></A></B></FONT><FONT SIZE=3><B>PROXY STATEMENT  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>FOR THE 2017 ANNUAL MEETING OF STOCKHOLDERS<BR>
to be held on June&nbsp;7, 2017  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This proxy statement and the proxy card contain information about the 2017 Annual Meeting of Stockholders of Catabasis Pharmaceuticals,&nbsp;Inc. (the "Annual
Meeting") to be held on Wednesday, June&nbsp;7, 2017 at 10:00&nbsp;a.m. Eastern Time, at the offices of WilmerHale located at 60 State Street, Boston, Massachusetts 02109. The Board of Directors
of Catabasis Pharmaceuticals,&nbsp;Inc. is using this proxy statement to solicit proxies for use at the Annual Meeting. In this proxy statement, unless expressly stated otherwise or the context
otherwise requires, the use of "Catabasis," "our," "we" or "us" refers to Catabasis Pharmaceuticals,&nbsp;Inc. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
properly submitted proxies will be voted in accordance with the instructions contained in those proxies. If no instructions are specified, the proxies will be voted in accordance
with the recommendation of our Board of Directors with respect to each of the matters set forth in the accompanying Notice of Meeting. You may revoke your proxy at any time before it is exercised at
the meeting by giving our corporate secretary written notice to that effect. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Annual Report to Stockholders for the fiscal year ended December&nbsp;31, 2016 and this proxy statement and proxy card are first being made available to stockholders on or about
April&nbsp;26, 2017. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>Important Notice Regarding the Availability of Proxy Materials for<BR>
the Annual Meeting of Stockholders to be Held on June&nbsp;7, 2017:  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> This proxy statement and our 2016 Annual Report to Stockholders are<BR>
available for viewing, printing and downloading at www.proxyvote.com.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>A copy of our Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2016, as filed with the Securities and
Exchange Commission, or SEC, except for exhibits, will be furnished without charge to any stockholder upon written request to Catabasis Pharmaceuticals,&nbsp;Inc., One Kendall Square, Building
1400E, Suite B14202, Cambridge, MA 02139. This proxy statement and our Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2016 are also available on the SEC's website at
http://www.sec.gov and our website at www.catabasis.com.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=4,EFW="2231901",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=985759,FOLIO='1',FILE='DISK104:[17ZAE1.17ZAE74701]DA74701A.;4',USER='HYUNG',CD='26-APR-2017;11:29' -->
<A NAME="page_da74701_1_2"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="da74701_important_information___da702385"> </A>
<A NAME="toc_da74701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  IMPORTANT INFORMATION ABOUT THE ANNUAL MEETING AND VOTING    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Purpose of the Annual Meeting  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At the Annual Meeting, our stockholders will consider and vote on the following matters: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>1.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Election
of two Class&nbsp;II directors to our Board of Directors, to serve until the 2020 annual meeting of stockholders;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>2.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Ratification
of the appointment of Ernst&nbsp;&amp; Young&nbsp;LLP as our independent registered public accounting firm for the fiscal year ending December&nbsp;31,
2017; and
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>3.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Transaction
of any other business properly brought before the Annual Meeting or any adjournment or postponement thereof. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of the date of this proxy statement, we are not aware of any business to come before the meeting other than the first two items noted above. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Board of Directors Recommendation  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board of Directors unanimously recommends that you vote: </FONT></P>

<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2><B>FOR</B></FONT><FONT SIZE=2> the election of the nominees to serve as Class&nbsp;II Directors on our Board of Directors for a three-year term; and </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B>FOR</B></FONT><FONT SIZE=2> the ratification of the appointment of Ernst&nbsp;&amp; Young&nbsp;LLP as our independent registered public accounting firm for the fiscal year
ending December&nbsp;31, 2017. </FONT></P>

</UL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Notice of Internet Availability of Proxy Materials  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to rules adopted by the SEC, we have elected to provide access to our proxy materials via the internet. Accordingly, we are sending a
notice of internet availability of proxy materials to our stockholders. All stockholders will have the ability to access the proxy materials on the website referenced in the notice and to request to
receive a printed set of the proxy materials by mail. Instructions on how to access the proxy materials over the internet and how to request a printed copy may be found in the notice. In addition,
stockholders may request to receive proxy materials in printed form by mail or electronically by email on an ongoing basis. We encourage stockholders to take advantage of the availability of the proxy
materials on the internet or through email to help reduce the environmental impact of our annual meetings. The proxy materials, including this proxy statement, a proxy card or voting instruction card
and our 2016 Annual Report on Form&nbsp;10-K, are also available for viewing, printing and downloading on the internet at www.proxyvote.com. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Who Can Vote at the Annual Meeting  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Only stockholders of record at the close of business on the record date of April&nbsp;12, 2017 are entitled to receive notice of the Annual
Meeting and to vote the shares of our common stock that they held on that date. As of April&nbsp;12, 2017, there were 19,997,197 shares of common stock issued and outstanding. Each share of common
stock is entitled to one vote on each matter properly brought before the Annual Meeting. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Difference between a "stockholder of record" and a beneficial owner of shares held in "street
name"</I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stockholder of Record.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If you have shares registered directly in your name with our transfer agent, American Stock Transfer&nbsp;&amp;
Trust
Company,&nbsp;LLC, then you are considered a "stockholder of record" of those shares. For these shares, your set of proxy materials has been made available to you directly by us. You may vote these
shares by proxy prior to the Annual Meeting by following the instructions contained on the proxy card. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=5,EFW="2231901",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=950377,FOLIO='2',FILE='DISK104:[17ZAE1.17ZAE74701]DA74701A.;4',USER='HYUNG',CD='26-APR-2017;11:29' -->
<A NAME="page_da74701_1_3"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Beneficial Owner of Shares Held in Street Name.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If you hold shares in a brokerage account or by a bank, trust or other nominee or
custodian, then you
are considered the beneficial owner of those shares, which are held in "street name." For these shares, your set of proxy materials has been made available to you by that organization. The
organization holding your account is considered the stockholder of record for purposes of voting at the Annual Meeting. As the beneficial owner, you have the right to instruct that organization as to
how to vote the shares held in your account by following the instructions contained on the voting instruction card provided to you by that organization. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


How to Vote  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stockholder of Record.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If you are a stockholder of record, you can vote your shares in one of two ways:
either by proxy or in person at the Annual Meeting. If you choose to vote by proxy, you may do so by telephone, via the internet or by mail. Each of these methods is explained below. </FONT> <FONT SIZE=2><B>If you hold your shares of Catabasis common
stock in multiple accounts, you should vote your shares as described in each set of proxy materials you
receive.</B></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> By Telephone.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;If you request printed copies of the proxy materials by mail
and you live in the United States or Canada, you may vote by proxy by calling the toll free number found on the proxy card. You must have the control number that is on the proxy card when voting. If
you choose to vote by telephone, you do not have to return the proxy card.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> By Internet.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;You may transmit your proxy voting instructions&nbsp;via the
internet by following the instructions provided on the notice of internet availability of proxy materials or the proxy card. You will need to have the control number that is on the proxy card when
voting. If you choose to vote via the internet, you do not have to return the proxy card.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> By Mail.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;If you request printed copies of the proxy materials by mail, you
may vote by proxy by completing, signing and dating the proxy card and returning it in the envelope provided.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> In Person at the Annual Meeting.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;You may vote in person at the Annual
Meeting. We will give you a ballot when you arrive. Even if you plan to attend the Annual Meeting, we urge you to vote your shares by proxy in advance of the Annual Meeting so that, if you should
become unable to attend the Annual Meeting, your shares will be voted as directed by you. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Telephone
and internet voting for stockholders of record will be available up until 11:59&nbsp;p.m. Eastern Time on June&nbsp;6, 2017, and mailed proxy cards must be received by
June&nbsp;6, 2017 in order to be counted at the Annual Meeting. If the Annual Meeting is adjourned or postponed, these deadlines may be extended. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Beneficial Owner of Shares Held in Street Name.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If your shares are held in street name (held for your account by a broker or
other
nominee): </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> By Telephone or Internet.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;You will receive instructions or a voting
instruction form from your broker or other nominee if you are permitted to vote by telephone or internet.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> By Mail.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;You will receive instructions from your broker or other nominee
explaining how to vote your shares by mail.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> In Person at the Annual Meeting.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;If you attend the Annual Meeting, you may
vote in person. To do so, you will need to show a picture identification as well as an account statement or a letter from the record holder indicating that you owned the shares as of the record date,
and obtain from the broker or other nominee who holds your shares a legal proxy or broker's proxy card and bring it with you to the meeting. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
voting deadlines and availability of telephone and internet voting for beneficial owners of shares held in "street name" will depend on the voting processes of the organization that
holds your </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=6,EFW="2231901",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=944685,FOLIO='3',FILE='DISK104:[17ZAE1.17ZAE74701]DA74701A.;4',USER='HYUNG',CD='26-APR-2017;11:29' -->
<A NAME="page_da74701_1_4"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>shares.
Therefore, we urge you to carefully review and follow the voting instruction card and any other materials that you receive from that organization. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Quorum  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A quorum of stockholders is necessary to hold a valid meeting. Our bylaws provide that a quorum will exist if stockholders holding a majority of
the shares of stock issued and outstanding and entitled to vote are present at the meeting in person or by proxy. Abstentions and broker non-votes count as present for establishing a quorum but will
not be counted as votes cast. Broker non-votes occur when your broker or other nominee submits a proxy for your shares (because the broker or other nominee has received instructions from you on one or
more proposals, but not all, or has not received instructions from you but is entitled to vote on a particular "discretionary" matter) but does not indicate a vote for a particular proposal because
the broker or other nominee either does
not have the authority to vote on that proposal and has not received voting instructions from you or has discretionary authority but chooses not to exercise it. If a quorum is not present, the meeting
may be adjourned until a quorum is obtained. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Ballot Measures Considered "Routine" and "Non-Routine"  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The election of directors (Proposal No.&nbsp;1) is a matter considered non-routine under applicable rules. A broker or other nominee cannot
vote without instructions on non-routine matters, and therefore there may be broker non-votes on Proposal No.&nbsp;1. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
ratification of the appointment of Ernst&nbsp;&amp; Young&nbsp;LLP as our independent registered public accounting firm for 2017 (Proposal No.&nbsp;2) is a matter considered
routine under applicable rules. A broker or other nominee may generally exercise discretionary authority and vote on routine matters. If they exercise this discretionary authority, no broker non-votes
are expected to exist in connection with Proposal No.&nbsp;2. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Votes Required to Elect Directors and Ratify Appointment of Ernst&nbsp;&amp; Young&nbsp;LLP  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To be elected, a director must receive a plurality of the votes cast by stockholders entitled to vote at the meeting (Proposal No.&nbsp;1).
Shares represented by proxies that withhold authority to vote for a nominee for election as a director will not be counted as votes "for" a director. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
ratification of the appointment of Ernst&nbsp;&amp; Young&nbsp;LLP as our independent registered public accounting firm requires the affirmative vote of the majority of the shares of
common stock present or represented by proxy and voted "for" or "against" such matter (Proposal No.&nbsp;2). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Abstentions
and broker non-votes will not be counted as votes cast on any of the proposals. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Method of Counting Votes  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each holder of common stock is entitled to one vote at the Annual Meeting on each matter to come before the Annual Meeting, including the
election of a director, for each share held by such stockholder as of the record date. Votes cast in person at the Annual Meeting or by proxy by mail, via the internet or by telephone will be
tabulated by the inspector of election appointed for the Annual Meeting, who will also determine whether a quorum is present. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=7,EFW="2231901",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=73287,FOLIO='4',FILE='DISK104:[17ZAE1.17ZAE74701]DA74701A.;4',USER='HYUNG',CD='26-APR-2017;11:29' -->
<A NAME="page_da74701_1_5"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Revoking a Proxy; Changing Your Vote  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you are a stockholder of record, you may revoke your proxy before the vote is taken at the
meeting:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> by submitting a new proxy with a later date before the applicable deadline either signed and returned by mail or transmitted using the
telephone or internet voting procedures described in the "How to Vote" section above; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> by voting in person at the meeting; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> by filing a written revocation with our corporate secretary. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
your shares are held in "street name," you may submit new voting instructions by contacting your broker or other organization holding your account. You may also vote in person at the
Annual Meeting, which will have the effect of revoking any previously submitted voting instructions, if you obtain a legal proxy from the organization that holds your shares as described in the "How
to Vote" section above. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Your
attendance at the Annual Meeting will not automatically revoke your proxy. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Costs of Proxy Solicitation  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We will bear the costs of soliciting proxies. In addition to solicitations by mail, our directors, officers and regular employees, without
additional remuneration, may solicit proxies by telephone, facsimile, email, personal interviews and other means. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Voting Results  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We plan to announce preliminary voting results at the Annual Meeting and to publish final results in a Current Report on Form&nbsp;8-K to be
filed with the SEC within four business days following the Annual Meeting. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=8,EFW="2231901",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=701447,FOLIO='5',FILE='DISK104:[17ZAE1.17ZAE74701]DA74701A.;4',USER='HYUNG',CD='26-APR-2017;11:29' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dc74701_1_6"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc74701_proposal_no._1_#151;election_of_class_ii_directors"> </A>
<A NAME="toc_dc74701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PROPOSAL NO. 1&#151;ELECTION OF CLASS II DIRECTORS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board of Directors is divided into three classes, with one class of our directors standing for election each year, for a three-year term.
The authorized size of our Board of Directors is currently seven. Directors for each class are elected at the annual meeting of stockholders held in the year in which the term for their class expires
and hold office until their resignation or removal or their successors are duly elected and qualified. In accordance with our certificate of incorporation and bylaws, our directors may fill existing
vacancies on the Board of Directors by appointment. The members of the classes are divided as follows:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the Class&nbsp;I directors are Jill C. Milne and Michael D. Kishbauch, and their term will expire at the annual meeting of stockholders to be
held in 2019; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the Class&nbsp;II directors are Nicholas Galakatos and Jean George, and their term expires at the Annual Meeting; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the Class&nbsp;III directors are Kenneth Bate, Michael Ross and Burt Adelman, and their term will expire at the annual meeting of
stockholders to be held in 2018. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
certificate of incorporation and bylaws provide that the authorized number of directors may be changed only by resolution of our Board of Directors. Our certificate of incorporation
and bylaws also provide that our directors may be removed only for cause by the affirmative vote of the holders of at least 75% of the votes that all our stockholders would be entitled to cast in an
annual election of directors, and that any vacancy on our Board of Directors, including a vacancy resulting from an enlargement of our Board of Directors, may be filled only by vote of a majority of
our directors then in office. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
bylaws require that each of the classes of our Board of Directors consist, as nearly as may be possible, of one-third of the total number of directors constituting our entire Board
of Directors. Our Board of Directors, on the recommendation of our nominating and corporate governance committee, has nominated Jean George for re-election as a Class&nbsp;II director at the Annual
Meeting and has nominated Kenneth Bate, who is currently a Class&nbsp;III director, for election as a Class&nbsp;II director at the Annual Meeting. Each Class&nbsp;II director that is elected at
the Annual Meeting will be elected to serve for a three-year term that will expire at our annual meeting of stockholders to be held in 2020. In connection with his nomination as a Class&nbsp;II
director, we anticipate that, prior to the Annual Meeting, Mr.&nbsp;Bate will tender a conditional resignation as a Class&nbsp;III director, which will become effective only if he is elected at
the Annual Meeting. If Mr.&nbsp;Bate is not elected as a Class&nbsp;II director at the Annual Meeting, he would continue to serve as a Class&nbsp;III director until our annual meeting of
stockholders to be held in 2018. The term of one of our directors, Nicholas Galakatos, will expire at the Annual Meeting and he is not standing for re-election. Upon the expiration of
Dr.&nbsp;Galakatos' term, the authorized size of our Board of Directors will be six. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
no contrary indication is made, proxies in the accompanying form are to be voted for Mr.&nbsp;Bate and Ms.&nbsp;George or, in the event that any of these candidates is not a
candidate or is unable to serve as a director at the time of election (which is not currently expected), for any substitute nominee who is designated by our Board of Directors. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have no formal policy regarding diversity of our Board of Directors. Our priority in selection of Board members is identification of members who will further the interests of our
stockholders through their established record of professional accomplishment, the ability to contribute positively to the
collaborative culture among Board members, knowledge of our business and understanding of the competitive landscape and adherence to high ethical standards. Certain individual skills and
qualifications of our directors, which we believe contribute to the effectiveness of the Board of Directors as a whole, are described in the paragraph below. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=9,EFW="2231901",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=931067,FOLIO='6',FILE='DISK104:[17ZAE1.17ZAE74701]DC74701A.;7',USER='HYUNG',CD='26-APR-2017;11:29' -->
<A NAME="page_dc74701_1_7"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Information Regarding Directors  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The information set forth below as to the directors and nominees for director has been furnished to us by the directors and nominees for
director: </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc74701_nominees_for_election_to_the_b__nom04912"> </A>
<A NAME="toc_dc74701_2"> </A>
<BR></FONT><FONT SIZE=2><B>  Nominees for Election to the Board of Directors<BR>  For a Three-Year Term Expiring at the<BR>  2020 Annual Meeting of Stockholders (Class&nbsp;II)    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="246pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Age </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Present Position with Catabasis Pharmaceuticals,&nbsp;Inc. </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Kenneth Bate</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>66</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jean George</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>59</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Kenneth Bate</I></B></FONT><FONT SIZE=2> has served as a member of our Board of Directors since January 2014, and as Co-Chairman since February 2016. From May 2009
until January 2012, Mr.&nbsp;Bate was the President and Chief Executive Officer of Archemix, a privately held biotechnology company. From January 2007 to April 2009, Mr.&nbsp;Bate was President
and Chief Executive Officer of NitroMed, a public pharmaceutical company. From March 2006 until January 2007, Mr.&nbsp;Bate was Chief Operating Officer and Chief Financial Officer of NitroMed. From
January 2005 to March 2006, Mr.&nbsp;Bate was employed at JSB-Partners, a banking and advisory services firm for biopharmaceutical and life sciences companies that he co-founded. From 2002 to
January 2005, Mr.&nbsp;Bate was head of commercial operations and Chief Financial Officer at Millennium Pharmaceuticals. Mr.&nbsp;Bate served as a member of the Board of Directors of Cubist
Pharmaceuticals, a public biopharmaceutical company, from June 2003 to January 2015 and was its non-executive Chair from March 2011 to January 2015. Mr.&nbsp;Bate is a director of five other public
biopharmaceutical companies, AVEO Pharmaceuticals, Genocea Biosciences, Epizyme Pharmaceuticals, Vanda Pharmaceuticals and Madrigal Pharmaceuticals. During the last five years, Mr.&nbsp;Bate also
served as a director of NitroMed and Coley Pharmaceutical Group. He holds an M.B.A. from The Wharton School of the University of Pennsylvaniac and a B.A. in chemistry from Williams College. We believe
Mr.&nbsp;Bate's qualifications to serve on our Board of Directors include his operating, finance, commercial, transactional and senior management experience in the industry, as well as his
experience serving on the boards of directors of other public companies in the life sciences industry. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Jean George</I></B></FONT><FONT SIZE=2> has served as a member of our Board of Directors since October 2013. Since February 2002, she has been a Managing Director at
Advanced Technology Ventures, a venture capital fund, where she currently serves as the East Coast lead partner for healthcare investments. Since March 2012, Ms.&nbsp;George has served as Managing
Director at Lightstone Ventures, a venture capital firm. Ms.&nbsp;George currently serves as a member of the Board of Directors of the public companies Acceleron Pharma and Calithera Biosciences,
and previously served as a member of the Board of Directors of Portola Pharmaceuticals from 2005 to 2013 and of Zeltiq Aesthetics from 2005 to 2015. Ms.&nbsp;George holds an M.B.A. from Simmons
College Graduate School of Management and a B.S. in biology from the University of Maine. Because of Ms.&nbsp;George's extensive investment and financial experience, we believe she is able to add
valuable expertise in guiding the strategic direction of our Board of Directors. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Recommendation of the Board of Directors  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B>OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT THE STOCKHOLDERS VOTE FOR THE ELECTION OF KENNETH BATE AND JEAN GEORGE.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=10,EFW="2231901",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=821657,FOLIO='7',FILE='DISK104:[17ZAE1.17ZAE74701]DC74701A.;7',USER='HYUNG',CD='26-APR-2017;11:29' -->
<A NAME="page_dc74701_1_8"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc74701_members_of_the_board_of_direct__mem04595"> </A>
<A NAME="toc_dc74701_3"> </A>
<BR></FONT><FONT SIZE=2><B>  Members of the Board of Directors Continuing in Office<BR>  Term Expiring at the<BR>  2018 Annual Meeting of Stockholders (Class&nbsp;III)    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="279pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Age </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Present Position with Catabasis Pharmaceuticals,&nbsp;Inc. </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Michael Ross, Ph. D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>67</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Director, Co-Chairman of the Board of Directors</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Burt Adelman, M.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>65</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Michael Ross, Ph.D.</I></B></FONT><FONT SIZE=2>, has served as a member of our Board of Directors since April 2010, and as Co-Chairman since February 2016. He
previously served as our Chairman from October 2010 until February 2016. Since 2002, Dr.&nbsp;Ross has served as a Managing Partner at SV Life Sciences Advisers, a venture capital firm that he
joined as a venture partner in 2001. Previously, Dr.&nbsp;Ross served as the Chief Executive Officer of CyThera, Carta Proteomics, MetaXen and Arris Pharmaceuticals. Earlier in his career,
Dr.&nbsp;Ross was employed at Genentech, serving in several roles, including Vice President of Development and later Vice President of Medicinal and Biomolecular Chemistry. Dr.&nbsp;Ross currently
serves on the board of directors of Ophthotech, a biopharmaceutical company, and on the Board of Overseers of the Thayer School of Engineering at Dartmouth College. Dr.&nbsp;Ross received a Ph.D. in
chemistry from the California Institute of Technology and completed post doctorate training in molecular biology at Harvard University and received an A.B. from Dartmouth College and. We believe that
Dr.&nbsp;Ross is qualified to serve on our Board of Directors because of his extensive executive leadership experience and knowledge of the life sciences industry and his service on the board of
directors of other life sciences companies. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Burt Adelman, M.D.</I></B></FONT><FONT SIZE=2>, has served as a member of our Board of Directors since April 2016. Dr.&nbsp;Adelman was Executive Vice President,
Research and Development and Chief Medical Officer of Dyax, a biotechnology company, from February 2012 until its acquisition by Shire in January 2016. Prior to joining Dyax, he worked at Eleven
Biotherapeutics, a biotechnology company, where he served as interim President of Research and Development from 2010 to 2011 and as Senior Advisor from February 2011 until December 2011. From 1991 to
2007, Dr.&nbsp;Adelman held positions of increasing responsibility at Biogen, a global biotechnology company, ultimately as Executive Vice President, Portfolio Strategy. Since 1998,
Dr.&nbsp;Adelman has served as a lecturer in medicine at Harvard Medical School and as an Associate Physician at Brigham and Women's Hospital. Dr.&nbsp;Adelman holds an M.D. from Cornell Medical
College and a B.S. in biology from Trinity College. He completed residency training and a hematology fellowship at the Peter Bent Brigham Hospital. We believe that Dr.&nbsp;Adelman is qualified to
serve on our Board of Directors because of his broad experience in drug development. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc74701_term_expiring_at_the_2019_annu__ter02326"> </A>
<A NAME="toc_dc74701_4"> </A>
<BR></FONT><FONT SIZE=2><B>  Term Expiring at the<BR>  2019 Annual Meeting of Stockholders (Class&nbsp;I)    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="268pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Age </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Present Position with Catabasis Pharmaceuticals,&nbsp;Inc. </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jill C. Milne, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>49</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>President, Chief Executive Officer and Director</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Michael D. Kishbauch</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>68</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Jill C. Milne, Ph.D.</I></B></FONT><FONT SIZE=2>, is a co-founder of our company and has served as a member of our Board of Directors and as our President and Chief
Executive Officer since June 2008. Prior to co-founding our company, Dr.&nbsp;Milne worked as head of discovery biology at Sirtris Pharmaceuticals, a biotechnology company, from 2004 to 2008, when
it was acquired by GlaxoSmithKline. From 1998 to 2004, Dr.&nbsp;Milne worked at Pfizer Global Research and Development, where she served as the worldwide head of the Drug Pfinder Program and head of
the Enzyme Target Group at the Pfizer Discovery Technology Center in Cambridge, Massachusetts. Prior to joining Pfizer, she was an American Cancer Society postdoctoral fellow in the department of
biological chemistry and molecular pharmacology at Harvard Medical School from 1995 to 1998. Dr.&nbsp;Milne holds a Ph.D. from Harvard University and a B.A. in </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=11,EFW="2231901",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=946189,FOLIO='8',FILE='DISK104:[17ZAE1.17ZAE74701]DC74701A.;7',USER='HYUNG',CD='26-APR-2017;11:29' -->
<A NAME="page_dc74701_1_9"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>biological
chemistry from Wellesley College. We believe that Dr.&nbsp;Milne is qualified to serve on our Board of Directors because of her extensive leadership experience in the life sciences
industry and her extensive knowledge of our company based on her role as co-founder and Chief Executive Officer. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Michael D. Kishbauch</I></B></FONT><FONT SIZE=2> has served as a member of our Board of Directors since April 2016. Mr.&nbsp;Kishbauch has also served as a director
of Progenics Pharmaceuticals,&nbsp;Inc., a biopharmaceutical company, since September 2013 and of Achillion Pharmaceuticals,&nbsp;Inc., a biotechnology company, since July 2004.
Mr.&nbsp;Kishbauch previously served as President and Chief Executive Officer of Achillion Pharmaceuticals from July 2004 until his retirement in September 2013. Prior to that, he founded and served
as President and Chief Executive Officer of OraPharma, a commercial-stage pharmaceutical company focused on oral health care that was acquired by Johnson&nbsp;&amp; Johnson in 2003, from 1996 to 2004.
Mr.&nbsp;Kishbauch also held senior management positions with MedImmune,&nbsp;Inc., a biotechnology
company, from 1992 to 1995. Mr.&nbsp;Kishbauch formerly served as a director of TetraLogic Pharmaceuticals Corporation from 2014 through 2016. Mr.&nbsp;Kishbauch holds an M.B.A. from the Wharton
School of the University of Pennsylvania and a B.A. in biology from Wesleyan University. We believe that Mr.&nbsp;Kishbauch is qualified to serve on our Board of Directors because of his extensive
experience as an entrepreneur and manager and as a public company senior executive in the biopharmaceutical industry. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>9</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=12,EFW="2231901",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=588511,FOLIO='9',FILE='DISK104:[17ZAE1.17ZAE74701]DC74701A.;7',USER='HYUNG',CD='26-APR-2017;11:29' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_de74701_1_10"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="de74701_corporate_governance"> </A>
<A NAME="toc_de74701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  CORPORATE GOVERNANCE    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


General  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We believe that good corporate governance is important to ensure that Catabasis is managed for the long-term benefit of our stockholders. This
section describes key corporate governance practices that we have adopted. We have adopted a code of business conduct and ethics, which applies to all of our officers, directors and employees, and
corporate governance guidelines and charters for our audit committee, our compensation committee, our nominating and governance committee and our science and technology committee. We have posted
copies of our code of business
conduct and ethics and corporate governance guidelines, as well as each of our committee charters, on the "Corporate Governance" page of the "Investors" section of our website, www.catabasis.com,
which you can access free of charge. Information contained on the website is not incorporated by reference in, or considered part of, this proxy statement. We will also provide copies of these
documents, as well as our other corporate governance documents, free of charge, to any stockholder upon written request to Catabasis Pharmaceuticals,&nbsp;Inc., One Kendall Square,
Building&nbsp;1400E, Suite&nbsp;B14202, Cambridge,&nbsp;MA&nbsp;02139, Attention: Investor Relations. We intend to disclose on our website any amendments to, or waivers from, our code of
business conduct and ethics that are required to be disclosed by law or NASDAQ listing standards. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Director Independence  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rule&nbsp;5605 of the NASDAQ Listing Rules requires a majority of a listed company's Board of Directors to be comprised of independent
directors within one year of listing. In addition, the NASDAQ Listing Rules require that, subject to specified exceptions, each member of a listed company's audit, compensation and nominating and
corporate governance committees be independent, that audit committee members also satisfy independence criteria set forth in Rule&nbsp;10A-3 under the Securities Exchange Act of 1934, as amended, or
the Exchange Act, and that compensation committee members also satisfy heightened independence requirements contained in the NASDAQ Listing Rules as well as Rule&nbsp;10C-1 under the Exchange Act. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
Rule&nbsp;5605(a)(2), a director will only qualify as an "independent director" if, in the opinion of our Board of Directors, that person does not have a relationship that would
interfere with the exercise of independent judgment in carrying out the responsibilities of a director. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
order to be considered independent for purposes of Rule&nbsp;10A-3, a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the
audit committee, the Board of Directors, or any other Board committee, accept, directly or indirectly, any consulting, advisory, or other compensatory fee from the listed company or any of its
subsidiaries or otherwise be an affiliated person of the listed company or any of its subsidiaries. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;When
determining the independence of the members of our compensation committee under the heightened independence requirements contained in the NASDAQ Listing Rules and Rule&nbsp;10C-1,
our Board of Directors is required to consider all factors specifically relevant to determining whether a director has a relationship with us that is material to that director's ability to be
independent from management in connection with the duties of a compensation committee member, including, but not limited to: (1)&nbsp;the source of compensation of that director, including any
consulting, advisory or other compensatory fee paid by us to that director; and (2)&nbsp;whether that director is affiliated with our company, a subsidiary of our company or an affiliate of a
subsidiary of our company. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Board of Directors has reviewed the composition of our Board of Directors and its committees and the independence of each director. Based upon information requested from and provided
by each director concerning his or her background, employment and affiliations, including family relationships, our Board of Directors has determined that each of our directors, other than </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=13,EFW="2231901",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=693823,FOLIO='10',FILE='DISK104:[17ZAE1.17ZAE74701]DE74701A.;4',USER='HYUNG',CD='26-APR-2017;11:29' -->
<A NAME="page_de74701_1_11"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Dr.&nbsp;Milne,
is an "independent director" as defined under Rule&nbsp;5605(a)(2) of the NASDAQ Listing Rules. Our Board of Directors also has determined that Mr.&nbsp;Bate, Dr.&nbsp;Ross and
Mr.&nbsp;Kishbauch, who comprise our audit committee, and Mr.&nbsp;Bate and Dr.&nbsp;Galakatos, who comprise our compensation committee, satisfy the independence standards for such committees
established by the SEC and the NASDAQ Listing Rules, as applicable. In making such determinations, our Board of Directors considered the relationships that each such non-employee director has with our
company and all other facts and circumstances our Board of Directors deemed relevant in determining independence, including the beneficial ownership of our capital stock by each non-employee director. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Board Leadership Structure  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board of Directors has chosen to separate the role of our Chief Executive Officer and the role of Chairman of the Board of Directors, and to
have Co-Chairmen of the Board of Directors. Our Board of Directors is currently co-chaired by Mr.&nbsp;Bate and Dr.&nbsp;Ross, who both possess an in-depth knowledge of the issues, opportunities
and challenges we face. We believe they are the persons best positioned to ensure our Board of Directors' time and attention is focused on the most critical matters. We currently separate the roles of
Co-Chairmen of the Board of Directors and Chief Executive Officer because we believe that this structure enhances the Board's oversight of, and independence from, management, and enables the Board to
carry out its responsibilities on behalf of our stockholders. This leadership structure also allows Dr.&nbsp;Milne, our Chief Executive Officer, to focus her time and energy on operating and
managing the Company, while leveraging the experience and perspective of Mr.&nbsp;Bate and Dr.&nbsp;Ross. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


The Board's Role in Risk Oversight  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board of Directors has responsibility for the oversight of the company's risk management processes and, either as a whole or through its
committees, regularly discusses with management our major risk exposures, the potential impact of these risks on our business and the steps we take to manage them. The risk oversight process includes
receiving regular reports from Board committees and members of senior management to enable our Board to understand the company's risk identification, risk management and risk mitigation strategies
with respect to areas of potential material risk, including operations, finance, legal, regulatory, strategic and reputational risk. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
audit committee reviews information regarding liquidity and operations, and oversees our management of financial risks. Periodically, the audit committee reviews our policies with
respect to risk assessment, risk management, loss prevention and regulatory compliance. Oversight by the audit committee includes direct communication with our external auditors, and discussions with
management regarding significant risk exposures and the actions management has taken to limit, monitor or control such exposures. The compensation committee is responsible for assessing whether any of
our compensation policies or programs has the potential to encourage excessive risk-taking. The nominating and corporate governance committee manages risks associated with the independence of the
Board of Directors, corporate disclosure practices, and potential conflicts of interest. The science and technology committee has responsibility for risk management in areas affecting our research and
development. While each committee is responsible for evaluating certain risks and overseeing the management of such risks, the entire Board of Directors is regularly informed through committee reports
about such risks. Matters of significant strategic risk are considered by our Board of Directors as a whole. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Board of Directors Meetings  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board of Directors met twelve times during 2016. During the year, each of our directors attended 75% or more of the total number of meetings
of the Board of Directors and the committees on which he or she served. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>11</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=14,EFW="2231901",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=917073,FOLIO='11',FILE='DISK104:[17ZAE1.17ZAE74701]DE74701A.;4',USER='HYUNG',CD='26-APR-2017;11:29' -->
<A NAME="page_de74701_1_12"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Committees of the Board of Directors  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have four standing committees: the audit committee, the compensation committee, the nominating and corporate governance committee and the
science and technology committee. Each of these committees has a written charter approved by our Board of Directors. A copy of each charter can be found on the "Corporate Governance" page of the
"Investors" section of our website at www.catabasis.com. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Audit Committee  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The members of our audit committee are Dr.&nbsp;Ross, Mr.&nbsp;Bate and Mr.&nbsp;Kishbauch. Mr.&nbsp;Bate is the chair of the audit
committee. Our Board of Directors has determined that each of Mr.&nbsp;Bate and Mr.&nbsp;Kishbauch qualifies as an "audit committee financial expert" within the meaning of SEC regulations and the
NASDAQ Listing Rules. In making this determination, our Board of Directors has considered the formal education and nature and scope of each such director's previous experience, coupled with past and
present service on various audit committees. Our audit committee assists our Board of Directors in its oversight of our accounting and financial reporting process and the audits of our financial
statements. The audit committee met eight times during 2016. The audit committee's responsibilities include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> appointing, approving the compensation of, and assessing the independence of our registered public accounting firm; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> overseeing the
work of our registered public accounting firm, including through the receipt and consideration of reports from such firm; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reviewing and discussing with management and the registered
public accounting firm our annual and quarterly financial statements and related
disclosures; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> monitoring our internal control over financial reporting, disclosure controls and procedures and code of business conduct and ethics; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT
SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> overseeing our internal audit function, if any; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> discussing our risk management policies; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT
SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> establishing policies and procedures for the receipt, retention and treatment of accounting-related complaints and concerns; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> meeting
independently with our internal auditing staff, registered public accounting firm and management; </FONT> <FONT SIZE=2>
 </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reviewing and approving or ratifying any related person transactions; and </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> preparing the audit committee report required
 by SEC rules. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe that the composition of our audit committee meets the requirements for independence under current NASDAQ listing standards and SEC rules and regulations. Our Board of
Directors has determined that Mr.&nbsp;Bate, Dr.&nbsp;Ross and Mr.&nbsp;Kishbauch are independent as independence is currently defined in applicable NASDAQ listing standards and SEC rules and
regulations. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Compensation Committee  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The current members of our compensation committee are Mr.&nbsp;Bate and Dr.&nbsp;Galakatos. Dr.&nbsp;Galakatos is the current chair of the
compensation committee. Dr.&nbsp;Galakatos is not standing for re-election to our Board of Directors at the Annual Meeting, and our Board of Directors has determined to appoint Mr.&nbsp;Kishbauch
as the chair of the compensation committee and Ms.&nbsp;George as a member of the compensation committee effective immediately after the Annual Meeting. Our compensation committee assists our Board
of Directors in the discharge of its responsibilities relating </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>12</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=15,EFW="2231901",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=729180,FOLIO='12',FILE='DISK104:[17ZAE1.17ZAE74701]DE74701A.;4',USER='HYUNG',CD='26-APR-2017;11:29' -->
<A NAME="page_de74701_1_13"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>to
the compensation of our executive officers. The compensation committee met seven times during 2016. The compensation committee's responsibilities include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reviewing and approving, or making recommendations to our Board of Directors with respect to, the compensation of our chief executive officer
and our other executive officers; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> overseeing the evaluation of senior executives; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> overseeing and administering our cash
and equity incentive plans; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reviewing and making recommendations to our Board of Directors with respect to director compensation; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT
SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reviewing and making recommendations to the Board of Directors relating to management succession planning; and </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> preparing the compensation
committee report required by SEC rules, if applicable. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe that the composition of our compensation committee meets the requirements for independence under current NASDAQ listing standards and SEC rules and regulations. Our Board of
Directors has determined that Mr.&nbsp;Bate, Dr.&nbsp;Galakatos, Mr.&nbsp;Kishbauch and Ms.&nbsp;George are independent as independence is currently defined in applicable NASDAQ listing
standards and SEC rules and regulations. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
compensation committee engaged Radford, an AON Hewitt company, as its compensation consultant during the fiscal year ended December&nbsp;31, 2016. Our compensation committee
considered the relationship that Radford has with us, the members of our Board of Directors and our executive officers. Based on the committee's evaluation, the compensation committee has determined
that no conflicts of interest exist between the company and Radford. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Radford
assisted the committee in conducting a competitive compensation assessment for our executive officers for the fiscal year ended December&nbsp;31, 2016. In evaluating the total
compensation of our executive officers, the compensation committee, with the assistance of Radford, established a peer group of 20 publicly traded companies in the biopharmaceutical industry that was
selected based on companies whose market capitalization, number of employees, maturity of product development pipeline and area of therapeutic focus are similar to ours. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
peer group for our executive benchmarking as approved by the compensation committee for 2016 was comprised of the following companies: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="32%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="32%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="32%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Akebia Therapeutics,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Endocyte,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Mirati Therapeutics,&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>aTyr Pharma&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Fate Therapeutics,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Proteon Therapeutics,&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>BIND Therapeutics,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Genocea Biosciences&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Regulus Therapeutics&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Capricor Therapeutics,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>GlycoMimetics,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Stemline Therapeutics,&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Cellular Biomedicine Group,&nbsp;Inc.</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Immune Design Corp.</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Trevena,&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>ChemoCentryx,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Kura Oncology,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Vital Therapies,&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Concert Pharmaceuticals,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Matinas BioPharma Holdings,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Radford
then supplemented the peer group information with published survey data, which provided a broader market representation of companies and deeper position reporting. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
compensation committee approves the compensation objectives for the Company, provides a recommendation to our Board of Directors on the compensation of the Chief Executive Officer
and the Company's other executive officers. The compensation committee reviews all compensation components including base salary, bonus, benefits, equity incentives and other perquisites, as well as
severance arrangements, change-in-control benefits and other forms of executive officer compensation. See "Executive Compensation&#151;Narrative to Summary Compensation Table" below for more
information regarding the roles of the compensation committee, the Board of Directors, and </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>13</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=16,EFW="2231901",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=682752,FOLIO='13',FILE='DISK104:[17ZAE1.17ZAE74701]DE74701A.;4',USER='HYUNG',CD='26-APR-2017;11:29' -->
<A NAME="page_de74701_1_14"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>compensation
consultants in determining or recommending the amount or form of executive compensation. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Nominating and Corporate Governance Committee  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The members of our nominating and corporate governance committee are Ms.&nbsp;George, Dr.&nbsp;Galakatos and Dr.&nbsp;Ross.
Dr.&nbsp;Ross is the chair of the nominating and corporate governance committee. The nominating and corporate governance committee met five times during 2016. The nominating and corporate governance
committee's responsibilities include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> identifying individuals qualified to become members of our Board of Directors; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> recommending to our Board of Directors the persons to
be nominated for election as directors and to each committee of our Board of Directors;
</FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> developing and recommending corporate governance principles to the Board of Directors; and </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> overseeing periodic
evaluations of the Board of Directors. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe that the composition of our nominating and corporate governance committee meets the requirements for independence under current NASDAQ listing standards and SEC rules and
regulations. Our Board of Directors has determined that Ms.&nbsp;George, Dr.&nbsp;Galakatos and Dr.&nbsp;Ross are independent as independence is currently defined in applicable NASDAQ listing
standards. Dr.&nbsp;Galakatos is not standing for re-election to our Board of Directors at the Annual Meeting. Consequently, Dr.&nbsp;Galakatos will no longer be a member of the nominating and
corporate governance committee following the Annual Meeting. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Science and Technology Committee  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The members of the science and technology committee are Dr.&nbsp;Adelman and Dr.&nbsp;Ross. Dr.&nbsp;Adelman is the chair of the science
and technology committee. The science and technology committee met twice during 2016. The science and technology committee's responsibilities include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reviewing, evaluating, and advising the Board of Directors and management regarding the long-term strategic goals and objectives and the
direction of our research and development programs; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> monitoring and evaluating trends in research and development, and recommending to the Board of Directors and management emerging
technologies
for building our technological strength; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> recommending approaches to acquiring and maintaining technology positions; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>
regularly reviewing our research and development pipeline; and </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT>
<DD style="font-family:times;"><FONT SIZE=2> assisting the Board of Directors with its oversight responsibility for enterprise risk management in areas affecting our research and
development. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Compensation Committee Interlocks and Insider Participation  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During 2016, the members of our compensation committee were Mr.&nbsp;Bate and Dr.&nbsp;Galakatos, each of whom is an independent director.
None of our executive officers served as a director or a member of a compensation committee (or other committee serving an equivalent function) of any other entity, one of whose executive officers
served as a director or member of our compensation committee during the fiscal year ended December&nbsp;31, 2016. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Code of Business Conduct and Ethics  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have adopted a written code of business conduct and ethics that applies to our directors, officers and employees, including our principal
executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. We have posted on our website, www.catabasis.com, a current copy of
the code and all disclosures that are required by law or </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>14</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=17,EFW="2231901",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=3218,FOLIO='14',FILE='DISK104:[17ZAE1.17ZAE74701]DE74701A.;4',USER='HYUNG',CD='26-APR-2017;11:29' -->
<A NAME="page_de74701_1_15"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>NASDAQ
stock market listing standards concerning any amendments to, or waivers from, any provision of the code. Information contained on the website is not incorporated by reference in, or considered
part of, this proxy statement. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Director Nomination Process  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our nominating and corporate governance committee is responsible for identifying individuals qualified to serve as directors, consistent with
criteria approved by our Board of Directors, and recommending the persons to be nominated for election as directors. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Director Qualifications  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In evaluating director nominees, the nominating and corporate governance committee will consider, among other things, the following
factors:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reputation for integrity, honesty and adherence to high ethical standards; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> demonstrated business acumen, experience and ability to
exercise sound judgments in matters that relate to the current and long-term objectives
of our company; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> commitment to understand our company and its industry; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> interest and ability to understand the sometimes
conflicting interests of the various constituencies of our company, which include
stockholders, employees, customers, governmental units, creditors and the general public, and to act in the interests of all stockholders; and </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> diversity of expertise and experience in
substantive matters pertaining to our business relative to other members of our Board of Directors. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
nominating and corporate governance committee's goal is to assemble a Board of Directors that brings to the company a variety of perspectives and skills derived from high quality
business and professional experience. Moreover, the nominating and corporate governance committee believes that the background and qualifications of the Board of Directors, considered as a group,
should provide a significant mix of experience, knowledge and abilities that will allow the Board of Directors to fulfill its responsibilities. Nominees are not discriminated against on the basis of
race, religion, national origin, sex, sexual orientation, disability or any other basis proscribed by law. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
nominating and corporate governance committee has not adopted a formal policy with respect to a fixed set of specific minimum qualifications for its candidates for membership on the
Board of Directors. The committee may consider such other facts, including, without limitation, diversity, as it may deem are in the best interests of our company and its stockholders. The committee
further believes it is appropriate for at least one member of our Board of Directors to meet the criteria for an "audit committee financial expert" as that phrase is defined under the regulations
promulgated by the SEC, and that a majority of the members of our Board of Directors be independent as required under the NASDAQ qualification standards. The committee believes it is appropriate for
our chief executive officer to serve as a member of our Board of Directors. Our directors' performance and qualification criteria are reviewed periodically by the nominating and corporate governance
committee. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Identification and Evaluation of Nominees for Directors  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The nominating and corporate governance committee identifies nominees for director by first evaluating the current members of our Board of
Directors willing to continue in service. Current members with qualifications and skills that are consistent with the nominating and corporate governance committee's criteria for Board of Director
service and who are willing to continue in service are considered for re-nomination, balancing the value of continuity of service by existing members of our Board of Directors with that of obtaining a
new perspective or expertise. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>15</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=18,EFW="2231901",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=258435,FOLIO='15',FILE='DISK104:[17ZAE1.17ZAE74701]DE74701A.;4',USER='HYUNG',CD='26-APR-2017;11:29' -->
<A NAME="page_de74701_1_16"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
any member of our Board of Directors does not wish to continue in service or if our Board of Directors decides not to re-nominate a member for re-election, the nominating and
corporate governance committee identifies a new nominee that meets the criteria above. The committee generally inquires of our Board of Directors and members of management for their recommendations.
The committee may also review the composition and qualification of the Boards of Directors of our competitors, and may seek input from industry experts or analysts. The nominating and corporate
governance committee reviews the qualifications, experience and background of suggested candidates. Final candidates, if other than our current directors, would be interviewed by the members of the
nominating and corporate governance committee and by certain of our other independent directors and executive management. In making its determinations, the nominating and corporate governance
committee evaluates each individual in the context of our Board of Directors as a whole, with the objective of assembling a group that can best contribute to the success of our company and represent
stockholder interests through the exercise of sound judgment. After review and deliberation of all feedback and data, the nominating and corporate governance committee makes its recommendation to our
Board of Directors. The nominating and corporate governance committee utilized a third-party search firm to identify Board of Director candidates, including Dr.&nbsp;Adelman and
Mr.&nbsp;Kishbauch, both of
whom joined our Board of Directors in April 2016. The nominating and corporate governance committee may in the future continue to use a third party search firm in those situations where particular
qualifications are required or where existing contacts are not sufficient to identify an appropriate candidate. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have not received director candidate recommendations from our stockholders and do not have a formal policy regarding consideration of such recommendations. However, any
recommendations received from stockholders will be evaluated in the same manner that potential nominees suggested by members of our Board of Directors, management or other parties are evaluated. We do
not intend to treat stockholder recommendations in any manner different from other recommendations. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
our bylaws, stockholders wishing to suggest a candidate for director should write to our corporate secretary. In order to give the nominating and corporate governance committee
sufficient time to evaluate a recommended candidate and/or include the candidate in our proxy statement for the 2018 annual meeting, the recommendation should be received by our corporate secretary at
our principal executive offices in accordance with our procedures detailed in the section below entitled "Stockholder Proposals." Such submissions must state the nominee's name, together with
appropriate biographical information and background materials, and information with respect to the stockholder or group of stockholders making the recommendation, including the number of shares of
common stock owned by such stockholder or group of stockholders, as well as other information required by our bylaws. We may require any proposed nominee to furnish such other information as we may
reasonably require to determine the eligibility of such proposed nominee to serve as an independent director or that could be material to a reasonable stockholder's understanding of the independence,
or lack thereof, of such proposed nominee. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Director Attendance at Annual Meetings  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under our corporate governance guidelines, members of our Board of Directors are responsible for attending our Annual Meeting, and we encourage
all of our directors to attend. All of our directors then serving attended our 2016 annual meeting of stockholders, except for Ms.&nbsp;George and Drs. Ross and Galakatos. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Communications with Our Board of Directors  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stockholders seeking to communicate with our Board of Directors should submit their written comments to Catabasis Pharmaceuticals,&nbsp;Inc.,
One Kendall Square, Building 1400E, Suite
B14202, Cambridge, MA 02139, Attention: Corporate Secretary. The corporate secretary will forward such </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>16</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=19,EFW="2231901",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=1029814,FOLIO='16',FILE='DISK104:[17ZAE1.17ZAE74701]DE74701A.;4',USER='HYUNG',CD='26-APR-2017;11:29' -->
<A NAME="page_de74701_1_17"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>communications
to each member of our Board of Directors; provided that, if, in the opinion of our corporate secretary, it would be inappropriate to send a particular stockholder communication to a
specific director, such communication will only be sent to the remaining directors (subject to the remaining directors concurring with such opinion). </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Director Compensation  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We do not provide any compensation to Dr.&nbsp;Milne, our President and Chief Executive Officer, for her service as a director.
Dr.&nbsp;Milne's compensation as an executive officer is set forth below under "Executive Compensation&#151;2016 Summary Compensation Table." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
February 2016, our Board of Directors adopted an amended director compensation program, which became effective as of January&nbsp;1, 2016. Under this director compensation program,
we pay our non-employee directors a cash retainer for service on the Board of Directors and for service on each committee on which the director is a member. The Co-Chairmen of the Board of Directors
and the chairman of each committee receive higher retainers for such service. These fees are payable in arrears in four equal quarterly installments on the last day of each quarter, provided that the
amount of such payment is prorated for any portion of such quarter that the director is not serving on our Board of Directors. The fees paid to non-employee directors for service on the Board of
Directors and for service on each committee of the Board of Directors on which the director is a member are as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="54pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="58pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Member<BR>
Annual Fee </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Chairman<BR>
Incremental<BR>
Annual Fee </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Board of Directors</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>35,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>35,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(1)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Audit Committee</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Compensation Committee</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Nominating and Corporate Governance Committee</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,750</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,750</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Science and Technology Committee</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>In
the event co-chairmen are appointed, the retainer for Chairman of the Board will be divided equally between the co-chairmen.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
also reimburse our non-employee directors for reasonable travel and out-of-pocket expenses incurred in connection with attending our Board of Directors and committee meetings. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, under our director compensation program, each new non-employee director elected to our Board of Directors receives an option to purchase 13,000 shares of our common stock,
which option vests in equal annual installments over a three-year period measured from the date of grant, subject to the director's continued service as a director. Further, on the date of the first
Board of Directors meeting held after each annual meeting of stockholders, each non-employee director that has served on our Board of Directors for at least six months will receive an option to
purchase 6,500 shares of our common stock. Each of these options will vest in full after a one-year period measured from the date of grant, subject to the director's continued service as a director.
The exercise price of all options granted to directors will equal the fair market value of our common stock on the date of grant. Options granted to non-employee directors become exercisable in full
upon a change in control of Catabasis. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
policy is intended to provide a total compensation package that enables us to attract and retain qualified and experienced individuals to serve as directors and to align our
directors' interests with those of our stockholders. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table sets forth information regarding compensation earned by our non-employee directors during 2016. Dr.&nbsp;Laufer's term as a Class&nbsp;I director expired at our
2016 annual meeting of </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>17</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=20,EFW="2231901",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=500621,FOLIO='17',FILE='DISK104:[17ZAE1.17ZAE74701]DE74701A.;4',USER='HYUNG',CD='26-APR-2017;11:29' -->
<A NAME="page_de74701_1_18"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>stockholders
in June 2016 and he did not stand for reelection. Dr.&nbsp;Adelman and Mr.&nbsp;Kishbauch joined our Board of Directors in April 2016. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="72pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name


<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Fees Earned or<BR>
Paid In Cash<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Awards<BR>
($)(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Michael Ross, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>74,644</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>19,218</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>93,862</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Nicholas Galakatos, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>49,939</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>19,218</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>69,157</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jean George</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>38,689</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>19,218</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>57,907</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ron Laufer, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>30,124</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>30,124</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Kenneth Bate</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>71,731</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>19,218</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>90,949</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Burt Adelman, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>22,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>40,409</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>62,909</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Michael Kishbauch</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>21,250</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>40,409</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>61,659</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
amounts included in the "Option Awards" column reflect the aggregate grant date fair value of awards granted during 2016 calculated in accordance with Financial
Accounting Standards Board, or FASB, Accounting Standard Codification, or ASC, Topic 718. Assumptions used in the calculation of these amounts are included in Note&nbsp;12 to the consolidated
financial statements included in our Annual Report on Form&nbsp;10-K previously filed with the SEC. As of December&nbsp;31, 2016:</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Dr.&nbsp;Ross held a stock option to purchase 17,594 shares of common stock, 3,698 shares of which were vested as of December&nbsp;31,
2016; 7,396 shares are scheduled to vest in equal installments on June&nbsp;30, 2017 and June&nbsp;30, 2018, and 6,500 of the shares are scheduled to vest on June&nbsp;15, 2017; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Dr.&nbsp;Galakatos held a stock option to purchase 17,594 shares of common stock, 3,698 shares of which were vested as of December&nbsp;31,
2016; 7,396 shares are scheduled to vest in equal installments on June&nbsp;30, 2017 and June&nbsp;30, 2018, and 6,500 of the shares are scheduled to vest on June&nbsp;15, 2017; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Ms.&nbsp;George held a stock option to purchase 17,594 shares of common stock, 3,698 shares of which were vested as of December&nbsp;31,
2016; 7,396 shares are scheduled to vest in equal installments on June&nbsp;30, 2017 and June&nbsp;30, 2018, and 6,500 of the shares are scheduled to vest on the first anniversary of the vesting
commencement on June&nbsp;15, 2017; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Mr.&nbsp;Bate held a stock option to purchase 27,477 shares of common stock, 10,905 shares of which were vested as of December&nbsp;31,
2016; 2,676 shares are scheduled to vest in equal monthly installments through and including January&nbsp;1, 2018; 7,396 shares are scheduled to vest in equal installments on June&nbsp;30, 2017
and June&nbsp;30, 2018, and 6,500 of the shares are scheduled to vest on the first anniversary of the vesting commencement on June&nbsp;15, 2017; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Dr.&nbsp;Adelman held a stock option to purchase 13,000 shares of common stock, none of which were vested as of December&nbsp;31, 2016; the
shares are scheduled to vest in equal annual installments over a three-year period with the first annual vesting date to occur on April&nbsp;15, 2017; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Mr.&nbsp;Kishbauch held a stock option to purchase 13,000 shares of common stock, none of which were vested as of December&nbsp;31, 2016;
the shares are scheduled to vest in equal annual installments over a three-year period with the first annual vesting date to occur on April&nbsp;15, 2017.  </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>18</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=21,EFW="2231901",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=727258,FOLIO='18',FILE='DISK104:[17ZAE1.17ZAE74701]DE74701A.;4',USER='HYUNG',CD='26-APR-2017;11:29' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dg74701_1_19"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dg74701_executive_officers"> </A>
<A NAME="toc_dg74701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  EXECUTIVE OFFICERS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth information regarding our executive officers as of April&nbsp;15, 2017: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="268pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Age </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Position(s) </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jill C. Milne, Ph. D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>49</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>President and Chief Executive Officer, Director</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Joanne Donovan, M.D., Ph. D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>60</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Chief Medical Officer</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Andrew Nichols, Ph. D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>56</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Chief Scientific Officer</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Edward (Ted) Hibben</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>58</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Chief Business Officer</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deirdre A. Cunnane</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>52</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Senior Vice President, General Counsel and Treasurer</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
biography of Dr.&nbsp;Milne can be found under "Proposal 1&#151;Election of Class&nbsp;II Directors&#151;Members of the Board of Directors Continuing in Office." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Joanne M. Donovan, M.D., Ph.D.</I></B></FONT><FONT SIZE=2>, has served as our Chief Medical Officer since July 2011. Since 1989, she has worked as a staff physician
at the VA Boston Healthcare System, where she was formerly Chief of Gastroenterology. Dr.&nbsp;Donovan has held an appointment at Harvard Medical School since 1990, most recently as associate
clinical professor of medicine. From 1998 to July 2011, Dr.&nbsp;Donovan served in positions of increasing responsibility, ultimately as vice president of clinical development, at Genzyme, a
biotechnology company, which she joined through its acquisition of GelTex. Dr.&nbsp;Donovan holds a Ph.D. in medical engineering and medical physics from the Massachusetts Institute of Technology,
an M.D. from Harvard Medical School and an S.B. from the Massachusetts Institute of Technology. She completed residency training in internal medicine and a fellowship in gastroenterology at the
Brigham and Women's Hospital. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Andrew Nichols, Ph.D.,</I></B></FONT><FONT SIZE=2> has served as our Chief Scientific Officer since October 2016. Previously, he served as our Senior Vice President,
Research and Development from February 2014 to October 2016. From October, 2013 to February, 2014, Dr.&nbsp;Nichols was Associate Vice President, Cardiometabolic Diseases at Merck Research Labs, a
pharmaceutical research company, leading drug discovery and early clinical development programs. Dr.&nbsp;Nichols was also Associate Vice President/Executive Director, In Vivo Pharmacology at Merck
Research Labs from August, 2010 to October, 2013, and Executive Director, In Vivo Sciences at Merck Research Labs from August, 2009 to August, 2010. Prior to Merck, Dr.&nbsp;Nichols was Vice
President of Preclinical Research at Zafgen, Vice President of Research at Alinea, Vice President of Drug Discovery Project Leadership at Millennium and Director of the Alliance
Management Group at SmithKline Beecham. He holds an M. Phil. and Ph.D. in Cardiovascular Pharmacology from the University of Cambridge, England and a B.Sc. in Pharmacology from the University of
Leeds, England. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Edward (Ted) Hibben</I></B></FONT><FONT SIZE=2> has served as our Chief Business Officer since February 2017. Previously, he served as our Senior Vice President,
Corporate Development from April 2015 to February 2017. From September, 2010 to April, 2015, he was Senior Vice President, Corporate Development at Ensemble Therapeutics, a biopharmaceutical company
that discovers and develops small molecule therapies for cancer and other serious diseases. Prior to Ensemble, Mr.&nbsp;Hibben was Chief Business Officer at Cequent Pharmaceuticals until its merger
with MDRNA,&nbsp;Inc. (now Marina Biotech), and was Vice President, Business Development and Alliance Management at Coley Pharmaceutical Group, until its sale to Pfizer. Mr.&nbsp;Hibben holds an
M.B.A. from Harvard University and an A.B. from Dartmouth College. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Deirdre A. Cunnane</I></B></FONT><FONT SIZE=2> has served as our Senior Vice President and General Counsel since November 2015 and as our Treasurer since April 2016.
Prior to joining Catabasis, Ms.&nbsp;Cunnane served as General Counsel at Advanced Technology Ventures, or ATV, from January 2006 to October 2015, and at Lightstone Ventures, or Lightstone, from its
founding in January 2012 until October 2015. Prior to ATV and Lightstone, Ms.&nbsp;Cunnane was an investment officer at BancBoston Ventures and Deputy General Counsel at BancBoston Capital.
Ms.&nbsp;Cunnane started her law career with, and later became a Partner in, Goodwin Procter's corporate department. Ms.&nbsp;Cunnane holds a J.D. from Boston College Law School and a B.S. in
Finance from the Boston College School of Management. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>19</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=22,EFW="2231901",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=582152,FOLIO='19',FILE='DISK104:[17ZAE1.17ZAE74701]DG74701A.;12',USER='HYUNG',CD='26-APR-2017;11:32' -->
<A NAME="page_dg74701_1_20"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dg74701_executive_compensation"> </A>
<A NAME="toc_dg74701_2"> </A>
<BR></FONT><FONT SIZE=2><B>  EXECUTIVE COMPENSATION    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This section describes the material elements of compensation awarded to, earned by or paid to each of our named executive officers, or NEOs. Our
NEOs for 2016 are Jill C. Milne, Joanne M. Donovan, and Andrew Nichols. This section also provides qualitative information regarding the manner and context in which compensation is awarded to and
earned by our executive officers and is intended to place in perspective the data presented in the tables and narrative that follow. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


2016 Summary Compensation Table  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth information regarding compensation earned in 2016 and 2015 by our NEOs. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:57%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"140%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="140%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="30pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="70pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name and Principal Position

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Salary<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Bonus<BR>
($)(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option Awards<BR>
($)(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>All Other<BR>
Compensation<BR>
($)(3) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Jill C. Milne, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>453,200</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>163,152</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>431,230</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,822</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,049,404</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><I>President and Chief Executive Officer</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2015</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>420,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>158,400</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,575,611</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,442</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,155,454</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Joanne M. Donovan, M.D., Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
2016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
381,982</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
130,256</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
321,806</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
1,822</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
835,866</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Chief Medical Officer</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2015</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>360,360</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>130,979</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,442</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>592,781</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Andrew Nichols, Ph.D. (4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
2016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
316,750</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
118,627</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
238,744</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
1,822</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
675,943</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><I>Chief Scientific Officer</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
amounts reported in the "Bonus" column represent discretionary annual cash bonuses awarded to our NEOs.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
amounts reported in the "Option Awards" column reflect the aggregate grant date fair value of share-based compensation awarded during the year computed in
accordance with the provisions of FASB ASC Topic 718. See Note&nbsp;12 to the consolidated financial statements included in our Annual Report on Form&nbsp;10-K previously filed with the SEC.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
amounts reported in the "All Other Compensation" column reflect, for each NEO, the cost to us of life insurance premiums paid for the NEO.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Dr.&nbsp;Nichols
was appointed Chief Scientific Officer in October 2016.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Narrative to Summary Compensation Table  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We review compensation annually for all employees, including our executives. In setting executive base salaries and bonuses and granting equity
incentive awards, we consider compensation for comparable positions in the market, the historical compensation levels of our executives, individual performance as compared to our expectations and
objectives, our desire to motivate our employees to achieve short- and long-term results that are in the best interests of our stockholders, and a long-term commitment to our company. We do not target
a specific competitive position or a specific mix of compensation among base salary, bonus or long-term incentives. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Chief Executive Officer typically proposes base salary, target bonuses, and equity incentive compensation for members of our executive team (excluding herself) to the compensation
committee. Her proposals are based on the Company's pay philosophy and methodology and in-line with executive compensation for similarly situated executives at peer companies. Our compensation
committee then typically reviews and discusses the proposals with the Chief Executive Officer for all executives other than the Chief Executive Officer. The compensation committee, without the
applicable members of management present, further discusses the Chief Executive Officer's recommendations and ultimately recommends for our Board of Directors' approval the base salary, target bonuses
and equity incentive </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>20</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=23,EFW="2231901",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=1046227,FOLIO='20',FILE='DISK104:[17ZAE1.17ZAE74701]DG74701A.;12',USER='HYUNG',CD='26-APR-2017;11:32' -->
<A NAME="page_dg74701_1_21"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>compensation
of our executive officers for the current year, as well as the amount of executive officer cash bonuses for the prior year, based on the attainment of corporate and individual goals. The
Chief Executive Officer is not present during voting or deliberations regarding her compensation by the compensation committee or the Board of Directors. During 2016, our compensation committee
engaged Radford as its independent compensation consultant, to review our executive compensation peer group and program design and assess our executives' compensation relative to comparable companies.
See "Corporate Governance&#151;Committees of the Board of Directors&#151;Compensation Committee" for more information about the engagement of Radford by the compensation committee. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Base salary.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In 2016, we paid annual base salaries to Dr.&nbsp;Milne, Dr.&nbsp;Donovan and Dr.&nbsp;Nichols in the amounts of $453,200,
$381,982, and $316,750, respectively. These 2016 annual base salaries reflected a market-based merit increase from 2015 of 3% for Dr.&nbsp;Milne and Dr.&nbsp;Nichols and 6% for Dr.&nbsp;Donovan.
These base salaries were determined using a competitive assessment of similarly situated executives at our peer companies to make them competitive with the 50<SUP>th</SUP>&nbsp;percentile, as
well as to address customary annual base salary increases and to recognize their individual performance. Dr.&nbsp;Nichols' base salary was further increased in October 2016 to $340,000 when he was
promoted from Senior Vice President, Research and Development to Chief Scientific Officer. We use base salaries to recognize the experience, skills, knowledge and responsibilities required of all our
employees, including our NEOs. None of our NEOs is currently party to an employment agreement or other agreement or arrangement that provides for automatic or scheduled increases in base salary. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Annual bonus.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our Board of Directors may, in its discretion, award bonuses to our NEOs from time to time. We typically establish annual
bonus targets
based around a set of specified corporate goals for our NEOs, along with individual goals, and conduct an annual performance review to determine the attainment of such goals. Our employment agreement
or offer letters with our NEOs specify target percentages of annual base salary, which for 2016 were 50%, 40% and 35% for Drs.&nbsp;Milne, Donovan and Nichols, respectively. Our management may
propose bonus awards to the compensation committee or the Board of Directors primarily based on such review process and such target percentages. Our compensation committee makes a recommendation to
the Board of Directors regarding eligibility requirements for and the amount of such bonus awards. With respect to 2016, we awarded and paid bonuses of $163,152 to Dr.&nbsp;Milne, $130,256 to
Dr.&nbsp;Donovan and $78,427 to Dr.&nbsp;Nichols, in each case as determined by our Board of Directors upon the recommendation of the compensation committee. With respect to Dr.&nbsp;Milne, the
amount of her bonus was based on her bonus target and the achievement of 72% of our company goals, and, with respect to Dr.&nbsp;Donovan and Dr.&nbsp;Nichols, the amounts of their respective
bonuses was based on their respective bonus targets and the achievement of both individual and company goals. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Equity incentives.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Although we do not have a formal policy with respect to the grant of equity incentive awards to our executive
officers, or any
formal equity ownership guidelines applicable to them, we believe that equity grants provide our executives with a strong link to our long-term performance, create an ownership culture and help to
align the interests of our executives and our stockholders. In addition, we believe that equity grants with a time-based vesting feature promote executive retention because this feature incentivizes
our executive officers to remain in our employment during the vesting period. Accordingly, we typically grant stock option awards at the start of employment to each executive officer and our other
employees and our compensation committee and Board of Directors periodically review the equity incentive compensation of our NEOs and other employees and from time to time may grant equity incentive
awards to them in the form of stock options. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
2016, our Board of Directors granted options to purchase 148,000, 111,000 and 66,000 shares of our common stock to Dr.&nbsp;Milne, Dr.&nbsp;Donovan and Dr.&nbsp;Nichols,
respectively, as part of a review of their overall compensation. In addition, in connection with the appointment of Dr.&nbsp;Nichols as our Chief </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>21</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=24,EFW="2231901",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=694319,FOLIO='21',FILE='DISK104:[17ZAE1.17ZAE74701]DG74701A.;12',USER='HYUNG',CD='26-APR-2017;11:32' -->
<A NAME="page_dg74701_1_22"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Scientific
Officer in October 2016, our Board of Directors granted Dr.&nbsp;Nichols an option to purchase 13,000 shares of our common stock. For grants in connection with initial employment, vesting
begins on the initial date of employment. Time vested stock option grants to our executives and other employees typically vest 25% on the first anniversary of grant or, if earlier, the initial
employment date and 2.0833% per month thereafter, through the fourth anniversary of the vesting commencement date, and have a term of 10&nbsp;years from the grant date. The exercise price of all
options is equal to the fair market value of our common stock on the date of grant. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Outstanding Equity Awards at 2016 Fiscal Year End Table  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth information regarding outstanding stock options held by our NEOs as of December&nbsp;31, 2016. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="58pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="65pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="40pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option Awards </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Securities<BR>
Underlying<BR>
Unexercised<BR>
Options (#)<BR>
Exercisable </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Securities<BR>
Underlying<BR>
Unexercised<BR>
Options (#)<BR>
Unexercisable </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Exercise<BR>
Price<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Expiration<BR>
Date </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Jill C. Milne, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>84,276</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.67</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2/28/2021</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>32,477</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.31</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12/17/2022</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>22,292</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.31</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12/17/2022</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>28,009</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>596</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.31</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4/16/2023</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>42,558</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>15,807</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.81</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3/18/2024</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,086</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,252</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11.05</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3/25/2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>56,667</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>103,333</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14.05</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7/16/2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>103,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4.57</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2/10/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>45,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(6)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4.31</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9/7/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Joanne M. Donovan, M.D., Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
27,237</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
1.93</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
9/6/2021</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>24,072</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>512</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(7)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.31</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12/17/2022</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10,496</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.31</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12/17/2022</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,204</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.31</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12/17/2022</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14,007</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>298</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.31</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4/16/2023</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>18,442</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6,849</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.81</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3/18/2024</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,042</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,627</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11.05</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3/25/2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>66,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4.57</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2/10/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>45,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(6)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4.31</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9/7/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Andrew Nichols, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
41,342</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
17,023</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>(8)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
6.81</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
3/18/2024</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,192</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,531</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11.05</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3/25/2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,919</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,863</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(9)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11.05</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4/29/2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>26,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4.57</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2/10/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>40,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(6)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4.31</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9/7/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>13,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(10)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5.79</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10/2/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
unvested awards are scheduled to vest in equal monthly installments through June&nbsp;18, 2017.  </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
unvested awards are scheduled to vest in equal monthly installments through January&nbsp;1, 2018.  </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
unvested awards are scheduled to vest in equal monthly installments through March&nbsp;26, 2019.  </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
unvested awards are scheduled to vest in equal monthly installments through July&nbsp;8, 2019.  </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>25%
of the unvested awards vested on February&nbsp;11, 2017. The remaining unvested awards are scheduled to vest in equal monthly installments through
February&nbsp;11, 2020. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>22</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=25,EFW="2231901",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=160783,FOLIO='22',FILE='DISK104:[17ZAE1.17ZAE74701]DG74701A.;12',USER='HYUNG',CD='26-APR-2017;11:32' -->
<A NAME="page_dg74701_1_23"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(6)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>25%
of the unvested awards are scheduled to vest on September&nbsp;8, 2017. The remaining unvested awards are scheduled to vest in equal monthly installments
through September&nbsp;8, 2020.  </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(7)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
unvested awards vested on January&nbsp;1, 2017.  </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(8)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
unvested awards are scheduled to vest in equal monthly installments through February&nbsp;16, 2018.  </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(9)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
unvested awards are scheduled to vest in equal monthly installments through June&nbsp;1, 2019.  </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(10)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>25%
of the unvested awards are scheduled to vest on October&nbsp;3, 2017. The remaining unvested awards are scheduled to vest in equal monthly installments
through October&nbsp;3, 2020.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Employment Agreements, Severance and Change in Control Arrangements  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B>Employment Agreements with Current NEOs</B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have entered into an employment agreement with Dr.&nbsp;Milne, dated as of April&nbsp;7, 2010. The employment agreement confirms Dr.&nbsp;Milne's title, compensation
arrangements and eligibility for benefits made available to employees generally. The employment agreement with Dr.&nbsp;Milne provides that she is eligible to receive an annual cash bonus, as
determined by the Board of Directors in its sole discretion, with a target of 40% of her annual base salary earned in such particular calendar year, which percentage shall be subject to adjustment
from time to time by the Board of Directors in its sole discretion. The Board of Directors has approved for 2017 a target cash bonus (expressed as a percentage of base salary) of up to 50% for
Dr.&nbsp;Milne based on its assessment of the Company's performance against established annual goals. The Board of Directors has approved for 2017 a target cash bonus of up to 40% of annual base
salary for Dr.&nbsp;Donovan and up to 35% of annual base salary for Dr.&nbsp;Nichols, as determined in the sole discretion of the Board of Directors, based on its assessment of their respective
performance and that of Catabasis against established annual goals. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
of Drs. Milne, Donovan and Nichols is an employee at will and is entitled to certain benefits upon termination pursuant to our Severance Benefits Plan, or the Severance Plan, which
was adopted by the Board of Directors in April 2016, as further described below. In connection with the adoption of the Severance Plan, each of Drs. Milne, Donovan and Nichols has acknowledged that
their entitlement to severance benefits is governed by the terms of the Severance Plan and that any terms of their employment agreement or offer letter, as applicable, relating to severance have been
superseded in their entirety by the terms of the Severance Plan. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Severance Plan  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Severance Plan provides eligible full time executives holding the title of vice president or above ("Covered Employees") certain severance
benefits upon a termination without cause (as defined in the Severance Plan) or a resignation for good reason (as defined in the Severance Plan), including in each case within one year following a
change in control (as defined in the Severance Plan)
(each, a "Covered Termination"). Pursuant to the Severance Plan, each Covered Employee who is subject to a Covered Termination is entitled to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> continuation of such Covered Employee's monthly base salary (as defined in the Severance Plan) for a period ranging from six months to
18&nbsp;months (the "Severance Period") following such termination depending on the title/role of the Covered Employee and the type of Covered Termination; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> payment by Catabasis of a portion of the cost of COBRA continuation of benefits coverage for the Covered Employee and his or her applicable
dependents for no longer than the Covered Employee's applicable Severance Period or until the Covered Employee commences new employment and is eligible for new plan coverage, if sooner, subject to
certain conditions set forth in the Severance Plan; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>23</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=26,EFW="2231901",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=96054,FOLIO='23',FILE='DISK104:[17ZAE1.17ZAE74701]DG74701A.;12',USER='HYUNG',CD='26-APR-2017;11:32' -->
<A NAME="page_dg74701_1_24"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any unpaid annual bonus in respect to any completed bonus period which has ended prior to the date of the Covered Employee's Covered
Termination and which the Board of Directors deems granted to the Covered Employee in its discretion pursuant to Catabasis' contingent compensation program; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> in the case of the chief executive officer of Catabasis, a bonus amount equal to one-half of the average annual bonus paid to the chief
executive officer over the three calendar years preceding the calendar year in which the Covered Termination occurs, which bonus shall be prorated to reflect the number of days served in the calendar
year in which such Covered Termination occurs; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> in the case of a change in control termination, full vesting of any unvested equity awards. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Receipt
of any severance benefits under the Severance Plan requires that the Covered Employee: (a)&nbsp;comply with the provisions of any applicable noncompetition, nonsolicitation,
and other obligations to us; and (b)&nbsp;execute and deliver a suitable waiver and release under which the Covered Employee releases and discharges us and our affiliates from and on account of any
and all claims that relate to or arise out of the employment relationship between us and the Covered Employee, which release will become binding within 60&nbsp;days following the Covered Employee's
termination of employment. If a Covered Employee dies following a Covered Termination but before such Covered Employee has received all of the severance benefits to which such Covered Employee is
entitled under the Severance Plan, the remaining payments will be made to the Covered Employee's designated beneficiary or estate. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Severance Plan provides that the following employees will not be eligible for severance benefits, except to the extent specifically determined otherwise by the Severance Plan's
administrator:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> an employee who is terminated for cause (as defined in the Severance Plan); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> an employee who retires, terminates employment as a result of an inability to perform his or her duties due to physical or mental disability or
dies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> an employee who voluntarily terminates his or her employment, except in the case of a Covered Termination for good reason (as defined in the
Severance Plan); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> an employee who is employed for a specific period of time in accordance with the terms of a written employment agreement; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> an employee who promptly becomes employed by another member of the controlled group of entities of which Catabasis (or its successor in the
change in control (as defined in the Severance Plan)) is a member as defined in Sections&nbsp;414(b) and (c)&nbsp;of the Internal Revenue Code of 1986, as amended. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Severance Plan provides for recoupment of severance benefits under specified circumstances if the Covered Employee fails to comply with the terms of the Severance Plan. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Severance Plan supersedes (i)&nbsp;existing severance plans and separation policies applying to Covered Employees with respect to any termination that would constitute a Covered
Termination and (ii)&nbsp;the provisions of any agreements between any Covered Employee and us that provide for severance benefits. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>24</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=27,EFW="2231901",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=516942,FOLIO='24',FILE='DISK104:[17ZAE1.17ZAE74701]DG74701A.;12',USER='HYUNG',CD='26-APR-2017;11:32' -->
<A NAME="page_dg74701_1_25"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table summarizes the schedule of severance payments our NEOs would receive, assuming a qualifying termination occurred on December&nbsp;31, 2016. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:73%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"110%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="110%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="47pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="79pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Cash<BR>
Severance<BR>
($)(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Bonus<BR>
($)(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>COBRA<BR>
Continuation<BR>
($)(3) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Value of<BR>
Accelerated<BR>
Vesting of Equity<BR>
Awards<BR>
($)(4) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><I>Jill C. Milne, Ph.D.</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Termination without cause or upon resignation with good reason</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>453,200</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>73,592</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>25,398</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>552,190</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Termination upon a change in control</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>679,800</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>73,592</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>38,097</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>775</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>792,264</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Joanne M. Donovan, M.D., Ph.D.</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Termination without cause or upon resignation with good reason</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>381,982</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>25,398</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>407,380</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Termination upon a change in control</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>381,982</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>25,398</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,053</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>408,433</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><I>Andrew Nichols, Ph.D.</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Termination without cause or upon resignation with good reason</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>340,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>25,398</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>365,398</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Termination upon a change in control</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>340,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>25,398</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>365,398</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>This
amount represents 12&nbsp;months' base salary, each at the rate in effect immediately prior to the executive's termination of employment and, in the case of
Dr.&nbsp;Milne for a change in control termination, 18&nbsp;months' base salary.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>This
amount represents 50% of the average bonus received by Dr.&nbsp;Milne for the three most recently completed years.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>This
amount represents paid health coverage for 12&nbsp;months and, in the case of Dr.&nbsp;Milne for a change in control termination, 18&nbsp;months' paid
health coverage.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
values of accelerated vesting of equity awards included in the table above are based on the intrinsic values of such unvested awards on December&nbsp;31, 2016
(i.e.&nbsp;the difference between the closing price of our common stock on the NASDAQ Global Market on that date and the exercise price multiplied by the number of shares for which vesting would
have been accelerated).  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have also entered into employee confidentiality, non-competition and proprietary information agreements with each of our NEOs. Under the employee confidentiality, non-competition and
proprietary information agreements, each NEO has agreed (1)&nbsp;not to compete with us during his or her employment and for a period of 18&nbsp;months after the termination of his or her
employment, (2)&nbsp;not to solicit our employees during his or her employment and for a period of 18&nbsp;months after the termination of his or her employment, (3)&nbsp;to protect our
confidential and proprietary information and (4)&nbsp;to assign to us related intellectual property developed during the course of his or her employment. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


401(k) retirement plan  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We maintain a 401(k) retirement plan that is intended to be a tax-qualified defined contribution plan under Section&nbsp;401(k) of the
Internal Revenue Code. In general, all of our employees are eligible to participate, beginning on the first day of the month following commencement
of their employment. The 401(k) plan includes a salary deferral arrangement pursuant to which participants may elect to reduce their current compensation by up to the statutorily prescribed limit,
equal to $18,000 in 2016, and have the amount of the reduction contributed to the 401(k) plan. Participants over the age of 50 are entitled to an additional catch-up contribution up to the statutorily
prescribed limit, equal to $6,000 in 2016. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>25</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=28,EFW="2231901",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=746412,FOLIO='25',FILE='DISK104:[17ZAE1.17ZAE74701]DG74701A.;12',USER='HYUNG',CD='26-APR-2017;11:32' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_di74701_1_26"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="di74701_certain_relationships___di702236"> </A>
<A NAME="toc_di74701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following is a description of transactions since January&nbsp;1, 2016 to which we have been a party, and in which any of our directors,
executive officers or beneficial owners of more than 5% of our voting securities, or affiliates or immediate family members of any of our directors, executive officers or beneficial owners of more
than 5% of our voting securities, had or will have a direct or indirect material interest. We believe the terms obtained or consideration that we paid or received, as applicable, in connection with
the transactions described below were comparable to terms available or the amounts that would be paid or received, as applicable, from unrelated third parties. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Employment, Severance and Change in Control Agreements  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;See "Executive Compensation&#151;Employment Agreements, Severance and Change in Control Arrangements" above for a discussion of these
arrangements. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Indemnification of Officers and Directors  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our certificate of incorporation provides that we will indemnify our directors and officers to the fullest extent permitted by Delaware law. In
addition, we have entered into indemnification agreements with each of our directors and executive officers that may be broader in scope than the specific indemnification provisions contained in the
Delaware General Corporation Law. These indemnification agreements require us, among other things, to indemnify each such director and executive officer for some expenses, including attorneys' fees,
judgments, fines and settlement amounts incurred by him or her in any action or proceeding arising out of his or her service as one of our directors or executive officers. In addition, we maintain
standard policies of insurance under which coverage is provided to our directors and officers against losses arising from claims made by reason of breach of duty or other wrongful act, and to us with
respect to payments which may be made by us to such directors and officers pursuant to the above indemnification provisions or otherwise as a matter of law. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Policies and Procedures for Related Person Transactions  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board of Directors has adopted a written related person transaction policy to set forth policies and procedures for the review and approval
or ratification of related person transactions. This policy covers any transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships, in which we were
or are to be a participant, the amount involved exceeds $120,000, and a related person had or will have a direct or indirect material interest, including, without limitation, purchases of goods or
services by or from the related person or entities in which the related person has a material interest, indebtedness, guarantees of indebtedness and employment by us of a related person. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
related person transaction policy contains exceptions for any transaction or interest that is not considered a related person transaction under SEC rules as in effect from time to
time. In addition, the
policy provides that an interest arising solely from a related person's position as an executive officer of another entity that is a participant in a transaction with us will not be subject to the
policy if each of the following conditions is met:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the related person and all other related persons own in the aggregate less than a 10% equity interest in such entity; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the related person and his or her immediate family members are not involved in the negotiation of the terms of the transaction with us and do
not receive any special benefits as a result of the transaction; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the amount involved in the transaction equals less than the greater of $200,000 or 5% of the annual gross revenue of the company receiving
payment under the transaction. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>26</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=29,EFW="2231901",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=999626,FOLIO='26',FILE='DISK104:[17ZAE1.17ZAE74701]DI74701A.;8',USER='HYUNG',CD='26-APR-2017;11:29' -->
<A NAME="page_di74701_1_27"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
policy provides that any related person transaction proposed to be entered into by us must be reported to our general counsel or chief financial officer and will be reviewed and
approved by our audit committee in accordance with the terms of the policy, prior to effectiveness or consummation of the transaction whenever practicable. The policy provides that if our general
counsel or chief financial officer determines that advance approval of a related person transaction is not practicable under the circumstances, our audit committee will review and, in its discretion,
may ratify the related person transaction at the next meeting of the audit committee. The policy also provides that alternatively, our general counsel or chief financial officer may present a related
person transaction arising in the time period between meetings of the audit committee to the chair of the audit committee, who will review and may approve the related person transaction, subject to
ratification by the audit committee at the next meeting of the audit committee. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, the policy provides that any related person transaction previously approved by the audit committee or otherwise already existing that is ongoing in nature will be reviewed
by the audit committee annually to ensure that such related person transaction has been conducted in accordance
with the previous approval granted by the audit committee, if any, and that all required disclosures regarding the related person transaction are made. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
policy provides that transactions involving compensation of executive officers will be reviewed and approved by our compensation committee in the manner to be specified in the
charter of the compensation committee. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
related person transaction reviewed under this policy will be considered approved or ratified if it is authorized by the audit committee in accordance with the standards set forth in
the policy after full disclosure of the related person's interests in the transaction. As appropriate for the circumstances, the policy provides that the audit committee will review and
consider:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the related person's interest in the related person transaction; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the approximate dollar value of the amount involved in the related person transaction; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the approximate dollar value of the amount of the related person's interest in the transaction without regard to the amount of any profit or
loss; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> whether the transaction was undertaken in the ordinary course of business of our company; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> whether the transaction with the related person is proposed to be, or was, entered into on terms no less favorable to us than the terms that
could have been reached with an unrelated third party; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the purpose of, and the potential benefits to us of, the transaction; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any other information regarding the related person transaction or the related person in the context of the proposed transaction that would be
material to investors in light of the circumstances of the particular transaction. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
policy provides that the audit committee will review all relevant information available to it about the related person transaction. The policy provides that the audit committee may
approve or ratify the related person transaction only if the audit committee determines that, under all of the circumstances, the transaction is in, or is not inconsistent with, our best interests.
The policy provides that the audit committee may, in its sole discretion, impose such conditions as it deems appropriate on us or the related person in connection with approval of the related person
transaction. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>27</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=30,EFW="2231901",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=496602,FOLIO='27',FILE='DISK104:[17ZAE1.17ZAE74701]DI74701A.;8',USER='HYUNG',CD='26-APR-2017;11:29' -->
<A NAME="page_di74701_1_28"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="di74701_proposal_no._2_#151;ratificati__pro06344"> </A>
<A NAME="toc_di74701_2"> </A>
<BR></FONT><FONT SIZE=2><B>  PROPOSAL NO. 2&#151;RATIFICATION OF THE APPOINTMENT OF ERNST&nbsp;&amp; YOUNG&nbsp;LLP AS CATABASIS'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING  DECEMBER 31, 2017    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our stockholders are being asked to ratify the appointment by the audit committee of the Board of Directors of Ernst&nbsp;&amp; Young&nbsp;LLP
as our independent registered public accounting firm. Ernst&nbsp;&amp; Young&nbsp;LLP has served as the company's independent registered public accounting firm since 2010. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
audit committee is solely responsible for selecting our independent registered public accounting firm for the fiscal year ending December&nbsp;31, 2017. Stockholder approval is not
required to appoint Ernst&nbsp;&amp; Young&nbsp;LLP as our independent registered public accounting firm. However, the Board of Directors believes that submitting the appointment of Ernst&nbsp;&amp;
Young&nbsp;LLP to the stockholders for
ratification is good corporate governance. If the stockholders do not ratify this appointment, the audit committee will reconsider whether to retain Ernst&nbsp;&amp; Young&nbsp;LLP. If the selection
of Ernst&nbsp;&amp; Young&nbsp;LLP is ratified, the audit committee, in its discretion, may direct the appointment of a different independent registered public accounting firm at any time it decides
that such a change would be in the best interest of Catabasis and its stockholders. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
representative of Ernst&nbsp;&amp; Young&nbsp;LLP is expected to be present at the Annual Meeting and will have an opportunity to make a statement if he or she desires to do so and to
respond to appropriate questions from our stockholders. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table summarizes the fees Ernst&nbsp;&amp; Young&nbsp;LLP, our independent registered public accounting firm, billed to us for each of the last two fiscal years. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Audit Fees(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>382,383</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,082,688</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Audit-Related Fees(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Tax Fees(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12,800</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>All Other Fees(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>395,183</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,091,688 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Audit
fees consist of fees billed for professional services performed by Ernst&nbsp;&amp; Young&nbsp;LLP for the audit of our annual consolidated financial
statements, the review of interim consolidated financial statements, and related services that are normally provided in connection with registration statements, including the registration statement
for our initial public offering.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Audit-related
fees may consist of fees billed by an independent registered public accounting firm for assurance and related services that are reasonably related to
the performance of the audit or review of our consolidated financial statements. There were no such fees incurred in 2016 or 2015.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Tax
fees may consist of fees for professional services, including tax consulting and compliance performed by an independent registered public accounting firm.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>There
were no such fees incurred in 2016 or 2015.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
such accountant services and fees for 2016 were pre-approved by our audit committee in accordance with the "Pre-Approval Policies and Procedures" described below. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>28</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=31,EFW="2231901",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=779759,FOLIO='28',FILE='DISK104:[17ZAE1.17ZAE74701]DI74701A.;8',USER='HYUNG',CD='26-APR-2017;11:29' -->
<A NAME="page_di74701_1_29"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Pre-approval Policy and Procedures  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board of Directors adopted policies and procedures for the pre-approval of audit and non-audit services for the purpose of maintaining the
independence of our independent auditor. We may not engage our independent auditor to render any audit or non-audit service unless either the service is approved in advance by the audit committee, or
the engagement to render the service is entered into pursuant to the audit committee's pre-approval policies and procedures. Notwithstanding the foregoing, pre-approval is not required with respect to
the provision of services, other than audit, review or attest services, by the independent auditor if the aggregate amount of all such services is no more than 5% of the total amount paid by us to the
independent auditor during the fiscal year in which the services are provided, such services were not recognized by us at the time of the engagement to be non-audit services and such services are
promptly brought to the attention of the audit committee and approved prior to completion of the audit by the audit committee. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From
time to time, our audit committee may pre-approve services that are expected to be provided to us by the independent auditor during the following 12&nbsp;months. At the time such
pre-approval is granted, the audit committee must identify the particular pre-approved services in a sufficient level of detail so that our management will not be called upon to make a judgment as to
whether a proposed service fits within the pre-approved services and, at each regularly scheduled meeting of the audit committee following such approval, management or the independent auditor shall
report to the audit committee regarding each service actually provided to us pursuant to such pre-approval. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
our 2016 fiscal year, no services were provided to us by Ernst&nbsp;&amp; Young&nbsp;LLP or any other accounting firm other than in accordance with the pre-approval policies and
procedures described above. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Recommendation of the Board of Directors  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT THE STOCKHOLDERS VOTE FOR THE RATIFICATION OF ERNST&nbsp;&amp;
YOUNG&nbsp;LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>29</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=32,EFW="2231901",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=435938,FOLIO='29',FILE='DISK104:[17ZAE1.17ZAE74701]DI74701A.;8',USER='HYUNG',CD='26-APR-2017;11:29' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dk74701_1_30"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dk74701_principal_stockholders"> </A>
<A NAME="toc_dk74701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PRINCIPAL STOCKHOLDERS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth information, to the extent known by us or ascertainable from public filings, with respect to the beneficial
ownership of our common stock as of March&nbsp;20, 2017 by:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> each person, or group of affiliated persons, who is known by us to beneficially own more than 5% of our common stock; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> each of our directors and our director nominees; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> each of our NEOs; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> all of our current directors and executive officers as a group. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Beneficial
ownership is determined in accordance with the rules and regulations of the SEC. These rules generally attribute beneficial ownership of securities to persons who possess sole
or shared voting power or investment power with respect to those securities and include shares of common stock issuable upon the exercise of stock options that are immediately exercisable or
exercisable within 60&nbsp;days after March&nbsp;20, 2017. Except as otherwise indicated, all of the shares reflected in the table are shares of common stock and all persons listed below have sole
voting and investment power with respect to the shares beneficially owned by them, subject to community property laws, where applicable. The information is not necessarily indicative of beneficial
ownership for any other purpose. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
percentage ownership calculations for beneficial ownership are based on 19,997,197 shares of common stock outstanding as of March&nbsp;20, 2017. Except as otherwise indicated in
the table below, addresses of named beneficial owners are in care of Catabasis Pharmaceuticals,&nbsp;Inc., One Kendall Square, Building 1400E, Suite B14202, Cambridge, MA 02139. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
computing the number of shares of common stock beneficially owned by a person and the percentage ownership of that person, we deemed outstanding shares of common stock subject to
options held by that person that are currently exercisable or exercisable within 60&nbsp;days after March&nbsp;20, </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>30</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=33,EFW="2231901",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=735341,FOLIO='30',FILE='DISK104:[17ZAE1.17ZAE74701]DK74701A.;5',USER='HYUNG',CD='26-APR-2017;11:29' -->
<A NAME="page_dk74701_1_31"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>2017.
We did not deem these shares outstanding, however, for the purpose of computing the percentage ownership of any other person. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="63pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name of Beneficial Owner

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Shares<BR>
Beneficially<BR>
Owned </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Percentage of<BR>
Shares<BR>
Beneficially<BR>
Owned </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B><I>5% Stockholders</I></B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Entities affiliated with SV Life Sciences(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,857,667</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14.3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Clarus Lifesciences II,&nbsp;L.P.(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,752,488</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>13.8</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Advanced Technology Ventures VIII,&nbsp;L.P.(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,133,943</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5.7</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Camber Capital Management,&nbsp;LLC(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,000,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5.0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B><I>NEOs and Directors</I></B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jill C. Milne, Ph.D.(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>589,297</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Joanne M. Donovan, Ph.D., M.D.(6)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>128,368</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Andrew Nichols, Ph.D.(7)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>60,693</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Burt Adelman, M.D.(8)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,333</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Kenneth Bate(9)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,934</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Nicholas Galakatos, Ph.D.(10)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,756,186</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>13.8</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jean George(11)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,894,550</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9.5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Michael D. Kishbauch(12)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,333</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Michael Ross, Ph.D.(13)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,861,365</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14.3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>All current executive officers and directors as a group (11 persons)(14)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8,384,466</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>40.7</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>*</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Represents
beneficial ownership of less than 1% of our outstanding stock.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of 2,798,528 shares of record held by SV Life Sciences Fund V,&nbsp;L.P. ("SVLS V&nbsp;LP") and 59,139 shares of record held by SV Life Sciences Fund V
Strategic Partners,&nbsp;L.P. ("SVLS V SPP"). SV Life Sciences Fund V (GP),&nbsp;LP ("SVLS V&nbsp;GP") is the general partner of SVLS V&nbsp;LP and SVLS V SPP. The general partner of SVLS
V&nbsp;GP is SVLSF V,&nbsp;LLC. The members of the investment committee of SVLSF V,&nbsp;LLC are Kate Bingham, James Garvey, Eugene D. Hill, III, David Milne and Michael Ross, a member of our
Board of Directors. SVLS V&nbsp;GP, SVLSF V,&nbsp;LLC and each of the individuals comprising the SVLSF V,&nbsp;LLC investment committee may be deemed to share voting, dispositive and investment
power over the shares held of record by SVLS V&nbsp;LP and SVLS V SPP. Each of SVLS V&nbsp;GP, SVLSF V,&nbsp;LLC and the individual members of the SVLSF&nbsp;V,&nbsp;LLC investment committee
disclaim beneficial ownership of the shares owned directly by SVLS V&nbsp;LP and SVLS&nbsp;V SPP except to the extent of any pecuniary interest therein. The address for the entities is One Boston
Place, Suite&nbsp;3900, 201 Washington Street, Boston, Massachusetts 02108. The information about SVLS V&nbsp;LP and SVLS V SPP is based upon a Schedule&nbsp;13D filed with the SEC on
February&nbsp;7, 2017.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of 2,752,488 shares held of record by Clarus Lifesciences II,&nbsp;L.P. ("Clarus"). Clarus Ventures II&nbsp;GP,&nbsp;L.P. (the "GPLP"), as the sole
general partner of Clarus, may be deemed to beneficially own certain of the shares held of record by Clarus. The&nbsp;GPLP disclaims beneficial ownership of all shares held of record by Clarus in
which the&nbsp;GPLP does not have an actual pecuniary interest. Clarus Ventures II,&nbsp;LLC (the "GPLLC"), as the sole general partner of the&nbsp;GPLP, may be deemed to beneficially own
certain of the shares held of record by Clarus. The&nbsp;GPLLC disclaims beneficial ownership of all shares held of record by Clarus in which it does not have an actual pecuniary interest. Each of
Nicholas Galakatos, a member of our Board of Directors, and Dennis Henner, Robert Liptak, Nicholas Simon, Michael Steinmetz and Kurt Wheeler, as individual Managing Directors of the&nbsp;GPLLC, may
be deemed to beneficially own certain of the shares held of record by Clarus. Each of Messrs.&nbsp;Galakatos, Henner, Liptak, Simon, </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>31</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=34,EFW="2231901",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=594391,FOLIO='31',FILE='DISK104:[17ZAE1.17ZAE74701]DK74701A.;5',USER='HYUNG',CD='26-APR-2017;11:29' -->
<A NAME="page_dk74701_1_32"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
<UL>

<P style="font-family:times;"><FONT SIZE=2>Steinmetz
and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which he does not have an actual pecuniary interest. The address for the entities is 101 Main Street,
Suite&nbsp;1210, Cambridge, MA 02142. The information about Clarus share ownership is based on a Schedule&nbsp;13D/A filed with the SEC on October&nbsp;4, 2016 and is as of September&nbsp;23,
2016.  </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>ATV
Associates VIII,&nbsp;LLC ("ATV A VIII") is the General Partner of Advanced Technology Ventures VIII,&nbsp;L.P. ("ATV VIII") and exercises voting and
dispositive authority over the shares held by ATV VIII. Voting and dispositive decisions of ATV A VIII are made collectively by Michael A. Carusi, Jean George, a member of our Board of Directors,
Steven N. Baloff, Robert C. Hower and William C. Wiberg (collectively, the "ATV VIII Managing Directors"). ATV A VIII and the ATV VIII Managing Directors disclaim beneficial ownership of the shares
held by ATV&nbsp;VIII except to the extent of their pecuniary interest therein. The address for the entities is 500 Boylston Street, Suite&nbsp;1380, Boston, MA 02116. The information about ATV
VIII share ownership is based on a Schedule&nbsp;13G filed with the SEC on February&nbsp;16, 2016 and is as of December&nbsp;31, 2015.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Camber
Capital Management&nbsp;LLC and Stephen Dubois filed a joint Amendment No.&nbsp;1 to Schedule&nbsp;13G with the SEC on February&nbsp;12, 2016
indicating that they have shared voting power and shared dispositive power with respect to 1,000,000 shares of our common stock. The address for Camber Capital Management&nbsp;LLC and Stephen DuBois
is 101 Huntington Avenue, Suite&nbsp;2550, Boston, MA 02199. Information is based on such Amendment No.&nbsp;1 to Schedule&nbsp;13G filed on February&nbsp;12, 2016 and is as of
December&nbsp;30, 2015.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
326,672 shares of common stock issuable upon the exercise of options exercisable within 60&nbsp;days after March&nbsp;20, 2017.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(6)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
128,368 shares of common stock issuable upon the exercise of options exercisable within 60&nbsp;days after March&nbsp;20, 2017.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(7)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of 60,693 shares of common stock issuable upon the exercise of options exercisable within 60&nbsp;days after March&nbsp;20, 2017.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(8)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of 4,333 shares of common stock issuable upon the exercise of options exercisable within 60&nbsp;days after March&nbsp;20, 2017.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(9)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of 11,934 shares of common stock issuable upon the exercise of options exercisable within 60&nbsp;days after March&nbsp;20, 2017.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(10)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
the shares described in note&nbsp;(2) above. Dr.&nbsp;Galakatos is a Managing Director of Clarus Ventures II,&nbsp;LLC, which the sole general
partner of the&nbsp;GPLP, which is the sole general partner of Clarus, and, as a result, Dr.&nbsp;Galakatos shares investment and voting control over the shares held by Clarus.
Dr.&nbsp;Galakatos disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Dr.&nbsp;Galakatos' address is 101 Main Street, Suite&nbsp;1210,
Cambridge, MA&nbsp;02142. Also includes 3,698 shares of common stock issuable upon the exercise of options exercisable within 60&nbsp;days after March&nbsp;20, 2017.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(11)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
the shares described in note&nbsp;(5) above and 666,145 shares of common stock held by Lightstone Ventures,&nbsp;L.P. and 90,764 shares of common stock
held by Lightstone Ventures (A),&nbsp;L.P. Ms.&nbsp;George is an ATV III Managing Director and, as a result, shares voting and dispositive power over the shares held by Advanced Technology
Ventures VIII,&nbsp;L.P. LSV Associates,&nbsp;LLC ("LSV&nbsp;GP") is the General Partner of Lightstone Ventures,&nbsp;L.P. and Lightstone Ventures (A),&nbsp;L.P. (collectively, "LSV") and
exercises voting and dispositive authority over the shares held by LSV. Voting and dispositive decisions of LSV&nbsp;GP are made collectively by Michael A. Carusi, Jean George, a member of our Board
of Directors, Ralph E. Christoffersen and Henry A. Plain, Jr. (collectively, the "LSV Managing Directors"). LSV&nbsp;GP and the LSV Managing Directors disclaim </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>32</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=35,EFW="2231901",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=397807,FOLIO='32',FILE='DISK104:[17ZAE1.17ZAE74701]DK74701A.;5',USER='HYUNG',CD='26-APR-2017;11:29' -->
<A NAME="page_dk74701_1_33"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
<UL>

<P style="font-family:times;"><FONT SIZE=2>beneficial
ownership of the shares held by LSV except to the extent of their pecuniary interest therein. Ms.&nbsp;George disclaims beneficial ownership of the shares held by ATV VIII and LSV except
to the extent of any pecuniary interest therein. Ms.&nbsp;George's address is 500 Boylston Street, Suite&nbsp;1380, Boston, MA 02116. Also includes 3,698 shares of common stock issuable upon the
exercise of options exercisable within 60&nbsp;days after March&nbsp;20, 2017.  </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(12)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of 4,333 shares of common stock issuable upon the exercise of options exercisable within 60&nbsp;days after March&nbsp;20, 2017.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(13)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
the shares described in note&nbsp;(1) above. Dr.&nbsp;Ross is a member of the investment committee of SVLSF V,&nbsp;LLC, which is the general partner
of SV Life Sciences Fund V (GP), which is the general partner of SV Life Sciences Fund V,&nbsp;L.P. and SV Life Sciences Fund V Strategic Partners,&nbsp;L.P., and, as a result, Dr.&nbsp;Ross may
be deemed to share voting, dispositive and investment power over the shares held of record by SV Life Sciences Fund V,&nbsp;L.P. and SV Life Sciences Fund V Strategic Partners&nbsp;L.P.
Dr.&nbsp;Ross disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Dr.&nbsp;Ross' address is One Boston Place, Suite&nbsp;3900, Boston,
Massachusetts 02108. Also includes 3,698 shares of common stock issuable upon the exercise of options exercisable within 60&nbsp;days after March&nbsp;20, 2017.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(14)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
620,425 shares of common stock issuable upon the exercise of options exercisable within 60&nbsp;days after March&nbsp;20, 2017.  </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dk74701_section_16(a)_benefici__dk702033"> </A>
<A NAME="toc_dk74701_2"> </A>
<BR></FONT><FONT SIZE=2><B>  SECTION&nbsp;16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;16(a) of the Exchange Act requires our directors, executive officers, and persons holding more than 10% of Catabasis common stock
to report their initial ownership of our common stock and other equity securities and any changes in that ownership in reports that must be filed with the SEC. The SEC has designated specific
deadlines for these reports, and we must identify in this proxy statement those persons who did not file these reports when due. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
solely on a review of reports furnished to us, or written representations from reporting persons, we believe all directors, executive officers, and 10% owners timely filed all
reports regarding transactions in Catabasis' securities required to be filed for 2016 by Section&nbsp;16(a) under the Exchange Act. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>33</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=36,EFW="2231901",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=600335,FOLIO='33',FILE='DISK104:[17ZAE1.17ZAE74701]DK74701A.;5',USER='HYUNG',CD='26-APR-2017;11:29' -->
<A NAME="page_dk74701_1_34"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dk74701_report_of_the_audit_committee"> </A>
<A NAME="toc_dk74701_3"> </A>
<BR></FONT><FONT SIZE=2><B>  REPORT OF THE AUDIT COMMITTEE    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The audit committee is appointed by the Board of Directors to assist the Board of Directors in fulfilling its oversight responsibilities with
respect to (1)&nbsp;the integrity of our financial statements and financial reporting process and systems of internal controls regarding finance, accounting, and compliance with legal and regulatory
requirements, (2)&nbsp;the qualifications, independence, and performance of our independent registered public accounting firm, (3)&nbsp;the performance of our internal audit function, if any, and
(4)&nbsp;other matters as set forth in the charter of the audit committee approved by the Board of Directors. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Management
is responsible for the preparation of the Catabasis financial statements and the financial reporting process, including its system of internal control over financial reporting
and its disclosure controls and procedures. The independent registered public accounting firm is responsible for performing an audit of the Catabasis financial statements in accordance with the
standards of the Public Company Accounting Oversight Board, or PCAOB, and issuing a report thereon. The audit committee's responsibility is to monitor and oversee these processes. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
connection with these responsibilities, the audit committee reviewed and discussed with management and the independent registered public accounting firm the audited consolidated
financial statements of Catabasis for the fiscal year ended December&nbsp;31, 2016. The audit committee also discussed with the independent registered public accounting firm the matters required to
be discussed by the PCAOB's Auditing Standard No.&nbsp;16, </FONT><FONT SIZE=2><I>Communication with Audit Committees</I></FONT><FONT SIZE=2>. In addition, the audit committee received written
communications from the independent registered public accounting firm confirming its independence as required by the applicable requirements of the PCAOB and has discussed with the independent
registered public accounting firm its independence. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
on the reviews and discussions referred to above, the audit committee recommended to the Board of Directors that the audited consolidated financial statements of Catabasis be
included in its Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2016, that was filed with the SEC. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF CATABASIS PHARMACEUTICALS,&nbsp;INC.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Kenneth Bate, Chairman<BR>
Michael Ross, Ph. D.<BR>
Michael Kishbauch</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>34</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=37,EFW="2231901",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=429765,FOLIO='34',FILE='DISK104:[17ZAE1.17ZAE74701]DK74701A.;5',USER='HYUNG',CD='26-APR-2017;11:29' -->
<A NAME="page_dk74701_1_35"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dk74701_householding"> </A>
<A NAME="toc_dk74701_4"> </A>
<BR></FONT><FONT SIZE=2><B>  HOUSEHOLDING    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Some banks, brokers and other nominee record holders may be participating in the practice of "householding" proxy statements and annual reports.
This means that only one copy of our documents, including the annual report to stockholders and proxy statement, may have been made available to multiple stockholders in your household. We will
promptly deliver a separate copy of either document to you upon written or oral request to Catabasis Pharmaceuticals,&nbsp;Inc., One Kendall Square, Building&nbsp;1400E, Suite B14202, Cambridge,
MA 02139, Attention: Corporate Secretary, or telephone: (617)&nbsp;349-1971. If you want to receive separate copies of the proxy statement or annual report to stockholders in the future, or if you
are receiving multiple copies and would like to receive only one copy per household, you should contact your bank, broker or other nominee record holder, or you may contact us at the above address and
phone number. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dk74701_stockholder_proposals"> </A>
<A NAME="toc_dk74701_5"> </A>
<BR></FONT><FONT SIZE=2><B>  STOCKHOLDER PROPOSALS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A stockholder who would like to have a proposal considered for inclusion in our 2018 proxy statement must submit the proposal in accordance with
the procedures outlined in Rule&nbsp;14a-8 of the Exchange Act so that it is received by us no later than December&nbsp;27, 2017, which is 120&nbsp;days prior to the first anniversary of the
mailing date of this proxy statement. However, if the date of the 2018 annual meeting of stockholders is changed by more than 30&nbsp;days from the date of this year's meeting, then the deadline is
a reasonable time before we begin to print and send our proxy statement for the 2018 annual meeting of stockholders. SEC rules set standards for eligibility and specify the types of stockholder
proposals that may be excluded from a proxy statement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
a stockholder wishes to propose a nomination of persons for election to our Board of Directors or present a proposal at an annual meeting but does not wish to have the proposal
considered for inclusion in our proxy statement and proxy card, our amended and restated bylaws establish an advance notice procedure for such nominations and proposals. Stockholders at an annual
meeting may only consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of the Board of Directors or by a stockholder of record on
the record date for the meeting, who is entitled to vote at the meeting and who has delivered timely notice in proper form to our corporate secretary of the stockholder's intention to bring such
business before the meeting. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
required notice must be in writing and received by our corporate secretary at our principal executive offices not less than 90&nbsp;days nor more than 120&nbsp;days prior to the
first anniversary of the preceding year's annual meeting. However, in the event that the date of the annual meeting is advanced by more than 20&nbsp;days, or delayed by more than 60&nbsp;days,
from the first anniversary of the preceding year's annual meeting, a stockholder's notice must be so received no earlier than the 120th&nbsp;day prior to such annual meeting and not later than the
close of business on the later of (A)&nbsp;the 90th&nbsp;day prior to such annual meeting and (B)&nbsp;the tenth day following the day on which notice of the date of such annual meeting was
mailed or public disclosure of the date of such annual meeting was made, whichever first occurs. For stockholder proposals to be brought before the 2018 annual meeting of stockholders, the required
notice must be received by our corporate secretary at our principal executive offices no earlier than February&nbsp;7, 2018 and no later than March&nbsp;9, 2018. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stockholder
proposals should be addressed to Catabasis Pharmaceuticals,&nbsp;Inc., One Kendall Square, Building 1400E, Suite B14202, Cambridge, MA 02139, Attention: Corporate
Secretary. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>35</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=38,EFW="2231901",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=286372,FOLIO='35',FILE='DISK104:[17ZAE1.17ZAE74701]DK74701A.;5',USER='HYUNG',CD='26-APR-2017;11:29' -->
<A NAME="page_dk74701_1_36"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dk74701_other_matters"> </A>
<A NAME="toc_dk74701_6"> </A>
<BR></FONT><FONT SIZE=2><B>  OTHER MATTERS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board of Directors does not know of any other matters to be brought before the Annual Meeting. If any other matters not mentioned in this
proxy statement are properly brought before the meeting, the individuals named in the proxy made available to stockholders intend to use their discretionary voting authority under the proxy to vote
the proxy in accordance with their best judgment on those matters. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>By Order of the Board of Directors</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><B>
<IMG SRC="g102608.jpg" ALT="GRAPHIC" WIDTH="148" HEIGHT="67">
 </B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Jill C. Milne, Ph.D.<BR></FONT> <FONT SIZE=2><I>President and Chief Executive Officer</I></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>36</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=39,EFW="2231901",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=975811,FOLIO='36',FILE='DISK104:[17ZAE1.17ZAE74701]DK74701A.;5',USER='HYUNG',CD='26-APR-2017;11:29' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<div id="container" style="width:100%;"><div id="ImgContainer" style="border:0;width:100%;height:auto;">
<p style="margin:0in 0in .0001pt;height:1px;"><font size="1" color="white" face="Times New Roman" style="color:white;font-size:1.0pt;">VOTE BY   INTERNET - www.proxyvote.com Use the Internet to transmit your voting   instructions and for electronic delivery of information up until 11:59 P.M.   Eastern Time on June 6, 2017. Have your proxy card in hand when you access   the web site and follow the instructions to obtain your records and to create   an electronic voting instruction form. CATABASIS PHARMACEUTICALS, INC. One   Kendall Square, Building 1400E Suite B14202 Cambridge, MA 02139 ELECTRONIC   DELIVERY OF FUTURE PROXY MATERIALS If you would like to reduce the costs   incurred by our company in mailing proxy materials, you can consent to   receiving all future proxy statements, proxy cards and annual reports   electronically via e-mail or the Internet. To sign up for electronic   delivery, please follow the instructions above to vote using the Internet   and, when prompted, indicate that you agree to receive or access proxy   materials electronically in future years. VOTE BY PHONE - 1-800-690-6903 Use   any touch-tone telephone to transmit your voting instructions up until 11:59   P.M. Eastern Time on June 6, 2017. Have your proxy card in hand when you call   and then follow the instructions. VOTE BY MAIL Mark, sign and date your proxy   card and return it in the postage-paid envelope we have provided or return it   to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717. TO   VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: KEEP THIS PORTION   FOR YOUR RECORDS DETACH AND RETURN THIS PORTION ONLY THIS PROXY CARD IS VALID   ONLY WHEN SIGNED AND DATED. For Withhold For All Except To withhold authority   to vote for any individual nominee(s), mark &#147;For All Except&#148; and write the   number(s) of the AllAll The Board of Directors recommends you vote FOR the   following: nominee(s) on the line below. 0 0 0 1. Election of Directors   Nominees 1a Jean George 1b Kenneth Bate The Board of Directors recommends you   vote FOR the following proposal: 2. Ratification of the appointment of Ernst   &amp; Young LLP as our independent registered public accounting firm for the   fiscal year ending December 31, 2017. NOTE: The shares represented by this   proxy when properly executed will be voted in the manner directed herein by   the undersigned stockholder(s). If no direction is made, this proxy will be   voted FOR the election of the nominees listed in item 1 and FOR item 2. If   any other matters properly come before the meeting, the persons named in this   proxy will vote in their discretion. ForAgainst Abstain 0 0 0 Please sign   exactly as your name(s) appear(s) hereon. When signing as attorney, executor,   administrator, or other fiduciary, please give full title as such. Joint   owners should each sign personally. All holders must sign. If a corporation   or partnership, please sign in full corporate or partnership name, by   authorized officer. Signature [PLEASE SIGN WITHIN BOX] Date Signature (Joint   Owners) Date 0000335466_1 R1.0.1.15 </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="1008" height="1273" src="g24472bgi001.gif"></font></p>    </div></div>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</div>
<!-- ZEQ.=1,SEQ=40,EFW="2231901",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=621648,FOLIO='',FILE="DISK105:[17ZAE2.17ZAE74702]2447-2-BG_ZAE74702.CHC",USER="HYUNG",CD='Apr 27 00:23 2017' -->

<br clear="all" style="page-break-before:always;">
<div>
<div align="center">
<div id="container" style="width:100%;"><div id="ImgContainer" style="border:0;width:100%;height:auto;">
<p style="margin:0in 0in .0001pt;height:1px;"><font size="1" color="white" face="Times New Roman" style="color:white;font-size:1.0pt;">Important   Notice Regarding the Availability of Proxy Materials for the Annual Meeting:   The Notice and Proxy Statement, Annual Report and Form 10-K are available at   www.proxyvote.com . THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF   DIRECTORS OF CATABASIS PHARMACEUTICALS, INC. June 7, 2017 at 10:00 AM ET The   stockholder(s) hereby appoint(s) Jill C. Milne, Ph. D., and Deirdre A.   Cunnane, or either of them, as proxies, each with the power to appoint her   substitute, and hereby authorize(s) them to represent and to vote, as   designated on the reverse side of this ballot, all of the shares of Common   Stock of Catabasis Pharmaceuticals, Inc. that the stockholder(s) is/are   entitled to vote at the Annual Meeting of Stockholders to be held at 10:00   a.m., Eastern Time, on June 7, 2017, at the offices of WilmerHale located at   60 State Street, Boston, MA 02109, and any adjournment or postponement   thereof. THIS PROXY, WHEN PROPERLY EXECUTED, WILL BE VOTED AS DIRECTED BY THE   STOCKHOLDER(S). IF NO SUCH DIRECTIONS ARE MADE, THIS PROXY WILL BE VOTED FOR   THE ELECTION OF THE NOMINEES LISTED ON THE REVERSE SIDE FOR THE BOARD OF   DIRECTORS, AND FOR PROPOSAL 2. IN THEIR DISCRETION, THE PROXIES ARE   AUTHORIZED TO VOTE UPON SUCH OTHER BUSINESS AS MAY PROPERLY COME BEFORE THE   MEETING OR ANY POSTPONEMENT OR ADJOURNMENT THEREOF. PLEASE MARK, SIGN, DATE   AND RETURN THIS PROXY CARD PROMPTLY USING THE ENCLOSED REPLY ENVELOPE.   Continued and to be signed on reverse side 0000335466_2 R1.0.1.15 </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="1008" height="1261" src="g24472bgi002.gif"></font></p>    </div></div>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</div>
<!-- ZEQ.=1,SEQ=41,EFW="2231901",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=895597,FOLIO='',FILE="DISK105:[17ZAE2.17ZAE74702]2447-2-BG_ZAE74702.CHC",USER="HYUNG",CD='Apr 27 00:23 2017' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g102608.jpg
<DESCRIPTION>G102608.JPG
<TEXT>
begin 644 g102608.jpg
M_]C_X  02D9)1@ ! 0$!&@$:  #__@!%35),3%]'4D%02$E#4SI;0T%404)!
M4TE37U!(05)-04-%551)0T%,4U])3D-=2DE,3%]#7TU)3$Y%7TM?4TE'+D50
M4__; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_   L( $, E $!$0#_Q  =  $
M @,! 0$!            " D!!@<* @0%_\0 +A   00#  (! P,$ P #
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MOJIGZ\::XVS\[8UQC.,8T"M;GJ^X7%DM:RF8B9*U#9TAIFQLALNE4(O9\3'
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M>/6:#9]A-3+557&FV<19[)[AJGBN-10E.(]95D36P7DF;UW3M,19M,;2F[.
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M#@9!FYT>#B(F WE9EAP5B2$/$TW00BC&\/@J^F%1:[3?'U>608QC7'QC\?\
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M!QA+33Z-2 P=, YAJ.?8T^=,.V22"_T9VT^Y].V<9@ZOZ9_7'EXS:#Z(D<9
MCU5WPZ$P?H?IN UN-</]MM7N!M90FY %?#F[M)JT:N&;*,H,U631HPW0RS:M
MT$Y7<X\8<H\ALR8OFCGZK:9P>10Q)"T+B@YC*I7EIG35IO+YFNFYETN4;8UQ
?ENK)#911';YW3VUVVSG,H/'CQX\>/'CQX\>/'CS_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g24472bgi001.gif
<DESCRIPTION>G24472BGI001.GIF
<TEXT>
begin 644 g24472bgi001.gif
M1TE&.#=A\ /Y!'<  "'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "P
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MZU$4^B"%5H ( $O@Q9EL5BP$F8 #68B"*Y8% -,)(5;1ZH'_*A:(]_@!$RW
MP0[" (E&T.,/QLJ6_T3PG0-DH!5H&X@L/."!=>'H#IWH5@VDH(0B9.($?Q@
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M+ 4$!,#TBSA@!RO8,LKWWA0.$!>Y7G\ $X@P"5DS@0ZQ)L@>>-8!/IB@%R)
M0X6I$/F"E%<' O !&Y:=@#VT 1,L.( !B$""%Y6 ;VQ@@@$HO^42L'Y?9;#?
M SC@A4) P!:'3WR1Q[ A?3!!!#)P%!$ <0$'\&/U(4?5X LO^,&S80(*P!,.
M^)$],E1![/-@U9@!X'KB V ";  /_S^T$ +4"\L!^A@0^K5P !\0@0T)8$ *
MOC")":B@_/H@_6(ASP0V4 O,1R  +T4%@)  !; &5(!X#Y !93 )'>!2@&
ME7( ;$!H$T" %[ '4E ',L $%DAY6H U_.!\EX: @)!VWT<$1& *6*, ^5=X
M<\8$^4 $,\!QK9(!ST " C !PT=H:X!Z.X: (C @HE '";"#I+=ERD9\&/ ,
M5G !-!5R%YA\#Y!Z[U< G'4J%UB !7$ ^4<%$J "3<9Y!T ((R  3 "%@@9_
M7IB$)Z, 1)!\W(=LD]<H!5 $4K )=,AW?'@4*@<F3G )6D *44 %-+ [+D '
M(N "C>0$G_^G!7Q0!H#@ 5N0!.DP RJH" ?4:F"@ QK  R9 !1%@!8NW"1U
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M XINBFD $\"?LE '$]"1$_"<DT *9^(  E +,P %#% R4"D_ - )(R *^0D
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M5C">3DH(I\"TQAM*F90(/Y"UX1DK#[ &8# "&#"@%<!0/.JC?7H"P2EI"OD
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M'X3)!K6H!7, !'PC!1$[L07A5EN"#XHY>&(@LUN !B4W#R\, 68XK590 BE
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M'K(  K2"$7NPR(00Z"7Q  IPASI@MR&=<WP J*C"!]$T$(OW#/U"?C P,8#
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M'1\>12L"; #2S40(F\!T)3 $M>)Y+$"[,V,%HTPU\N;9LO!YIB!VAEPI .&
MPXH'G?!L0@, @R0 #FY\V(5)DXD" "SN4>0!A)4$#TC1 ')$5AM,;"#(.I5D
MCR J6Q( 6".(A46:-6W>Q)E3YTZ>/7W^!!I4Z%"B18T>19I4Z5*F39T^A1I5
MZM2<-TKMR70"'Y@1^&Y8>?!B10$,=3J@&W$A'1ZM@WHD$46F@P<5 .:02<*E
M:P8EM22H<#B"0::Q2R*]I(GA3@$'G91@*'/D 9@5-0_$J/S#$8LE/1*DDP %
MR9<%BAFT.8.SDA*:#@*YLWD#3_\03"(N$!JQ@$&7*14MXABD@PD3&"866'3
MQ02'$PZ(B##S :?#.L.9L"FPRPH$'"ET+%D\[\D"+J6\YMZ#FDN/#AUX"[B;
MY&8M1_(51EK31L>#+F2TS/FB S"LR(Z,#6I" @@6'HC!"JP*<8 KWVIRH))$
M]G#D0"2 R8$''2Z8XRT^1BA@CPBJ0#"(*-H8HHH)<?HA@D)(J<PU'2PZ( /I
M+(IQ1YQJ<0.0X3@(X@@?"$SO!%E<6B,"%91+P$0?DXL$ @;&,"4#'0HHP8PT
M+&2LBQ5V">.("R9,YYD5\-&+ 4,DN0"#+S:(\00&4K!BAQ%P&.,$A<1 C"I!
M!R6T4$/_#T4T44479;111X=RR$$%[Q, LR)FD&\/( QPH3(,DW -MEV D&\"
M _K3HCQ\NI"$BT0L0N*2>^"! @!99@C4@3F$:(@/);A8#(!*(CG.(@91 & /
M"5@8$0 &X$E#E!Y*FV*/&5*SJ4+6D*L$MIKF80. !URH8HT,AC@%G2EJPD$7
M,:*@ Y #D2-DBEIJ6(,4-L; UJ8#^  "7CI$>.D! WR0P@I9@GC"  @ *,]-
M3!J@ 8\5," VK,KHLZ^F6O!JB)!3<D@!14((+ $(2J28F(9,^G6@BVTQ,"%E
M+0X@Q(2'LUUB"@W*D"_$$,:0[@<S#/CC"XI!J(RF(LJH:Y<O_P*]J3$K!* ,
M M=>%=<#'V^EVJ9=@A"$"#HR"*(N@SG  P436:"YPR :<.'-FD 3[0L#9IC)
M@0Q6Z#E,%*0->Y?Z $AG4WX=V %9 ' #0!0IYH38A MN&.M1S3?GO'///P<]
M=-%'K^HJ>&;"0(P+:"QB:IC,,"4&9'\ VH$E8/M!KAM,8(*#99=(!)\,) ED
MVTOO,:,N)%RJJ9+%'/#5^8HPF"+0 VA,=K,E;GQ@AP^0F-;Y-69 ,5LNMK7H
MM9P8'^N!#B;PE5T>^J50.0;*%@P>^EN#X4:/9Q !$UY (A]0(05UR,L4<F &
M0!B@ VB   <B48#+((MC-]&,?3"P"?\&1. * .# $QQ0BR^P(0* ,%4' O4
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MA@,1B( B6-"8&31@!^QAJ]$V8"+/GF(FWXI"8@%#"/I!CP*8\.P*U@"&!9L
M,0[PFD5"VR\YG.!%M1B"?:0)!3D$80@>D/\ 0]?PA]X@3L$,!B^._N")JY;
M!>QHP!,@4(L(L*,/C7#'+H91+--F80@N$(0*GI6:-4#XOEHHBWRO!8 B@,(=
M6OQKGO6\9S[WV<^$>L##S@2  _P# /]0P\-"T $U6.0?#\-'!RKR  $TI .$
MGL %+I"# D"@ P)XP'$\?0$(5$32A*ZT3=S7@5 #*P>#SM:B-5V 1ULD! ][
M@!8$< $'P%K55'O 50F-F%7[)M*<SI8MM'B 2P>[(<*^-0!N_:)5M^?3SNK
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M(E $&> #EJ"![KN(,< $ TB!C<1) 2B"(3#)\*.).3@,)'@&-8N 2;@!05
MH\2'06 $$?" 1C3 U%& #!@!]I&%9RB$"5"$@7&! N0 P9PL%<@ F_2 3=@
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M@;8M(PZX??L 3^D8%188B2#8 I$ A3)@@TX$""1!7 0)HN(!C"":4MPI
M@VP?YC BB&G#O!AM&!6:I^M9C1V:@- QHP+ G"T)2FC$!&@,KQ%(@+ H$B'(
M)A+XNK"[:27!0P>#*'PYDE"3(!:[@K09DN&+!Q"8HO#H<>0AUJQ:MW+MZO4K
MV+!BQY(M:_8LVK1JU[)MZ_8MW+ARY]*M:_<NWKQY'X!9 8"0B9DM'/]P$#,A
M0AH HNIH05>J@$, Z?"<<3"G3@('-ZSL,?/! 1,#.U84J(682YT+:UP4<H#!
MBXP7?N>AP;J&28$#?*8P ($" (8O.<940?GLY,-*4PI@B)0$!RDKD=-)2/.
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ME1M8D#:'*&<>[/"6XD;XK$X\AG!&/"(2DZC$)3*QB4XLRP&XD(5(U- ,9SA
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MH T@T %YYA$!$)@@"0P 0Q P88H3E0^&-P@"#?0TCS$$80:1/&H0G!*)>T3
M6^G &0,R4 8/(,YR;;!"_PXX\-(3! L $+!)$+0XJ5C-XP59-<4!.! $-_3!
M=GLXZP1N<"H1!% R;9# $R(0OD@ A1";>X@3P("'&4PB!QZPCEYAFBT?I$"S
M16@#K?X$@,CZZ@C;^\U1CX!3!\S#IZ=H*\PDP%(?M"$(@O#H'"3PQ@_L8A.M
MJX02\"$+$+@A!5%Z2-/., <3:' )[MC#"Z1"M5VTX0F7* YPV@"$&VRBD#<
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MXE5@  A E&3P@G34$DMQ@1]4@2R @AVY1B;<@0$. !\ZP!^H# ->  =D@23
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M!?S3]GA!%?"!,+YE$G0!+[C"".3 'TP!FS+"F4;D:#E>YK!CA9U.)?@#)M"
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M+(')3$ ^DJ\)R/^"*YS!&AB"\/Q#DY!!/1K %X* $?^K9(1H<K"**$C 23R
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M T&X,(()M$&3LMB" >#!JY[^5'=Q3-D/@&" -C!(%$#HP [TXV*I)6(/<&3
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MH,!@;NZ6$.T<"2F6@';*# !YH!4 @0>:"GGD"+ T9-_\A0%F<$! X9T H.0
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MR@"0$JD72. M'@D -" *CB 'N@!../(EO0(#X.@/DZ+@B&!HD.!H"@X2=@H
MK"VN"&$31N >7F ,5B"F1L+%LE _(@P* @$.,& *PC!1%FMWZ,W>B*!+ HL2
M.S*H<F )#X#>$"RH"B#"0D0AL,47#^D:+4Y#N*!4"J+@1JXC%7'EG T0_XB1
M*?8$+N6$:@P"$V0  ":@%_!@!7 H1)KC!LK@Y2J(J41!"$8B$$)!%'91)Z!.
MZLA2D5"@ .9@!OP/%PWB4\(N!C2IW:" ].3A$C:E:!!2CMZN(>(1DQC3(?8M
M3J+K)6J!&E/@/S#@%.)O!F0@'@&+$*:  S"!"0R Z1X3L+@@JBI!".@M*0Z
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MI :8( 9.X$\NX "HH K6H ^NY#04Z:5(HA<\0 0DV)F^96QT0%A X0X0K@A
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M\$'-:LZ+1H)_%'  /$$&<$BK1B)^9* 2;'0-4H !B2^DF;HQ4H..TL$$*.1
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M48\!+54@ 8J#)7Q_].C @PD7M6$%!I'__/;<''4D, <0(FC!G%T,2 < #BD
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MQ($@@+PJPT %_SP0P4(O_8"'517*VM@,&  34FGX^!"%"YO<PP<F(I"*QBY
ML$F("5#5").[6G3A3E]UI/?2L04P8,@3I.83ZY5SD$''NB3D@,X'#[@ R XH
M,#!&9\@ZT,4*^+I$2"EANN0$#8!0(842&-RQQPQIV+4A#*8E]$&,"V"P!9^D
MK+#+%TG@L(,8:>7#!G.VN(!"A6-,0HH5 "#QQ7@XQ' " %SP4C3/HB7BXP1]
M>.!&%:*XD<0$'I0J17SORA'$ND0H4 (0&^R7K[L&\""P B*PL*$#-\NQ10(X
M^""("[@"6>5"%F)H%7]'A8?0(&'4F(X;1V08(7TJ B!+JS#@87$!/_^04=<>
M;JC 0!]11%##LI"NSGKKKBOI !=?'&$+&%,(P$$;SXBAA1P2:(+)K7OP@ D(
M$SG =Q\@U*$%(8UDH71S8.#A1B,K3) !'@VT\8$#&/BY@H] +L%)#^AP<H=+
M2_C3"KUVI=-(%7MD\L$/(%1!V K;-=+/0@_<((()$$@ 79C" [@PB@6([W4,
M;* #'PC!"+8))P5 PA L%1R<"&!X$?F"%KA0!Q,)0 !.<$2-D-"#>8!* !@P
M";YPP",&\*!H0!(%'B(0-2[\)78C, @+', '9+TD=@=JSA[,H +OE0$*)5K#
M);3EDLTLY  ""(H"M22*4>A$4OBXP&W 8(7_3C!& !"8QR62< !"]- -;)K*
MNRI!$ <0P@J <8E@"H"#&>K$BYTXD ,>@(0RU,4! GA "KJ'@0B(AP'P.(-G
M,+8"*P( #,L9R@.2A@_"N",H# #"$693B@1P(1)/,<,'>I, 6?2- 3N0A$^
M.,8ZNB0A2OO!)63 AUJ^"P#S@HH'#K(3/"S1+H0LI!AE,8,+9, *%UA#&TZP
MAXF$AUX7V(,)]U.TSW5@$$K0R0-X$XF?Q& %<IA! B @ 'S(Q%H2,L1"UN "
M-O! *J(PYTXV,3-,>& $E@)#$,3S/D$V1X!G$(!C5. 95BX$"4& PC?Q,0=@
M2G"B%*WHCQS  X(P_P0 #( 8!YY1!4(\ QTC'043&F&"A^A@/WX0A ].@9!>
M-*)H0*R# ;K@!T" P00=Z$(8CD ?^Y1A94-RP"""D 4)-$(2=P%! [)U44*
M1 .-F"*>\%"%"42A#\-T"?8P03H>K.  "+R<1<^*UK2J]8$",4TMQ)" XGP
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M "(0E(OB /_0)"4@>D3"+TBR_P:,2"1527='620.0# ,] #YD 3I(!6(0D4
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ML0G5$B0/TP<+ K&D8 (&($/N(#X1=3EY&06 <%__<@ELT@DTB D5^07WP+Y
M^A+I, -U\0,S< 3C-&QMIUO+02V%\'-% L!(E!73_!P+[#YZLQR;816[X @&
MT 8<.-4*1"7H(!7.04,Q,FPAT OP<0,ZP-(AH1GE7 33^R.!H&%YU+6YA0$C
MX(F%(PM?H!,:( 'Y:J8*+=S#3=SZ2&$K( !<(& ;4B4GH$H7\! 7K<-C.#R!
MJQ#2JP4W$VXTP@'%4@2-4 CQ@@_LEPA[D&-DO  "43-[H AHL -"< $*(@"$
MD-1.4!488,\\D?\#I-")%*S.N#T!BA K5@ 5A0")5K =(X [JIW4>^L<.B
M*B$#+:S/D9 #A\LJ8(0/LG",G2PQ.@P*CMPF7$ FZ34)N;3A)?XC4'$"D*A1
M?3$8\- 1I2'&6D 80E#*+>#+3O("-8 [F'$SQ,P%.5$BM>PU0- "*_B!Q/3,
MCBW-"= )*Y #RB$ )2 (6N!7X08$LK$+GI $7<!/EL4"2%!$C8A79JJ^6@ 5
MQ0H E7<!P\L'*^ $F[T&/# %>T #5N$AET>PJY)^7=L*5; &-$!=_XP"&A 5
M!V3A@W &LEG<CP[ID5YL>Q #:7-;\R "?,(!J.8#1NL!!KUA;; )5"#_"#E
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M2".5=%)**[44*@S$N,<'-X[ P(0<P%BA T),N ",_Q$F>$B4(*J8 X])#.
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M9((7&([!BAQ26&$-%VIX^,Z$'%A"A\+1*80+N$\9Z0PNR*#)C"KV:&-70Z9
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M'P "K*2/O P@F!* /10)4BA)ANBY#4B\C.0((N"\\)G)CV2* ^B TMS).3C
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M@34XVX&8@^"#1$A8@\L ^TN(.1"* ^ "'>BG(] <'>#!3M K(5B 'VB$*G"
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M:YO:@QOX,"I- ?T^XL!VB \HF@6([U,RF(\)Y0#!O!#9GL<<I$H(;-GVHA-
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M'+J!W(X ,6@#?"':S6^#OP" W@@",T% V76 $J !=A 4A2"$VPHK31"#=>$
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M(%0ZCFC!AQ4X/> "9_8M,86!&W+8H8<?@ABB3R%P8 =E$&!@U1XQ@+ %1'N
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MT(56;&"[8N;",_IE25V8>0([\ ,4N."%J1#X AP !:-"XH<51)#)Q,I$*1Z
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M#V2 (  ")FV "%I!+TP"/J1?S+$ %[1"%<Q## P!( !>$E"A#OC 92%!%GR
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M&:A +1 )469E%!3$6#P !P2!2-X2FI#!$3Q '_! ':!!$I7"-[*(#C21"\1
M?EQ !#5 G4)$4 :!&/PI(3Q!%Y1!EZS6&)2!"-0'$E#D"AR 6GX%2A3!Z7T
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M%<V!$ "G@$( $F"O%12!CG(-$,A U(C.!WPPV*S JEC&]-2'C>; V/C>#'3
M#@1.2"W.&?R "UF--./NKT;- 8S!!W1"H + '-1!";C!8TS/'J3 $)" &MA'
M6KB)&[1 )RQ=$DW(+65 OC  #6AP_[YH0 2D@2P8B1PH0A)T@0.K1"\PTTD@
M@7B@A!/(Y@IQK0?0@"" 07K2L V;M$K(PF L#T3I#YU:02=,00?<PP1 CJC*
M#A,,0BC4PK"\,S! @"Q\ 0?XI@I%#1(4BIT, @J4$ YDPQ4LP8<J5_ " +*$
M6IW2;1K,P3HJS1&D0)L@\#VDP E, !IT *=,BT3"PR1,0 >4M8%B0 \8@$QW
M0"VX$!*L<0QLCO3.0P0\Q@-D R-/B%\7@KG<0P>@P2PRJ-:T"2A]8=;"30%4
MJ" P 1?@*Q 8QBXX@@4(@ \0 0BL@+5\4B"HQ0^ +;V$SU06@4'@"A]<@V4
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M=P ZM$DM8((,@,%G;-1ZW.\' *(25)\!"$#OU$(9G $1H<$/-,+_6'# $^0
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MR>I=?/" 1XBI'5H>_1IV;-FS:=>V?1MW;MV[>??V_1MX<.'#B1<W?AQY<N7
M'?2*4$6XZ^6R]UR=?MVV@WDT3F ?/<\%'2**6'@_?J.4]-WJS;=W_QY^?/GS
MZ=>W?Q___0,^3+'/G_L!?DK[[[@2)AG0/ <FH (0%OPCD*H)T("0P@HMO!##
M##7<D,,./?P0Q!!%')'$$DT\$<4455R1Q19=?!'&&&6<D<8::90E@AS=$*&
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M19@!"DZ [FN0( $:%,M_"5&DA_]9X !"7%+)-G'U AQO!1CB-@*C8D VSL"
M'6"B; +[ CM\9>;&2F2''6#N%/9@5^G6KL([<4!V"7W@+SBY]4Q"@B,,$%J-
ME2$)?)"$F2-PA2[LV@%@ "=$=A$$=DQB"4'X'XC7<(E)D#HL<KY 40,9D24
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MT4:&+N612>;!'0\@']C$";*(#0I ,AT@'>AR#E, N732 SI'(G:2"0!!"@\
M-&WF $(2$)B@$!)GVPIG'9>3.9O3.5TD'1Y.0VZM-P)0-W#P'&?D!Q[F.;O3
M.[\3/"5E'K[.0AX@]GH#":Q [FIC#]1O7])!$V@S/.>3/NO3/N\3/_-3/_>3
M/_O3/_\30 -40)L3 B:@:-)'(UY3-PI4*0%M0@S@0&OC 'Q"'^8E(CH@)U_#
M,214&@V@_@841$-41$=T1:B3(?I@ ](!V70C'=K )6U"%F;@S;J1-AP/"G0P
M-NA&.6-C'@3_14*U1#4_E$2'E$B+U$C-XZ4\XUQ>ZES<PA;*#.+,H KVH Q8
MX*68Z$H!0%=>RBY";5NR= ZVX +.JBYS)7VX@BL<XP%HKH7.@$O=(DLA DV9
M-"OHE!"H+7U.PC%> @*N= W&@$9/8DX]X\+H]$@/%5$355'?T0=BH VD+X\D
MP - (%KVX :"( (D +ZB!!2$@ KP8 C:@!%4 #AIP(9( !^Z !/8H:648@W^
MP _JP # ( (PH2C#U!8_X %NX%&?  -W+96 :P;*P_% H0<@8<LT 0@FH0 :
M]52YPEU6H @D-0B X A"  8>=03V0 JRX)S*( B>H WF9!>0S9&"_T 3, <4
MOH *R( %QL2WGN "9"$(/*!:S28#@J"E+'11^]5?_S4_)61L)* **N$+/$;E
M/,X)I "^S,R%?J 1YL35<@!01ZL-6F!Z$J!%#^T@@"D!N& $$D #!"M,Q[00
M9LL!YF]@>JP'6$ 6RA  <. /KH !#.%/KI!BYP0)9D"I'( 45B =7"YE2Z$(
M@&!\F""/3& !Z.("0N YQH:REF *<.LPQ^ *PN4(8,"O/ \%YL"N<$#9,$ (
M$N ?W =@SQ9MTS8\'T ?F" #6B$-KA "&&L%8B"L3-1AK6Y%P\L'&D%?\: ,
M)N'XB$^T0DT+T$^Z2B%,<^#@@*K5Q."U#/_@$H1(OFC0QYQN5.)(RU8*<%_.
M9ZV@!-A.NJQ@#= !#T1@2P+PXO9K3GZ #.[!/0=B#*H@7-B H Z""Z9 %OC,
M <+M!U(@"%!7;8>7>(L7_Y)/#'C*##Y@K2IB!R3A9XVK81\ \&IA;WN@!.PJ
M(MK+P:3M('8V!\SMT^1@"W(@!@!A< 5F$W(@ ]A!$F3! P"/!G'JS,*T%N27
M)S)@!9#@$M@D4QXB!#@ !%9@K0I 7AP(.G:!#%9IUQBB#:Q. HX %7LW$7;W
M>J9KQF!@>8V7@SO8@_D'5DZ@J+R@"EP-,W: GY@E'2+VR7;+VIAD#B+A'IZW
M /: "((OPB8, (K_X!*28/]^())*]JQ$X2J&9 4.@ ^R8,UXP!.<S $N]^G>
M2DS;P'[VX"E1XUWF808HHK8NQW-^]@H3 /M2;@6D:Q3F(A(6H 2>( 1B90V
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MFU[O9X,0VH#MQN82ZOT 9.%1GS(=HB %Q( N"D 4UO_9)IP >,%$%.#E ;H
M"*(@SV" #M#!6B.B2QY5W4M $/+UBHN !F8@!DR +!R)R[Q]#6[ FZL@'?Y
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M8,/1'O 9TAF@J0N0[WXDSY,)B+0#%P#L3BR\GWN@H0,Z:8WE.R"4!Q@ #1=
M@Z4[( , A,  !C"M,". 7HUT0*0\N7T',,^ )+R.%",0:=AL,%8'3$ ?1XMO
MV ZPP1N,H* ;^<?IP_9Z-(2@ _%]T 'Z7EK%A<#R_[@'/DH+  %T0".O3[WB
M'G!BRP?6^)]Y?0=L<(%_' T"(6") [Q\$\&;OJ#[EQ1Z!WT<A 8"P!J+<WX
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M '(0K1G0"'S&*1$0!1G )!IP"A?  <?J 59@6H;"H \I"B @"( P=<PZ!"R
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M$4 #;B "7. ZTI&GDZ-7FR,!1^ "'^E-V5(&^T@#04PB!?89,!0A5[*4E])
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M,P#FF; "SPP ,,0F-5 "!&M1@G /&0 W&/ %:&#CC/'!.&T",F!>50/.5_@
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MR<46F,>,_ [Z888CP# A@0 +< "#1C#132-1#A1HCQX@*[,."1W@@\-=R-B
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MV,4OAG&,93QC&M?8QC?&<8YUO&,>8W8-1(A"D*- !Q4\P <>B,(1I$<0'Y
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M/A,8<"R#)^""9Z@# QA>^UN E/TM:/2$I>B"$>B "4B!)3R6.7B&*+W5-Q4
M*,V3"OS&+OC_@@ZP7^,) 2I@@1!Q -AH#@:0 D P@RL0Q" X@J2="S-8@5TP
M$@?HA!X0O?1L@Q/H !] 6 !> ?L]QR6 RPD02P34 @_6@2)) BSL 2W@S1%
MX4Z($(?A V#H@'L@A2^XAQ0P 0W^!T>D8/L5 $(XX1P8WQSX@_H#A=@Y" '8
M T-8 8.X3[SY@S!00S*0@0F0A3=%@C(PA?MMEQN>@U'8@'1XABJXWR4;D$G
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M#L"X7P81_TP_< R3NL:#+S@"@2B"GS0N#)V #O (?%#5![B'ZY,>"'" QQ:
ML8#%O]X(5=6(YCB QJBV@PB1-1-*A',  *B6 [!?Z7& #D@(CX" #D"#[G4.
M , 'V!X(QXYMH73LT!Z+PJX6Q/Z( ^"VL6CLO;37V(YM@8"  PAMWR8( XA+
MZME,US$>!]!LCL '?&CLQUXST>9L4S, VPXVCC@ 9YQNZ?[NC-@-WCZ >^@
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MT.0+T.0*1@=*-#5-G@BB9($;\(Y>V-0G\8H?D/^ -$B]#C  TVT<!Q"[AN
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M+7KM>]WU@D2_UWUO33CAWP& U0T#)C!,#ZP(]@XX"WPYL&U!$H$#'S4?!_:
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M6:1NN+:]^^QA!;1;TGJF-P3B#7 W@Z3@_*: 2",PZX(+'"2 4/_XH2E-;P%
MF^(4V#)4'!YNB-?DW_L>.8Q%+FX1@.0!'0_XQVL2A(G#',!*%C?.]7SE"3Q\
MT92V- #LO.B'3[O4T<8YO;%,ZZ-3(-\@&7G.1;KNG!_:#TF_.-4/#7*Q9'W1
MP(Q"UP]-9V>2O>QF/SMDFHGVM;.][6Y_.]SC+O>YT[WN=K\[WO.N][WSO>]^
M_SO@ R_XP3_I !TXB2X%,(&3('X":)C X>-Y #24Z0 38$('&/* 'F_>+P[H
MP%X^KTO06[X#H/>+XB.O^<C?HP.*?_SC71_/SW< \B=A2 AZ+( >0\7QCC<
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M$@B *$C %2S!%\B  /2B*^U!)DA"+XK"^@  #]X &=3B/(! (72!'X *(9A
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M(70"CZ2L*+VD!&MC'1 !#^A 1+9*3P-"%QR$!NC"LUBU>IYE5JM-*.!#+Z2
MH#\%(>#!$Q#!"YRC3YA/37 !$-#!#:3A\A!%5(9+9C9U2,# ;H-MQV!"ZSI-
M#Q> J/!EIZ2 &%!!"HP &Y,*66XD_)QYFL?*PB!VX.' <,,'66;Q'(JWG\SX
M&3"$R?3Q!1S1C<O(C"^,2/@!%-2&2$^$%7=!S#1$)_0#IZ0#*)3!0:IF;>!(
M%@A28"Q!/P@X%PFO,\KWK Q"&*!)7@\,@:..-L([CM8&&X5&15Y +U9EY0S"
M8H=[3/^6B";0,4-TB$CWA0:<MY+P1XCSLENO$!]8=(7P@A4P.">$P1G@MP#H
M-TC_ 1E PA^$^&#41A'J0P'PP3.T@#.>@0,4P4&RL3\P9:R#0C\(@1;P02OL
M]PHM 07H0(SL'DBD,]'G.QNM@0$DP$1S@BBON ZHC<Y+1[LCA\4/!A]F01O0
MO,E00")/A$"CLF7?>Y3._;L3Q2YD@J!%PK&X?+Y,--%'*Q9["[\CS&;L 1%X
M !TL;2U0:Q1X0.P2C_ J  =.@ @H7@:X ?F6P,@Z0 5PLD_(01FM01_4P/D1
MP09,0-9"K5\X@1'Y1"^0@ ]X0.<+ @UF*!&DSP_$  W0X![_//H!],(D^ ":
MX(,/&'30],)'E*P2R8'W8@#G$P4.] (-T( (N&0Z_&[+$0$-"$(+1,JUZ]"C
MSX,(Y(O?4NNURSX[V&<;D< @O3](. % Q*#Q) $ )%<  /!!HL \#U$\>'A2
M   #(AL29M2XD6-'CQ]!AA0YDF1)DR=1IE2YDF7+E X&A4F3$*:_9R :^4M$
M$8"#+GX^9!0%RM4S$VA&.N@$%, N*:U85**P"5 &3L >I&@%)2&&?CHR+N'D
MYTQ&''_\-.J19"0?IAOW_"$C#Q18GQ2>$$G1;X6#)116] S$"P5)!U)1\/P!
MBL(S,:9XBJS$%Q\?7F4!=&D%2-=:_P=S*"B)G)'!GS!L 6C0Y8DB@]6H/Q[X
MB7D.KQ$E= 4!-4(6KQ4X+(5AL=$!!@H@_*P8_5&4[UI .F CHX6/S2!2.-TI
M4,DZGB U'!#*TL9/(<TS1?[(U!@3F\A[I+#NZ3:HQCVY09DHXD<'/FS^\  !
MA#*@<( +IAQPJS"1&. A#!] N:.G09YYBHT41EG ."42X@(4#D,RT(_"$N0E
MJ -/,&VXA%3SI"  :I'"CR""P$.,),X2#H <57#)QY.6^U%(C2 (<LB/(##)
M 2-1.H!)CYX\4LHIJ:S2RBNQS/(CF&2B:1";&LE)-)H"(8LG"'Q(H1%."!/)
M@4 &B'. $?\!J(1-3OHQX8*L6L&H3E[ ZLG#TS1" I2W0J2/(PP^_"&^!&KR
M9X!GK"C +PH^L'0)4-PQ; F@(BL!G49 ^2K*C.X38H)'*])%B M^FDFJ,3=B
M(#X+$H+/DP5:)10DV5KI$8 Y.+DMDQ4&::4/WP0PC:N-'OARBA=%VL6VGR09
MI <MX'0%#U>RPZ>2 ;S% X_ EO "D#\\T0RS$&L!@U1>IN IQET3^JF*-:08
MH)]2]LA$!\T\H$"'FFYZ)@@5WD0P$$Q',C21TDZ#Z0LJLMCDUEF[ B41-\M$
MZ%(4SB*#!11YTB ^7@& #TP\,-G@ 7;9>F"6,)[54N>=>>[9YY__@0Y:Z*&)
M'M(!;,+ S('@)L'!PYUH6JH^C=;@ )2U$O6GCCZ><*_.J7XZP=)!_!"V$D 3
MLM6/?D:@UM8PJ W)L@4=0 ,"V7@Q@0JTTKBK!BF2%I3.!/N96C)_W%DN!%D:
M:04VD/@D8K>$D!C@"T# ^ H 1J'>2 .:$W(47PVN?KPCG]ZJ38=T,I&D""F>
M\<T!%3N22I*2U).@D2RNZV&!L!\82KM*_% B!P$$@""\+*#HA*A6CC!) ,8=
M3^A>GNC#@0@I_KU/!R1@!]2_5JYX0( 0-$70,L,_6H*73:C@P428R,AA$ HH
MR! T#L/C!$20_$*G!ZPO': H R!ND!V*_Q2@12R[CR?VA+P=T8YB.2O:!3&8
M00UND(,=]. '-8*#F*!'A%L!@"P^Q).&G8$B/VB#"190 /B,PG0<:1A",G*8
MT+@F:3XQ44(4U; :) N'%0'=2,Y6BH3L0F#WZ8<?LC"G%>!CA$,1 J3^DJD&
M]<DPQ M,15*P!8R$X _5<Q,A.)&%5@0%!W :  4X,8!=&<<=^."(:SR!JY:Q
MBU=(X(0)DO2KN25D,"O C1*BQ:85-,L3%J0)\?['(%T,H!54*%4I\-&%,""D
M"!$2ES\6],@LJ& /AJ#DNS[" #  H68IX,6S'L@R+O#""CU9PE<"9@4!=(%-
M5J!B&%J@D1L"8/\-9?032,XR %[ <0")$.%:AB)'"W#,AU4 F1\04AJHB,4?
M<.0$#5FT,HKHBF4)F9DGDN" 78"B#C4$X3OA&4]YSI.>]=32T5J!GJ7AS &B
MH #4'E""%%!@!$@1H2M,P(1.9"$2Y?2(4A"5$$B>D (]N$ GR0 (%/9@ Y]A
MZ )B-)VTF<:='8G+9A10Q@\T9Q,&, "$OI $;.3S !GHAR^Y,P(%#'0$ITK(
M 2;0!7^8('H-$P,3B) )=/JT*?W"FFO(P 8#"-0/:?!G'9B052:PH  /0.%F
MV.*HS1#!$%T2R>O"  @J2($,&ZA%)FI90-\ QP\UR*H"#'"!KH2&J1/_;*8(
M^Z$$?)0I***0PO HD-"L,H00?N#*N(+E)CY,A0E6 V?50.$)-K E'4\!1)KX
MLP9=C !&NO@*/BSA!TG<%0U*22P5T.$QGZX3JR\U1!FT, @R)(&* ] ?)Z9
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M1M;0@07,FB(.6 ,:%O_P )<:H .!)$D(YDWI81?[V!T)@;,3(H![++MN%Q#
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M/.$P/=GS/,U3/-L3/MU3/=%S/N,3->^3/.US/^6S/_&3/__3/QO3)1,.+M&
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MW;9MX99MY?9MYS9NZ;9JE^,"VM -KS8C!, LNW-E!7=P";=P#==G5I(-)D
M?$0 I(H-ENUP)7=R*;=R+=??ZI)Q72($D/( +O=S03=T15?W+B M-;<EK(X4
M3W=T69?_)?9- 4P!)9N$":XM!)C O/0!#63!!-A"5@M@$-HF(_C@BCYB'O!
M6&KN#SJG(PZ V&!7=CG"%I@ [:(E$?:@$=@'2-(!!+*@'URA##*E)3JA%)($
M D)  5X$!W9@:G!@#+)7(YQ N2(A;A[@$I!7)0X@'U:D%F: TDIB#5R@/IK7
MO$[B ?*AW_!7?U.B -8 #&SDF%H7[_XV#E=W)?X!*2LX@C68))P =D  AGRD
ME%   AB%#!) A'1@'IX  O: #CIJ$#[FI_B@#NBN4+P@9QA@$#HEE73A)@0!
M@1-B#@9@?C<L$6I! M[7))K-!X*@"HS/G(+U5XHD>0  >6P7_PTH0@"X(!*T
M($G.X@-"H"#.(@WJ32-"((HAX $XH+C([@+VX!(<B2.*;]G^(4F2QP%*P RJ
M0*_201/0H-XBX^BJN/@"Z>!H-R'6X 6L(%@=X!\HXE"?1 !$8124S6^-+TJ0
M)XM!KHJU[0!*0 *J8),30I _0HV'(.DXN9 /5=M 0B59V8JC.(H!H([[=H,M
M^ XS."7^5G5MN9?;3 I6X +@SMS@+GDHKJ\>H UZ:@D:(0PV@ $,X0/2$ +F
M( Q4 !]VP 0ZH.@ZH0ZV^44.8)N3I *.E^P03GF?Y &D8)$+PGS1X$6.CUH&
MZ!D(I.9@^ >PUT=^H']IHA>"( ), /^"-\()Z* #;F %]N 4?* -RD Y'  &
M0($7GB$P9B<(&N$+T  '#,&BOZ!'#H #_ED'> (#B/@ 8$ 3,"2.[2,%(@")
MJ\L%H.  >N$$G( ';")F8L2B-^':#BP(W$ YTD$,,N"B.VH.7,$1>B1:*&!&
MSF -% $CTN$4:I@F?$ 7&L,$"H(!,B (OJ *GL2I,4*%(4 6(@"@DZ"8*, 5
MOF X/II&*N4C<. &#F6B"R!^(V"M3T@04@ /K&"J XX+V.&%((40A@!V3@ '
M2"&I/<!_?5E+_K84<QDEP//J&KNR3<H,5L#X/KH1\* ,"B$$P(!&0DFRA* #
MP$ 0S. #=H'_ABIA%-:J'\C@" :A#+BWT#KA&32A$6AX#_9:MY, "6YX#< +
M!#@%)!IDD?=OJ"_Z"%Q#$\K@F-)! @"!!P*C>H_XQ5J"?U<D'2* !1S@!FK)
M(]9 # Q@M&1!B0" $%8@D$B:)T2(0[B@%,XB,#JA4GIA"!+@ 6*@/DB:5S#
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M(5(" $YH .KC1051  _ 6%%PH\?!#$S;J.S[-T&M-BP<D"H$H,@00#"V)-
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MR3@4/V (*Y ##\ !S\ "RB=%!F* .G !#X !>% (#Y%%0O"+J?]1!)D@!G0
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MRPKRARO##H*0!)]:"%=5!;PQ!(KP86+M M:%&PA( _B5#FT@"&*('7TQ U&
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M'7X 4;0 Z< #(Q,Q_A+@' )#9< #$"$4CR6%8XX:E1 &!I ))R"H3;;<7,,
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MAHPY8<X J!0&4J8@659$Q5G6[%FT:=6N9=O6[5NX<>7.I0M@C8@$(M?(D/N
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M$,$-(B& (@RAGB98S!Q&@,H,"((*;K!/.H# K[,X@ ]B4  -3E  >@FB#T
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MU_W=O%-<M[B +F."R$5=(P5>BD4"8C( %W51 ^B$+/@ OG6S0?@" W/>"3
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MNF:[)0^ HA_ A)N8MP48A*0P*(1")C[P;A?PC'38!)@V"P[0(85RM'F+KR4
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M81Y\G(<9,MP #FM[(0\ 0PTN( K%DJ(0 A"%%00 AA5L? 8#=^]$*U$* 6"
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M*'A!(91 &P2!$?F1 <2 &* !/C#JS[EF";P )C1-41F"$DR4$\2 )IB1GXH
M%;2!QM45I5IJ0C@'$?1"!&3I ?S>!643![2!"?32.&D"JDY<%(@!$0C"P7G
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M%XA7E91!$K0I'!AQK*25RH4 !WA!#43'709"FW%&*2A1QF;3'P#H T! >";
MK+" MTB77H"2(4R! 12 @[% K;Q)BMQ7"(S_["8PP3PGA"CX 8T] #X<20'(
M A#D %U.0,5UP4GABCQDPA/\@0GP@"1PV:KPP!04 ;]P!@K,@43#:"(X6!*T
M<BGL02,,FCY8Z)-. 8BN  X80B1]S!'P0"1U0@_0TAJT2"T$ ;N 01TL *Z@
MP /X "A8 6"DG$4; HV%%B?D);?,P3/<5R4\,2@@YB; ,T+@@PX) 7,< #J<
MBRQX@0R@0Q3IJ= >A"WTPE6CP0$LP;XQP!_0ZA,!9\J6P=@PK&<A="=\ 0<(
M@5-A"0,49UAU!C[P@2>4  CD6R!X0F;B,[GA2H9EP@K@PP,8*# L '*O@"BT
M@F?M@ EP0>2"J!74_T(C; )7^.M ?#-H,:QRK7)3X( N/$,0G,*0S$?*R4 G
M/ ,@:,&46H21($EGG D9R( H0*P#,,<<D.XQ)T"*5,%(I0$?1.[/= +I$OA!
MU$*?S$%Z 8 V5T$1-,()2.R "T!?HZ?:ANH'S' 54+@L@,!/J9\=]B$X?@0#
MM,C74&@!(,$S'$$@^ %^^$'6%748 ((LL(F;0( #O, (("L(!$$6))$:4Y&W
M: &<0FI"%, N> '4AL%]1?)RWB6G.M<?\-"$#J]_@G$!$#F%^$<*'QJ,*H%/
M@*FFJ9PHC +,_2LHN (:^Q82H/%!X, LY'<C/,,D)/=$#<)\/4 ;T(,AU/^
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MC3)5*C2J(2O3"@>51@T$4$**%2Z@[FAE@.X+(GA(#:],TMBJI&<:X*$'+0#
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M$*E.@/^.L(_A1*.N+)C@2Y];P]8NDI&-F*$0<SK)R)[!@VUA925ET,0S:E"
M<*F$#_\C'1+\$ 17F& ##N"""44 @0.0SWQ?XD,CAF"&B6$F@7,HPP94]S S
MGA&-:53C&MG8QJS(Q0HT20</GJ$S?"RA+VCY 0]R!:$Z3  ,>(A")N25J0:
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M%E%(%"QR> *[%=I@!)V=+4YP@;[!4@%Z+!<"<C@%S_Q;S%WD,25 5HLL!"$
ME.JX[)W>01HL7UR'> %H%>Y "&;4 Q5<O&,8R,()1A^T#C2S)PJ;@[.")OH)
M9. 9NE[+;ET[MN:JQ0%R($$!YC"*H7\%_PF1*-T-K"" 3BP\CD4PA#_P8(($
M.. &4B##B_: CBQ0 ($&D4(8?+6'%^ !$]R/02."\ 'J2 0/DG)*ZP@"<?3#
M#P@I"((5./P #H @"(IH#U(@"UP!@;1B "5B,C3 #&@ #R2- <  !-)O*^RO
M#(:O"S!A C6'$(*@U"9AR3( _4P! )P@!1HA$LZ)'5P #^K@ HJ !WCA&:8
M'XI $R*@ 52I -(A!?" _R!D"!CD"*)"(F"M5)S@_,2 !:Y("F0P=K)B#FHE
M)1A $:* ![Z@!40!$V*@^JXO?GQP!QN! IX!\K"B #A $#B@%-A-%F8 $MQ
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MK[D +#>E8YEBD7:*+R)=QV5; 0 ?,D"+)Z&GMP)")&5I[V(9 ZB,:^L!#(%
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M[4S ];7T$LZ7!OE@!$H@!=#T?3B@#LH=+_(("6;@PO)7>E4B HB?2CNJ$+C
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M'O<(;12#$A.9,$_ CG(YEW19E[&V:]&7&F#(/SID.WWI !,0 UN'.K-C&!P
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M!D><&BT:-:BJ SO@"D\,W4TQ&>=AQ4_V#!$0 0]Y&":[!PW  @]B!;40 35
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MK[1!$C1S !+*P#UK.6 ,5"S% F3!UB/BHU9R0&RN^% &ZRKE5TSTJP>@BX]
MX NZ:?\A17?I%*T1U=!:'*E$#QK5$3E$0, GV(,+/J"!"&AE%VX +&Z<T-T(
MB <).*(!UW[2AB%<:D:3A9,#;C $&@1A>AW!08/2(8&Z>%1A*%E'7UN9JQT
MP04SH,D/VB#;4@0/)D60 %;!("7/T& (-4C  3K!UB&H((PT< $>WLH2F/4/
M--4:ZQQ&6X5D>3@2$-C#"VC\A D7(&A[^4 Z_NJ!*(M"$!!PVAE\6*?&'( +
M;)U!AOBWE2(X%GS]$U4$2<, ,(B!!H)(PAHR0&/! L!I0["" (0T6<4\X :R
ME<+E1JDWD!KET +NR1Q*09KY"AAOV7N;</>PB=Q22TTNJ!?_#GA0KZ$6V]C'
M1G:R,;,? S#A'_D1W>A,UQX'^&!'"E"( 13 AL4:  T"^<ML -$I)X@*,S]
M@T,.8 !NK:$#&/&! M)=/!_DPP .<<)+'L#M!S!! 1W01R(#+B<JL %7:U#
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M09E4]S>N^FT?S!] ']BO4;6Y_W6UBUWIZ3B)"= ""%@WT7,[TE& X*$Y96/
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M&6!9%XB"&*"3 Y@R#\"#ONB$(8B"@-Q&#C"$32 D!A#:/@ "-A/<$\&(.8B
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M #R@ 27=$!EKVGQ@X.+*@5XK'"P!F? !J4(/*NDH4-(N !Q\3@C@ BS'CC,
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M$1Q0.1J X%O_."G8P/JDB0YY13-OR59.0A,!*^"K% O00 / -#8:1**,_,&
MX%P7KG@501.WTTP18E><X;6!!N,KF%J<$($AT(!5[)+5[@B8@:D5#P 'R$Q/
M< "&"H(&",GA G,VMTD59(E.;@N1]1 7MAMD!! >"XG"$H(!090$10P WAX3
M4#X:4,<!R.1CSZ(IS6E2LYK6S$E3GA*"FOW#*080FE(FH(\RVD)"ATC( 0Q@
M "SZS !:N$ "'G"!A'3 ,0*8 !HZH(:0K,&=" G!/!5R '&B(50=D) X#<"!
MOX4 (0>@#P!"8  TQ"L$^NA !WCR '4^C"[ZP)(I.[!.\DW  /,\_X -'(H&
M =23+M7!9T!-R16?732C$?VH/5L:*@RL8#\/^*C5N/ !Z#W ICM9@]$.L1];
M.(LG.1C7/!U@T:;N9*,=F%0($A"O-?!OH =1R 38$-.-4A2=!R6I/N+3 00)
M@*HZ>2KY+%I0G4 @I3E8P 004E(MK$$Z#L!G#N;9'9,V\13*VHE7Y]E2@"KD
MKN1#JE%5&(@1N%,A*848/ATS@7')0$)<@!M_.J!,G3K@L@K1:4@FH+W#B-2H
M&UWG:@4P5W3BDZCZ&"D$]IJ0W.83B"%I:$[$:<B\RD2T.QG91 'PCYFV])[Z
MB"E_2AK3 ^@TMVRPZ5_%*M ./)=\9Y7/./\3(H!_T#.V$\4'^4RK49PZP*8/
M>*EV=W+6 P2TGX9<:P?PH=,U[$N>(3EK4PAKRK!BY;70O2:"$ZS@!2]8I$X!
M9U*(9C0(,]B:81(#$5[@Q@HS&&6.TLD/Q,7A$4N%G3K; QZE>8#? ,#$07D
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MFG&3-Z794"#&^*P!%5P"KX3%#!!!!C3&!( !$ #"343-$Q#!$&B!$[R "&1
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M)FA!#!3"K/":*)A 2-CJ>NS+B;R2$C#,37! 8\Q!KFH/HS !$+#!L3)!!P@
M(=0(8?R'0@0"NHJ$PD6,!AC1 80%&:1!"(!43OQ &23']' !K4% M+H-NL0
MKR!!1'@ JVP*@&!(BV5@A?1C2RC<'(I"CP  $6A!G"S #*T :72"%1"!%3#
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M+XP:^GR! M0B"\"2B(!-"_^2M ! 8;1PH2H$(2B!E>R %3"!15_ #@#"(69
MR]F)I.I$.M#*>ESJL1+&IIH 0JPOP?S2\[8C -3",Q,)$I!!Q+%J2$@L^=R
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M=3)(\6"Q?@21!EI(%K@JI'Z!#.P!6=;"#+3 'G02++F(QRJ1!\' H 91"NA
M"+Q+R<*88?0R771="'PYS,X !./0!92 J>4$$AQKC(=+/)W;K$Q""/0!^X*+
M(OA )/ (IJ8!C.$Z*5S,[EE,EQP&*0L,N&0*:6P'&;!/"4Q93G!&RQ1 +[RR
M"RA)!!Q!"$@Z%JW!'ZQ !R1JU'Q MYQH0NX'#G0!9<! B/!!::Q&$G! A$@+
M1'2 #RRO3IPSR<Q!LY2 (3CN"IBQ$L!0%3!(#11,&B3-D:+MYLX0A!L6.=>M
M (1,,<W/DZ;#_Q>P0 [XJ8=_/=4] -"4.%*<J53 2 HY "E\2P$%01 XCKR
M01#P$3YP0!L$ ?QU0A!$ ";PJ4+ T$TL=$-/ZD.[Q]WW%,@&@294 4-, JW
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M%.[IA XZ< \F1"TB*=8($L00&<PBIK$43H\#4K<'()P-6S2YQ&+I^CXMZQ@
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M":@ $*@@'T3@BDF 4:PWAZ5X9CTT/T0!#\0@"M 8C47 N/[A9*(XC-4V1B?
M> &  T@@/),8COOV:._#84QD=O4X<;66( O@ 8[O? .9:/DX0#SUC1/_N6L5
MT)'3P897&)$?66=YV/D,P$F0]Y+Y5JD&,D#LY(,].6WOKXGS@T)R9)4CQ%$
MN93C5@-;ICZ*P T:P -P&9>?8%](&9:]MDC]-#P  6V(N7R8S9%]N6B;MOSF
MH8O9\(N367 7&53=&(RCV6"#%D(LU9*O^6/_ 5OT@8YKI4Z8I'*[.8XE9X3S
MHW?VI8#/&6NASI$/I5XZ^9VQ=G]?I .8(!\4  T28%IZV9X5F2O]] %@H&EH
M@ 9F( J,^94%.FJS&3]$09.D(HE,0'L.V9H?>ET7,IRMBQ#$C0$^;4:@6*,W
MVEP%4IUG8A<(XD$BXSAX.7A/>H>K.94Y@/*"_P /\$ 0O*>-67BFEU8Z=;0#
M!+ B\QBH<Y8E&7$- (& ?QJI!SI  5 $;"2CH?IJ$W9!&MFDK_I9)SA\N;JK
ME76!3,9B(X9-]*>42%>L:7:0\Z,(AB"7<WF7/?BHV1ID&Z0QTZ$-:@!!_#J?
M5AB9[]I@B9..?6#P'L:J!WN']0$6JU:P%SM?\=D^D(4QPSJR;168H<H'B "#
MMF>)%H!<:AJS<W:R.\T-2$H0/.""R/EI[9JT&7::2?A;&* -FGHFCOFR83M5
MR5)-_\T=$.L&TD  0,1)H'FW71:'\P,#V,$#&D 3: "7:7A&1ANY3[9;\>,!
MB'D"T #6UF5&MEFWK?][4^434Y?-G,<[8TW;,F4ZO?]U>RFGGMV;L"TX=>=;
M8\OW)B'[OJ=5?:/LM?G[7/=5G"G;H0-<7N7WO[GYP&-UP+7Z0/:;P8>5<1D0
MP"5<6Z.70!Z@I"_\8-?[/A+ G3O<7.&[$JM[Q/'UP\$EH%'\6?.[9TN'"QHA
M\*H 'S! ='Y/9=;  _X/9]:$*F@/#]KC_9+' =(!XL!#!'*W8QR@ JP,,28@
M'[[P ?H CI+F ,I#R\ ':*0)8ZA\+E)9%D2 R/D[<@ W0RW<1_C "@R  \A@
M PY -3)"9G  <:Q&ED(-(D(  Z; N#SI /H PJ;"DA9+:P[@!G*<)HB@T'W_
MQ+/(7&/X7"I8HN<274#@1@N(? )HI\67]T \FD!RP,#OX[H88+@N:['R)@,$
M03T.H!=B0! 60@#FP05XVD+VP -J/5EH8P@F 4<X@ 8HV4U@0!"(X 0>8(MC
M@*YKI1=<H 82X#D^((G&7 !D@09J_0 F@-;S219 X!F&P)D!8 [2"@(.&P(<
MH!<V/4WZ( (HF0$RX-N19 UHH82(0-6JG9)[H2+V(!_\0@%\@ 8*@6SR)A_Z
M@->OY=W'W >H( H4P(^$'=XAPG:^8PWZ . E9 Y"@O >@ AH@(0.@+-=0( /
M(*-"GC"<( 9.P7\G  S@_0$(*>2OI 1.P;A6'C6T_TP66@(Q#B #Z*'DW:07
M:  0A&("F* 7X/WC8=Y"?*#DDT@!,D ,!+T^KDTJ.  %+B(*FETH&( (AL!N
M'H *J #8>WQ.8( &P@<?Y(#62><KAH (=MD'%.#5"V(-7" "%FL/:J#LN[@
MYL$#GH (Z O;W[VI=^/=,>C1DYE)59H_N%8_5NTV+L(N'L #A(8!7J &B(!;
MA+D/N,7R 0$&O".QZ(#KO6="_+X7>L(!#*"T_)<+Q( *I. .'H '-L$ =H Z
MIF(74'OGE@.B,(([%(&D)&D-8J &"GXV.N$+F*")Q/TANL,O%"'J,X4+GH )
M4B#:EV $J. 2<AP'NF [YO] DHI@!@ A TRB$ZRL NR(!S"!ZW-\#O  $&2A
MU(!&!(@ "%J $+X ## !#)3 @P!"C((7'P XZ&6E    7 3&* C@QY8D"RM6
MQ""&"1@K$#J5.<+!B@ ^9 R$++ F B .FQ*L<0&("! 6#_Y\H9,!(H:$ '#L
MD$3E$HN%/^I8L%@11Y<O SG*&J) 40T(2/ ,(2(F 1(W"F[H ( $$Y4;)@0L
M(<.&0Z0$2-NFJZ.%#HL;'Q@8VD0EP@<(#170J((CQ28#,::VQ:C 1<$)/B(4
M6EAD!J =HR[L^'*D4Z0"#GR ^0H@W;,:C<\P*'SCV0>%%AUD>$(%2)H#?011
MF7'_I*WNW;Q[^_X-/+CPX<2+&S^./+GRY<R;.W\./;KTZ<4OZ--G0 #P!P8Z
M&)B ICN:BO^8&,B>W $?,43 U&'[0%&:A7.F%, !YHP34P=*"-UCQB0== !
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MA;D "&# =1P?YT @0-#PA H+X:#(@AH^XT8$>)SP  P11! $"PYT@D<0A12
M <X1-++"RGSZP ,>5E T["45UO\B1H:BW/& U0Z(D@BX,_/P,3MXU(F!%_,!
M\, -;= P0P(<,&J1+"/X6 I;#MQ0 PP\M;5'#!'8$781((!@P@*Z_1 !)!@Z
MD.FP'K1PPPH%I-.E!ECRUHL@$,PI<Q$_-_)!)2N$Q$4BM>"A201M?)&AL N5
MD,(SIU!]0.2ZK9%!&YJ8D(#?/5URA+""<H%'!.QD<J+H2Y\!^8>CDO+80K(4
M7<.3.&0C/5*N%52$(!.D$$0$*9"11"TM+?3 "^5'X$4+I-CL*1<U1(1O;PP
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M4[4N4 1+$4*1D4G"$O;$  XN1!]H@."H!M&#"PP"?3B@$ 0(L8+V$8P(-6!
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M(;R#"9,  3X@ A!P$ KW@##0!G"&#\N%#T60$/C  1% 9PLQ2IL@,[)0$&M
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MC6 "3* (6E!8 !4)2>"+.* +QX50"D%33\(!8F  'L!D?? $^A #*Z M@F
MU.,M@Q$IAX%%73 *.#(!'VA%)X($-=<^FLI^5@4!G;(":* F#2 S,_<#YBDA
M5#2'[<FO_>JO264=UQ$"P($!!8%7-'""DY!Y4/6*QG$ X,%X^'(2%6$C$7*N
M_Y="1?@!$1 P!^#W #2@ K5@H]H28BY@H43B&[DT4^!7 !Z12I!C)2H2)P;!
M!!<PLWO0)79B A71"9935QU5HLKW&P? #Q<0 GR@.@)E14JP!POJ!I!@1VPS
M30!06Z%AHP:A.W)4"&FZ$!P0+^RSI^>Y,1/ )E739[P* #^2.IWW&S[Q(270
M $D@!R.K&QYE)1@"%L+)H@O@MD4 ?E:T)Z_%MFXT<PNQ!OC2(-#C)@_0  Y$
M*S<@10]  JRA0DZ@ J?*0<@R%!&R"[#S8,#1(3*# >]6 FA;1+>"#\2X!J1@
M!1"(!FFJ4B^%MA*W+C,U+PLQ<QU[ 0QU.9ZY3+7D4O^&JULD6Y[U=!KI^:_)
MJ[S+VT--%)](R@4?PHMLX03(>3(]J!P-PCH21@AN5Q%R<"-86T4YP5^;) ?
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M 2%:T8]\!N96".5JL!CV4&L@ KHX,ZS; 1R02K6 &P2A+;!E(Q80%C(P#S,
M!1M"8UL*%G4@ YLU!U[D UBI4B%JN)>].+@Q :6%7 8P"/_#M*"8H,%#$5@,
MX0Z7HPC+.=9S<* ^, 0&O$!JZL\E(*M%8 @%T6%5P(09%]E ]=%B8]F8O1",
MMMDF  %#PH .J4@<L)3I$*E3:,.<D2D_X :]% -7\-V\ 5+,*,/X0BI/< _:
M=0%5>0\[8!\884T%UK)[8D7'M01CG#^SDPF]R$X3  C-5Q,ZD("AZL:*$WN;
M;05K0 .3, &'^>&,]N$8, +;&-H=P <]H"R%BP&9( D+ 495, &+K5KT+"$N
ML )[T :@L0;XVA,QX(=NC>1)KN2OTLD/X(TW@ =9L)"CQQHD]8_(4012H E1
MX(@2)#4*T7/-O !M@P?(QC:U_+W_IP#3'P4U4K.<2X"(G2O>$8$.9;X!!P!=
M^+#1"<  8%#F1U  !P #+[P@:S!!#3 $\-$)S] 2/0,"Y\0VM6L172W>B]8(
M0""@!4#'-* $R&( 0W /+T 1>F@0GRO/!F$,_](VA$Y=,? ,.H /\=%^# #E
MFY !6[)H(( ^LT8^]\8%QVT1Z1#A2.$$8  "%<3&Y%@1HUKF@X(?C0!^2& ?
M;HN:4D!NQBV!(.5<ADO)>P &9=  3[  4/,Q-4[FF.&!JQ$:9",(%#+DH,4
M$>"'&Z+&NJ )9O8D.6;C7? ,0W $BU;F&7 W>\#OF% G/^#GDDE7/A<$XPIO
MVUX+!TFQ_R" !RM0Z2/,)[(0F]>*UCV.O$L.\B&_U@'[O,'Q1EQ[550'98&S
M<P^0#W..0[:0#[ZH=$19C/<H $ ,6GL 9[K1(6E,'9UQ! )0'\HN\D>/]$E_
M,1GCR;RQ!U!8 A[@!H#P4&P8@$^V!R^02F V'D?U #*PKT?W $S8GK:$"=7#
M<S<O(3S0ET$O!S_C!FVO]'-/]W6O&T#D= 1K)9E:I(Z',E@6'1KX=:?,&R$
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M&0'A@2*RHI0 <- )!"8M)8>TP<3B9CI%20YP>/YU#3H\)B 4V!,E0_@$Z5*
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M,\[XH8TT<(-" T<0K204B2J@)R,'^)#DGINE5,@G S@0) $.GN@ !D$@H-@
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M800#68([-' )K^E@($4(&AC)@H$\D62&*!I"$B9P@0FX[@)$2- !V%" 39;
M1 VYFMQ0-LE3D.AA_P[(P HT  1$T;$A#!C#5V3Q! '$I4)Z8YZ4,! $$G1
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M&N  ><% 1'#JD12N$*>PP2W&0L $&8R13R;\P $,  $G@(&&8"E! A[ AT0
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M 7.;E"+@0ZNX 1 8D"(Y$"YQ  P(%Q!)@!\0%3H@!>C)1J&3!'&+0C?(GX&
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MRSFX*09 !U"@ -.(LPC @R]H@:;* !!X%  X*#Q8NZ_R@/"X@$[ A E)BD[
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M0H(ZT)TR@()*Z $M* $%M<^;(@@NT($D:)'6 80)Z 0?I)Y+RZ9(N( ET($
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M).""NP@@<<Y..?@)F4 +!A#IA;B/BMB#1$.S2,CC2-HE07ZB+4@/Y ")_X.
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MV"SF@($KL3\BV(GJ8?^$"+ "1$'%"&#4!Z #13-"3:@!(OB1?L7#,+U\J\@
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MJJD0E.I IUHQ,,,1 KR4J7:?+B= 3Q&%<,,*%VS$A1(7X%I=J0 4P"F; N3
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M &4(F*""CGCV 2)( @,X\X,A)*&6M!GES[@U3I"H#0 UA, 2#F=%9 )"$4P
MX'83\(#_SV3-#2IXCT%JX9W: N '0$CO$L 9T.U" !]974@G5E  #EZ@"]PJ
M00.2(*K'*F2>>;G!0G<A. 'X@ VRJ(RV/+N07?12)Z50"$(U0XB%YL48$,T
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ML"0#@C! /A+@ "JLT"$N$ $$)A", AS\(Q/(@'T&XH,HK0$&0Y!=" !!G7F
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M[-M5#-(6G5WNU9\/(F$2*N$2VHN^A-^8N($I4,<!!,M"%4D0,F$6:N$6<J&
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M0TJD0%)D0E:D0UYD1&;D1%ID1V*D1Z*C)VJ?[!%/EUB&$Y1$=>2@66@"$TS
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MS"$\#<G "@C"!W'IZT)".0 ,1O"X*! A!4+! 8FN@P04T3 !#. !!FL! D$
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MQ3.&,,,V1" "02@$$FSCD&? UET)\<(9EM<(/VCB4]V\R+-&U"@.2,$/0?A
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M*@H@")6K%AI@OVXP/QI*"JLPQ/KC/V O*P;KKP 06&@'E-#AJ(AF#QK!"F3
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8&9NS69NWF9N[V9N_&9S#69S'698# @ [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g24472bgi002.gif
<DESCRIPTION>G24472BGI002.GIF
<TEXT>
begin 644 g24472bgi002.gif
M1TE&.#=A\ /M!'<  "'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "P
M    \ /M!(?___\   #W__?W___W[^8Q.CK6UMX   CF[__F__\0" CW[_?W
M[\[6[__>[_>UUN\(  #W_^\A&2%S<WN,A(QK8V/%YO?W[]XI*2F<Q>:EI:6$
M>WOWYKW.Q<X9"  0&1D((4H  !EK2B$Z6I248T((""%CE+U"0D+%YO_.K92,
MO>:E>UKW_]Y[K=8I$"'FUK7WUK6]E&-C,1D9  !"&0A"&2$0&2D " CFYN9"
M0B%2>Z49.E):A+7FSJ4I0H1*A+4Z0EK.ULXI" ",6CICI=:,O=8 "!FUQ=:]
MA%IS>Y0Z*1EK0C%:8V-"6H3.E&L9.FM2>XS6O92MUN^,4BD94HP ""EK,2FE
MO<[FUL4 &3'FO8S.YN:MC'O.K7O.G'MS4C$(*6.M>THI6I2$0B%CE-8Q<YP0
M0H1S&>9[G+T9*5HZ" #%6EH "$)[&:7.I6MC(0C6Q;6]UMY**1D92F/%4N;%
M&>:EK;W6(6,9&4I[UHR,>UHQ$$KWWLXI&0A[6DHI4H3FYLZE<THQ*5)"4FM:
M6E)"*2F$E*7FUJ7>K7M*C,[FO9S%M=8  "D9*4+%A$JUM;6,C.80*2D(  @
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M=^_]]^"'+_[XY)=O_OGHIZ_^^NRW[_[[\,<O__STUV___?CGK__^_/?O__\
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MN8!809 !E"!A!HDHB!;4$( LV!8 +'C#6!.!7(?0M+APW10#1, (I9KD EQ
M0W<;<H$57/>S8>#L<0'P AE@52&]U4%0T7N)ITX$M*(EZPC6^Q$D!, 3].U$
M'#!R@0U<@:Z=K0@]^L!9SU($#IU 002>&UV$O.(#C4@L07JPCRVT]0/, ( U
M-/%@ ## P7(5[!P,$5P 7& *,PAP(YI+$C?DN J-!0 B/,!93"@$#DFH<4,4
M88C=&H0!,M!M0_A WB38@< +:; = ! !1S#"PA.)@A+D>Y(-0[<@*:#NEP7R
MBAP?6/\B$= $&FSZ @T\@%-'K8)2"1!3 CB IGSV+Y]G2@#_"B0"PABN0 B
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M5Q "'VR! /(/ &EM_ 5&3(#7QZ<')=<$ LA6;@57J$4%E:!]?W $ O$"?A
M5>!X2440CD!6]D=_4,!^C'!67 8'2\!93,!C!<$']G4%7V #U^4$'F!\-C8$
MC- "^#=FN0=8$4 ),1A89Q8!E4"#.V!^]/ !D9 $E+<#&1!4@1"#)P97TT4%
M!# $9#4'_<=C+W!5OC80+[ "%-9X#1 !FS568.!Y-C8%_?!:7%97.D  4^!_
M2C )#Q !<+ ).38'=M  ?/ % < #"/ ):L &5Q!QYO4"Y$6"CA4 (* '?[ %
M5-8$(A  C?]U =6@?0'P!U=07V/%6/3E!SE&B0AP5&PX"7$P!=9U?0+(68/
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M8;P;5!GZ I0G6E7 K0.1O$I) 9-G!)[% A%GAFJ%F4];>M(9G]<KNS2 6"S
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M<5WX6'.  S+ ",;= TH0M+/5WLC'ZLIU8)D)<&-Z Z-=?:0>KG=67ZJMS0K
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M70@5  P"B.!DA@\[#I"$((,048 R$7K(R#+!SX<_#0X"H$=C!XJ#%P(%T)$
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M=5(\!A*0L"-I5="*^!B$Z%\W*C^Z#@ $1'T8W8'$-5*A<P T@.LE78#/A_&
MLE1]&*3H#@)(\8!62#T!;2?%U">\^$W.M[V0VL$)"B#ICI-  @7XAQ(BB&,G
M/ $00_B#'9G;DRC\ P/Z*$ D3%"^&=@ "H"PPM8^@4A]2" -4:F$"PHP_WFR
M?@0&^CC]Y&DSWY=.GFX X,,2+E^ 6+B WP<![GWXX(<R]+0 A0!"!GI@>LRW
M@P<-X,,F4H+9(FBN[-;8A':U4(@D'$$8(/[]'#/1 ^"C_D4/B,&+ZZ0%W4_>
MOZ^P 4) /1>  C_8O4A  P @, PX@7]HA 2$ >Z;O#20@A10 B$Q,+,8%<2"
M@0+ I@M8@D; @,F+A,Y @N4S++((/TQP&$\ @!08P7_XAP]XG2B@MX- !!?(
M!%@X @JJAAW #?H+/A<(*J+:/7U0 A^ "44PO0;T/@3XA!KXAP* @H>Q@6"P
M%2_HOS@2%_X;P0)H!\JPP!$$@AQ0K_DJ TXX O\>!!@MW#TE\ L <(1&V#TT
MZ (\((0I'(Q-\+^,RHV-&P46Q+>'^X4K,@M$$(1'6 (;<+*/@ X,F$(7Z)P(
M^(4=F,(,2('E4X(TN *N\0P&-+X, $'R K BX"]05((L^(O.2XT  X!*4(+=
MJX$/R!$ED+S,8Q80=([D@\1_D(#OXZ85N+P34(*0T9P/P(!,68 'LY;"4XD'
M(X6L,PAS( 6S2SQI)#I2&#I2:*K"&X9K&(94R#JU&X9R1(%6 ,=R3 6FJX=K
M>*S"0P%AN 9KX8=K0(&H0Z?"0X!V3,=4B \Z2(6Y:P!T+,=PU*RJ$\=PA 0
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MS"Z'&H5, ,&M6BT>F*^& 0 #, #T.-0"Z ,J^* +@(5'>(\6T!SS*,X?((!
M($N\<3ZH% L/"  C:()0X:\/F0X$.P@^^(<$]),F& 02@H%8R  2?56S( !
M@(4-*(3)! #FLI8%(%5%Y(F>T@$ J*T8G, '@ '_^I;%6H! *(,NB@3,FSP\
MR( 7B-2SL#>!8<PE"8G+^X=VH,"-60+B?"X $+'%R2_BL )![*DR,(@#@86=
MD11ZZ"X<U$%.@ 4_0!F#6"W_&T#7 K"!2^@!E3P($B@#'.!5<_G5*-@#;"*
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M'TX4AA=8 @/2G,!<K:"(@4:@5";[@2X: 0-P #PZVJST@3C @?\J9H1+J,Q
MH1:K$*]O>H&T@4H(+@GJ$Q4D2(-,L(8W-TMK( &WFJ['"+]-<%!N@FQ#>#]
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M*UA6=[,50P9W." !!6B8"56]]VP$C]\7K4F WN: RLI8-%CW2E  9$9< V"
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MK&6MNH'7'D2VC:4M<_.*V.BZI+'4=8EU]?I8 &AWL%8%@'<1J]K&MK0#EMV
M[0Q0@'\,N, $/K"!"V!33KP&P0Y.\&WUT^ $/U@?!= '. G0" L_N,,%B#
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M1C\ZTI.N]*4SO>E.?SK4HR[UJ5.]ZE:_.M:SKO6M<[WK7I\2#CI@@ X$H1Z
M$#O9S8[VLI]][&Q?N]K='O>TMYWN<*_[V^6.][GGW>YZOSO@_RYXOQ.^[X;G
M.^+WKOC %S[QC#_\X@</^<<[_U[RE6]\Y#%/^<Q/WO*<OWSG->_YS9-^]*87
M/>I#KWK0L_[SKB]]ZEL/^]6__O2TG[WL;9_[V->>][CO_>UU#_S=!]_WPO\]
M[K%0]B!TP.SW[=T"")!F"4B@'=2/Q >J?_WL6U\"V->^][F_??!_O_OE'[_Y
MQ1]^\JO__.M//_OC#__YH[_^[[>_^_/?_OW+'__\I__]!:#^]9\ _I__$>
M F "'J "&F !(J #+N #-B $5B %7B #9N $:J $=F $?J %<B (8N &EJ '
MAJ )CJ (HN )DF +KJ +JF *LJ ,ON ,QB -YJ +1D+W24#V20 A<%ON&  3
M6)81'O\A$B:A$BXA$S:A$SXA%$:A%$XA%5:A%5XA%F:A%FXA%W:A%WXA&(:A
M&"(68XG5!#Q?[1! 98TA&[:A&[XA',:A',XA'=:A'=XA'N:A'NXA%6I:[41
M$HA5 3#!!A2B(1KB!!SB!B3B(3(B(BJB(Q9B)"XB)%9B(UKB(UZB)F8B)THB
M)GKB)H)B)U)B*)+B*$XB*GZB*8HB*ZZB*Z9B*<+B*:JB++9B+;XB+>9B+.KB
M+.ZB+_8B,-HB+PKC+Q)C,.)B,2+C,=XB,PZC,AHC-#ZC-#9C,E+C,CJC-49C
M-DXC-G9C-7KC-7ZC.(8C.2IB*1*"!)1A -@4[3R"!(05!6#_3Q1]'3W68_Y
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M"R )<82 #I1)%,B $>R$$42"#LP* [P!(_# "[P!6H4 #U0&6H% ?NSH6'U
MC=;G&'"H4N!+!"!!21B$0*2 &J3$R_P"676H7L3 DHI5%;2%%K0#(^2'0'
M#3""H0K$)_3!3GB"2[# &-#IISA"I&+I""@17&RH0!H!!M1FF*#JB8[ 9GUD
M;>V$4,9.26* 3'[D=8@E(9 %$! "8D9 &,P 6DAHC^Y% (#  P#'#-@ (52K
M'(1  '5)(/ $$QAK1]C&<O9!%<0"$XCE9F1!M@  I":%L>K#7*S_J4!4!1L8
M9R#,  @L!0-\ 0!-!0/\3QDHT2$8:;; @+@"0;GBZ Z S$%$@1)4@<$20B',
MP!R$BB* :B-T*R$,Q1SPZQN$ !& J16(J6PH@AP8P0YTZR:0!0\,Q"C0:7"V
MJP=4P2"4*RA$  EPJUAVJUQ.1)!V:P7H@P>(Z9&\P!($0"3$0@40@DZPP6TX
MPDZ 0$M$@!;T019$SVR00 A<K+ .!88 @!/,@,R&9<XNA188:6<R  V$@$.4
MB1.T0Q9X !YT9@24:F$@20QX0!:4:\ZB@5?AQEB,:[5VA)"&"1?,0"3,K-@:
MPH :9(&FX4[2) <D*GT^1+U&J$!TP0RP_T&%7J@%L, 0A,!HA DB!$#"JL;-
MABX '((,,()#E"U+'$3DAL /I&X-? 11\<$*>  (3.YJ0*@&J(':6L2/MH,-
MU*87S$#<(@D,3*@*2.NRIJ[ O@RDMHJG*D$6%$$"\(&^_D&HP&8?A(!!K$4(
M?.E;$(30AN@(/,L*# )]<H";UNU+M -7(,3_B&J2[*B1",NV[D!GELD*S$"3
MIDD/D,0?),"@8JD.6$07J$$C8"I"_(+:'D3OEH%L?&U%)$G97BKLTD _5"8
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M5@0 ",1HUSG$G-53&?%8T!%1NS0H.U:O'>*A]O!SI.,H B_ZJ,T&'DR+P)$
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M_@QQ!$Y48CT^",UFY)51= 9AB8K) AI4"HL29@$WZF,$^S"#_]%T:B<$&>+
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M"@H !2@N02]>8!QTQY<X8@$6I'X:0^] 8 M@!0NG\!(YXA \( NZ!2PJR@B
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M% D*'[V)X J#]OC2FYB0'V., (9@!JR0.!)!",V(-QJC"]I!6%KHID(C N!
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MCA)V-D@H^@I2_T\[6(26"2D#;KDG"F(_J!&3538GD<P3!R2?TX!\P6+;M L
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M00;,X!/D0 SH2,#3^\<P5,#2FT7"XOLLY,MENZIKVR)V38TP0PKTLE^AHO+
M(.LD2\_@/&I_0Q,J0!^.*/*B0B7_]-R8Q."U6J?R;*=_? W1(;BPZZ:;I1T?
MW>\&C& &XO 2(5L'  H6RF/DZ&$](N$?"H" &,$["$"S@> (#@N: $!%0(#<
MV& #9L 3UIIB&:"$JJ  TAU_4&[;SF%W!01V_F"M.&&MGF(J 1H]!/JZ8">W
M=YLG@BC#BV>6/@[@\4?5Y2?.RW@^=CH(G,.9HYM,%B2V"B(+)N"T-N(Q8OS:
M&1B\XZ)PK%WFA]"\2792%$"21= \LL/125%=@S "PNL?C_Q='T,";* (,!36
MP#EZS#+1N,D:ZL$T@!9!.N47VCF@9V"N93W:):/6E\(#-!HBL" R!A"6-@+.
M03Q(7E(S_R(*^< "V5-<V;E"[UR6R4($3::CC7%>6FE\FUO&AP-_"!=;V1YL
MG!VE51& */]@'#IA' QAG1@; #2[S-);Q>;]2B$S(Z1@W\O.F'9 \BF?"S[*
M.UB !&X@X2$"$+Z@$1JEY1H%+"Y#OL_MC\1>UFW612Q<+ 6U,C7A'Y*V3+@]
M"2;?$* %W#[>$Q/H,\XC MHJ2L4BSU$BY;\T>^0(7D "2"YS!P3[\ .3YN%"
MO!%'_'.^* T^-I JIJ>MREK#Y$LD!(B Z \&% \BQ1<$ZV+H?QH 0P'B Q$6
M;T+P ( 00(0A 48T '!(1H!($B2T"V"CA<(I 8Q4Q" ! X8, /]>O GPH>)%
M-B@2 B! (D 9EX@"@#BBT,N,&Q65? CP9 L+CF42)(R 9 :5+3WD3*SXL4B$
M%1U[>@@@)D&$0!A,(' )P,D,EA'"8#4*P-&, &"D(-2B)(0-E2% % $0I="@
M!V#[^OT+.+#@P80+&SZ,.+'BQ8P;.WX,.;+DOT<"6*8PN6\%RTH,9/X,.K3H
MT:1+FSZ-&@"B&6 L^.6@)@29A 0XCD@09L8YM BW!J!"P%&()@\11ND3XC95
M*@D8C,+:@(,,(RWHM6-SUZ66L7P! *JFQ'*509F^1OAE.;WE$"J,;[H8@!&0
M3 M<+I2)-@*]&VQ$]4ZQ!'R-,,'7(7+_5($&6#VTD\4E)JEW0T>S75!)#A&&
M@($.6R@T1 @Z?$736"TYTA!:%WP10",D(=3#$N&%$$DL*VK1#@ANI89CCCKN
MR&.//DH61'H;B$9 /I85X-F/2B[)9)-./HD8 YU<X8!?$:2@P8:]P:)!/0G
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M)*P50!J;1R#6),5UD;ONGIS^UP6& A:%$EED)^P0:X7PA. N\>''548(<B,
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MB@!2EB$_[11)*W(<Z=%71E%SZH%PXR- S>4[ 68!-3$'6\  *&(C5)9J+S9
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M\*;&0@ K4/]8O(&DM-L76E %%9 &<L,"2T (K/H2UH  4#9"N,N<>^L P=+
MA%NY@^&KO/$WA96R)H"[L!NN;_&L"/$"5E &]S@8["NB & -=#NYT<LFKIL
MD5JS3I &,0=V5C "J(2ZVOLJ_'"?O\N\"K&W9S(*LS&=!#7$N$NX,KJP3O '
ME1 4+.L%&!"F"'$(.7 ;C1N@,5PE%^#"[>O%J O"1V$ W;NB8UP/Y=L;.+#&
M3IR>%X"YWYF<2BR>9US&"L' >"$'.F  854[J)O&M-&]0TS$#C"Y<#RXB;L
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M#S( 7T'<P#O18* 1'HR %< 4!1J0#6YRT\%';&"ZD!U,EK,D2 >TMP%:4H@
M^1"8 7+Y2WM% !%$*LAH7/BP9,U >]HSHD7X4(UV!  #@ZA(!)P#G2^02D]*
M(,+QW$* 7X0  W%"$DLB0Q 4X2Z)2&B*%O8@!>H<ZC%M_T'",IG9%1\,1VQ0
M(TLEE(D!(&B.:1N[&95.(KD$>$&9]HR*#_>'"'L&( 32Z4(:_D8/+>VI-$/0
MD&7V-(,L)"%!^51$)*+$$C00@ 1;&PD>XC %<93J>Q<PY0*B8%  $  )YW#
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M:_@'X:-'>\0!$@!"F*B&&'RLQ'$6V_ O/Y".VKF=B1RV&@ "=W06*]@!I"(
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MHEK7(?")/7PN%<1'9=T!X*"'?C"!^@PLB1HEW;BD,62!!-F72$B"GWC$K@B
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M"6M@\6\J\] F\_,.$ (HQPO_Z #^L ;U)G313G,\SQKJOO&"(8 .V&6RM@8
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MC((<F-$  JP@$F@(0@KZP(P$>,$%@[ #(+C@ A/\;S9#2)J;EL##"UCA$BS
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MS0 DM!X#EG"^A*3@?1&(01;0L(6F%@!.G)"!. $ @QJPM -<\!\#WG!*+#B
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M)!5/&)9^'$ZG@47+A5\*&N'00M,@&'4Y=S(WCC$8T& $.F%S"RX0"#R()]"
M7G@$IE ,@DT$!@N7R"$*T4>2)B7,RZ*'!"+NF>"TS"._-)T6/@!3H_SB(O3X
M,0!(P,6K(R$-$>F"(,;'>0__I.%YP54B$/L$[TT58Y -%-EMXX:R\X?&*?^Q
MQ@MRL%HMU&!A+-[]1#CA0-XG) $2#  &% 1\$/-!!CM@0@4(48$:=)4/&ZC
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M ,K ""\B  ?(0/N%@1EPHQ7PP (<AY8100*,U \:&QE4D0*0Y61BP+;U30U
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MZ.U%FXK>/.; G+:68<[.:RI8I$H$#.C3!4Q!H%1*"&RHJ1J5"-@ C'Z!U;W
M"GS !]B #WS=5S;(53X0\ E?@"B!5RJK A&*/9IGF]S2Z6D!.>J%%QC=3]K9
M<2@"%$1!ORR9)GS?$,4%/0HFOXV$8=KA1/3 *M6:&.B$L2DH$DP"H=W*E7';
MB1J;)972O*5 $G3!NC5!)<BJ_Q-0&5 L&FS*F16(H X*RO:MZ424IU$@03^Z
M8!GH!(7.(.K]XA$P*'*:P$#Q#"X:1P\$826!X-!)A)G%! E*! <4@N$]5 T5
M@N:Q[$EFBYL:IG&DGTX0P M0@ QH'@%0PCGD!4ZZX7X"$8Q%P7C>V7YJ <@I
MD+'UHLNH 4R5+)#1R3M&J"%Z1D54:$RTP"V%ZT3PHD)82KS"@"!X&P=4:BGY
M "!LTWX\1,;,TU65Z=/"R-6&G%/91<>IK$0H AZH0-OZHC7RR=U(Q$A]X$3<
M4L3\A#6DP.ML;37R:I7E"K#]55#UUR^XZT\4Z5/]Y!P8QSHF:T>\8T10 F'.
MZLU>8_\1VNIKTFGN_6MK/FQ"Q$#'.4@-*6,&C,W%LH >)%?>C$++S&O2X::L
M9J0<Q-FG A:$[LSE5&=\P&1$S*1MT"-'7MT*F,$[)8VM]F1 I>X)30'N-HC+
M 4W=@4'&6$,/5$ ?E(%^3&N! ,B(:>6)I5C^+I"!)5JB*&KD&0>NB%,/#%W"
M0<$6N!RV#@'T@H<?R(T>C0(Y:)Q?<@"4)408\)J;&&9\$!XFU*MQ'((@M$P,
M70X'Y,/%\EW:282+%($+_N"<U465$$*%&!L0@$)"?(++5IF,\ G[EI%L)@"?
MF,''6@1LXISWL, 4@( H4!J56$'I(0$CS(C;O2;V_%K\8$#_A:P J<&9<4R>
M*"# Y$$"Q.)*E-5BKW +L4D$%Z!! M ,SDX&'U3 ^W8!!DC!Y$6<NO!,/\&Q
M+F:"]%Q.R0E:5^7+I?9GU.J$(["!=<20*"P ;H&O6FS ,_7')]B;1"!!/[0
M8F6=I>5:]@(6"5C=X3&G3M0;$0PL_'Q"D?0=WG!:2"5$%!0)#""<46P?T"B"
M((S#/[1CZ%%"4975ESU<^Y42([!(+':-/AA@5+DI$MAR*2U=D":$&U04G]C
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MB'@^X1 O&H>W2H$7S$#1=,"3%X:!:7A=V9D3S%)&*D'1< (72,#_W-CM8+.
M"!@6 02;YZ*?*Q%&"OQ#Q#354Z$CFOJN+9<8NUV"CW\!&&2W;D-LDQD'$$G3
M6,OF7Q8VG*AYQ'B@<71A9B]!I2U79I, QE21E/3W)FW+7-XK1MIL&1@ ;#+
M$%R36.F#!WBJ2[+ &MA*("B/6*UVY_KB*0W7G1.&;N<7G>H#!A05']  D7=
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M3*[T7,F&:+(UD$#ZLU25N3S4FZD8X)_0P12_PYMG1,$2<,\C0&H" (261E(
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M!4/X0P,(^;*2,& 3B<S*PC29E5>XH @10,(3+& 5_SY800>"A&0@$L* 49@
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M  *K^DUS9737&7^G-CYPX01HZ,$_,@J7>P+!$+/IWB90"YH40*$Z .!#)8
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M2P2F0)*YN("%)R"$"T3( 3GLP! )@$,-"N#!?\ )  Q80B18" 0U>,)O.Y'
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M@PNA<M2S0.IFB0:RB(WXC_;&'[LU3J_Q+=6W$'#@!X@U9OO1D ]I+CN#3*"
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M,@$$AL@'_W )7X0%>N "_XV0!)ZE!63A8UK6I3JA!SP0 RXP.00 "^XV!W'
MF#XF Y&@ W&@%7Q@!2;@IEVZ*0H0 G!Y:^/B 4:P T= E78S<\1ZD?NX B2V
M!$\R2TZ@! $0"00SK7@$!)=@;\1H1^<F0G.F#UH$D8IAKD_B<V[FJH**'7R
M=$K73F-P ^N:H5 T!'*J)%VP!T=@<  ;;STP;J<7FKG1 DP3*ZM6:9Y4J5#D
M!SR0 @C;.$.G0TAP41= K1)PJ)K!.VWI! A6 '%!#X+ !2^9(UP 9#;+&K @
M BY0;@O@$HJ*!B\@=P! C'90"4H@")D0;WO&*K"@#_,H84H@.?60 "I1KI$
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M Q>E*RVE!($#0\Y$"$E@ $,@6#F0!M9X;Y70!WA 8'H2"810 840(F;T!1B
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M$097$B23D!:59"F#0VJI63*U0@)/P@$T0)@C% CC,Q QT1O_OW$!(B"5^D(
MU:!4FA-GB+DDWQ/)OHT>AT NU!()<)5*N)*D!D,&&:%RSQ(>D#$13@TL:1=7
M3)H]5O D^KF28^G;+L #C\(!5L 2N1$R)D$R9BD6Y1$!8U &4D$/:J"S^.(
MGP("2Q%0_SD3HJ 5ZV0T)T8X[0*TFB(9&0!C>>(':$!;?)$P!/X%@/)JP?PO
M<.(2>/"X]4P#S/ H7TDLW]KGA3(%1G"C$4,GE50&6;-)KX'(D7 "3' ):@A#
MC9 XT>%P'$*]V&562( 6(;H1P6,24\"D'(8(D2 B9.Z*^S--CODB2,TD,T C
M.Y%;"A$%_Y!N$=TJE?,E%_ ( #@N_V21)/M52<T(2#D !G9#YD@"$ZXHYU B
M$CR]Y&!A'NSJBILP.9C%4)FTY HPO$/Z<?23*RG='U'TUUX -FQ4 R?*;7N
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MD!?TC"S&&XTB;&02-"2 $G]P@$-\U !$]($'YWN$'1Y1CP3$H$J0>D/>"D(
M.% @!S,($&?X)!6(!"\"+]C ^QJ1 0*L8'\P*$03'F$  \4O B00 ]7"  )#
MF ]]=H"-0RX@ C!@$'V/<(!W;H(($$BA:8P _U2($F K7 &@"WR"P0R@@$$-
M7@$L""3 BG)UD P8Q7I*+$RNR+6%.4:@&@T;B_X2D()J-<T%%R0C[N"2 @P8
MX@I1E($/'+#$+DY*) 2YE\)^: :CV*"(@5S,G!:EE;H<K"!(>,(6&."';0&
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M0)7$_@$I_?WA .C?>4OD2"1@HXB$2S*F(\#@XG"#FJ8W!C F$NB'3# ?2;X
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MS.&>34CXD!!+]&"@ D,$/'(% R*<Q$@1!'@!F$Q0;,&'DS(5 4 4A B'!@%
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M$\$!"3C(=D1BL"K!2Z&%]$J>3UD!$%P!(&C"*(3P6"@K2UQ /?P+2RQ ./&
M%'>  ?#@_-B! 23, A9":-K$^,2-*>=1*9, ('WR$G@ *G)I'$SC37A- RP3
MBDX<'I$3" 4! ]DA1.')P9# ;@HCN,H@'Y )F76RVDB R:T !O! /7 ""4AH
M#-Q0!V#!"@#RQLF V. HZ1#0(:ZPJV!  .]9#62!-:G2@<U-=_3 /TRIAB4:
M[C%0)F !+(B0=N3R-4WL S+ H * WC0!%9==/XS>Z_X,#P0!.Z?.()<8L+"
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MB77R653(G:-!0I0(D3_"WO1-"/RSG6]$!@@,9\Q&)"1!FU^/#%P($-@!'D;
M6J8IA72+BAM3"GA&"%"%P.&&2? $$!0!(?8!E-B)>)1W?UM%"JS=EGR"C<L(
MTOI+)?S#26R$JXOPVF7 5Z"+ G-X@##5)L2$#;R>0B2.!RRB%0178+5X:=B
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M0A(#Y ,R$?G8HC$488Q1QAEIK-%&[TR\T2613M2Q/3Y \Y% 3C*L#L $L@L
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M3,<&?V#*&T98PD:H1R!14&*WA!B_)GQA.CX(0C44F(:TO6" ]TM,! *Q@TT
M40<->($,IL.(#" D$!GZP0N48 (2*' 'F:C:"IX7@D9D "1.V($?9@""!UP
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MV, $9L$;RG"4+I WA7,(#&72(-(:U/0T5B J_U9(@%X8%$(%@6% (2[! A*
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M;&S_"^)*# 5BV!R$_9Z ; B"UU['[ @& C\,$22@"8!BR XB!B93(+K !:"
M)3>!&1VN!OZ )?_)%/4P ^& :D8R.[63S5!+M?B#SH2D!_R@6YC@"J:@IAX1
M*R(1+2@!!)31(7H@!V: $6YN J^B!S9!ADR 71  !@J 7K!@!?K A(3H(5:@
M'4+@#U1!$!QI(<6. NGA/T\-%_-N%]T0#C#)A-! )D:J^HIQD()J!O;+(;AF
MA1HAFQ#.!8>"$G: "Y0@!(  OO"J&E8(,'&B>58H"Y9*#6=@$K;@"^; 16?@
M#W1&('J 1@-@!W@@ BBS'1F,CDR4!SBT'@E2E7J1*2KA_XFR@ GNB 1D\R$.
MK@'[8,L((J\"X =HT0T!*.Q.T8)"8 Y@(^+B4# T 9" R0[XYPM*: YH3R"0
M8"/C:B.W<U )=7CB+&+VXTO"Y$F02QA X@(R(P(<=6?X@GMD<"B0*T0N0&X,
M(#,V-0+ZQPV]P@ Z5>^LP0 (( +XP5W$!P"L06YP (L,)0(,X,6L071(U0'(
MXU4I(E8%PP">YB1.]2@$@E>1+08M@%2)-2T, !!:%2M(E99\P@!\!0P2  =6
M0O"4E2"L@5B1JS$R]2G2XE9W1GQ&92 2X%1KE31P@"(,@"^LP79"PP : "K
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MO8+PK/?KQ"ZZB^#2/%9@.@9;,#A '\Q'HD,:1U(:H*D:BZ1Z#M"ID"[:")I
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MCIX 9K80C-*NT4X />0P^G@4H\D9%@=>&!( Q)8(C@+X&$MB!C.0 "*L_PC
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MQ8$<& $K5N17(Y*0R4UX( M;\DXOKR+*'%+AA6UI3".D\"U&0&$#%/"#2WZ
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MDA9@$'A@_U%!P\(&4M4F;Q "4M9<QK<<XK5H3D)*T1$6E>$;8T80X70?9]8
M,S$#BJ((0Z%KZL(7M4,#5^(:<' $=Z$T<T5*"/%$"?(4\_1SO3%!W(8342,3
MA^<#[.8@9N1;%$,ZAS$E;W1XZ#5Y* ,<P@%9EV8R?>@H@S0M9E(=H99(#3$;
M-I )#G !"A1DPJ81 V5Z! %K"0 2*= 'G2$1F=);H ")4;!) ==OJ*1[" 9L
M! < !$  8-8;JC1:6+-)XM)L7&$@T(:%3O**K@@2;D,=X9(FEX@:X<*'!X%Z
M4Y9D(#8P:8 &D @+.D-CGX$D<M@F^!8!O?B* S$;Y\ 67: &BO]Q$?30![/C
MB@[@BB\T<'5G&662 =I( "!QBE(0*V&S$Z]A$ZZ8CK&G& 9  (!0"0JP'PPP
M"B'P!W%  'Q $VP7($QA(!(56.G4BQM$ MTC#-D("P,V7]D(5\M!#VJF*&?%
M""C"*:U1%A!U 9"XC2YGC@0 B>AH'F!A ME( -90-LMG4WP!C^QX%*IF!#0B
M$X3%9O]8#3>U7;I7=#E1!!*93I]X+/K(!6H 03Q)AC1!!;TS,R64 C.0!2:
M P3P EHS7\1! %<G#*X(!UI3/5R7,0!R4BV2)W41!]DHD2M!"2&P U?@BIH@
M S:042$B5ZZQ<>BHCPF#5^-" #U )'[_QQN<,9.N: U<4!=]P@+.UI'- 43-
M0YD5(Q,7,Q9PV #ZZ(N$N!R31EF!A&DG0YHQV6EF='0#T6 U,VK]]DE2L5G$
M07H!,!H(D43JY@&B 9L:1E$V,#SHPH$<\%]B&%9M@8-4B1%.1VNW6!,@499[
M!YA&ME:?1"<P$#83 T9I,GV]D3@;(R(@$!,IN$S!V4MX(!CN8F0',3JP]1Y"
M&"[,U@,N 5C^-# @ICM#481.<'L% W86$9_Y"1(4\DDV &)4M56&]$H69B+6
M$R;7](YIT4N%ECB7V1LLL$D_R!;BI3@N5C:]M"/V<TU"9V//]1%;X62#YR Q
ML%6&4FL-"C+@_W<7^I.#2K5.*=433M8@RZ$ALT@0N&$&".!A:@8R.>:<]E1?
MAI0&0@>%."0FP)8DV6E(\Z60%UI/=":&B_4^ZZ2*?K9.AG,8?;>"OG%HB18F
ML4$0LX%V.(2D]F4"L+B:&3%IE69'QH$<?%"G,8EX4X9Y4G0=:+  +U!: \$'
M&U (P1$)4' %S:%JQ-B!WN@0.H-5+[ !798%27 %(,$ 5L@6"\ \<+F* H5O
M#K)^PI4GO#0\N_1LZ5(BZ^0)"5!MF-@.R[2DF0-C")&,L*DU5><77* /6Y,/
MX3$01Y(D!_%7GZ1E\'$.$;5);&.B@(6B\5<DCO(MZS0'G+!)/PIT:/]@K;W$
M;(OD!X4%!(9@% 2@"0H&!)F )ZYA<>I)H73U3DE @F43@,U! !-D \_#G37Q
M*"CE*>LD'Z(B3#QH&3)E2"E!*S:U3CG:=$,!4P2AKG[ 2_>%!CA@$*,$L,.R
M3COB5#WF:OE3GN.G-')Q;?_ 2UG !!E IUD!5@[:LBO!+QAS> 3W"?M4!@E@
MI2 SEGQ  3D0'&F0!#IU?8'9=J+UA(#EJ ZRK%R%KE2SG Y"57V06':XLYVY
M%V_D(=>TFWUJ&8L7,HUW64I0#V!+EF>)%]8@#*=A#704 1=@ '5R 6^+ R]+
M2080@LHJMZ=!  8PMW@!N&HK$V_+30N  W3_1+$&H"T%P0 KT'!^90 X<)MM
M ;@O]+<=N0!LNQ* Z[F 6P\:&P&,2[>*:QX&H*%\9 T.X+>D6Q UR;BMQ;DJ
MD[B?F[@2\8\:^R","P =]KF>V[KOZK1R^[N,&P&&:Q#(>P&U^[OI];>$N['$
MF[K_Z ![>R!O^[O"@+L&@+VNNQE=T 2I^U7"0"^N\;;"6Y-MBS63F[UM@0/,
MZ[EX6XGPB[IX0;^ 2XF600#$*S[$&P'6NQFFVQ;=:[OR2,#BRQNCR[KV]+8"
M-;CR"[,'S$WIZQ7U^R#D:[GWRRRP^XJ5J[J!N[C%&[@L +_6 ,%9L;R_JZ&^
MB\#+P;;.8<&JV[A__UN\=X*VEG&G@7@<F%6^-^S#C8>V?% !X_?#1?S#N6K$
M25R(7/"U2NS$3SQY +R:4@S%3TS%S('$58S#('.:=N1XP1%Y6BS&8IP 46 (
M+3S&::S&:TR(+S"R; S'<2S'<TS'=<P;?TAI@9B:=LS'G.7!?0S(@=S'62S(
MA6S(AXS(ABRV76Q'>YS(CPS)D2S)DTS)E6S)EXS)OI'#@:2GF*6:F0S*H2S*
MHTS*I6S*ITS*IDFV8"QYJ.S*KPS+L2S+LTS+M:S)>:3#@VC+N\S+O>S+OPS,
MP?S$B\Q9CBS&!! %FU  @F (Y<$!REP T2S-@2$OFJ /!0 $HG@0UJ )__]0
M (-@!PZP67GW#V\E$U'@S3S $H4 !4:!SD"@A'"@!][,!.5%5(2 7P>Q,M*L
M!(( !4;;%E[@S=(<S>1%%0,MS=G<D5& 7_*8 @.="8T; 940#/EK$",D"#MQ
M"-!,T$V@A ;Q LK< N^J$ 60<1?0S=&,!A>9L"EP O^P ^$\&/H0ODVX!(-0
M&0G0 ]40S45[?\KL13-ATAK! DM T 6@ P!] 7I@TOPV!$== *ZV /Q& E!=
M $U@(,BLS.W:N(IIU1FMF$! @E3A!][\S]&A#W- @B^P!$ P%0L ""L0S4V0
M7V%6"=ZL$JXAT$>-7T&C" A-T'.Z/-XL")EPFW__K=*' 0=&/0A#A4($K00Z
M\,E.\-5'P),I:]5OY03_  5P]=?P/"%*\ =]<0$I0 C+?,;RBPA0_8RP:=0$
M?:X/PP=W_<UV4"-1H ^%?7S77 3"*M9']="_C1!:\ ]8+4564 #F\@)?@%]>
M0-/H& /_P ,:2MR_=A3]P=?VS  \#=7&S1.!T-37]P]RUHIPX <%H 0\T&9:
M8-7?+ 4C9-70X29'W00(>13-!=B)S4<]4-88\,_""]\$O0.&H+XJ\]16;0($
M$ 8%4$5Y1],7R07Y_0]J3<A]B,=X6D=]]$=C'!ELM1/?$J>@-!H$((&U.=)\
M)!0]UBC5B5LD'HY-$(7._]8GNK@X%FI(!WFL_ 72M7A(K-5LS[4E6L!CG_2C
M88DYM =H$^,$58"P&6%T]S&MAM0('^T:]# 4"W4!/B@AK5CB"YL)\NMTAO0$
MC6(2!;(HPU3C@*7.I#&N4)8>&A&R@)5/JF<364ZPC;)7VMH:8,GCP=$(11 !
M*4"CAU0$:D--&Z%@(&/<9=X9;)&S3-X6,>![]L5Q68'D=I$JS]4"+46$GR2I
M Z%WCB18*P=*6UY\7M;$7B.N6%%6XLI E3BAO60&9?6J(ZDN(, N8.>D&7#%
M>>983H$3>NX5;_%)3_"HR3,93O&=;#-%019%M,>*KH%\,!5,*G=2Y[ %ARF%
MT?\. 'IG&+SQKS-U.'G>2ZJJK,IR:S@:>S.E R 2J[T$'L$N7_PV8("5<?!'
M$^(N$<L]4U^BH[UTA4A7[^SN &)I,7L1FH?72^\'Q:I<69BF65J<=PH0"4E
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MZ:*D '#"00JCD,,&^.A9*(/:&-C $*=Z4,((A$)B(9X >)".@3<8H2LD.'(
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M\'NZ!";X"0- !E><NJ-M@,(.81:HJCB (=Z0$81M,@Z/!^2"BRV4GN"DRSE
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M17_L4<(.N- .^G @4$E#R1RVD#<.\L]9091.5O)EDR@HH6F,RAH MY.@! *
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M/G]B YK*T3AU))4:&@$?0D:-+3"]P0E &E2,B)4M5AM43X@F!84%(&47>$,
M=A!40O0E"S#QV0Y"2HA\P*0_5 M6@)*E!5.I #A7>AW'$N"&&<Q!$Y%%0:U
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MIROCO';R//# @<;;T.C@@R4HB7I1F 5,/0JY(!]X (ALP/^@I4DYG108!+4
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M;B!@\*? @A6P;>[F#S^(A<R)@&KX!ZHRO.G6[@WO"3WX!R02EOV&;D% @PO
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MJ"T:-48 Q$6EC297$"0D@+/F1"]]TJ  BN2#$0\$K7Y(8P%1NQT/)O;H6 0
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MD\O]OC #1@0K EKP0*""AY(WA( ("BI+ "*C0 ^&@ =(T<('LF __!V!?!>
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MS*!P7AD6B]O,X4!&!Y[)W<W!W -L'2?*4[O=W%7%P0 & 0HAFD9P0!\$HK-
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M@<, 2<PBP&P^0<+Z:R=<P8KT";^>[#@DB48\T HH07W%DU^!0(CM)ZJT(!_
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M,024.%#0)"-VN,(@%L;H"S^%? S!!(9>\*.=&\++Y*K4WNI*B\RX8X@!*T)
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M,0'G"D !ZK& 03X2DI&4Y"0I64E+7A*3F=3D)CGY2 94 S"=O&,A [!%,Q)
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MZB$(?"A49I5W-.5:B,\  *$#)-((HG*G?N13%$93B^,U#2 (  $68@).",!
MNZ/B M/:RJ1/'F4DA/)G^FP24. M<V,0+D>F'B0-_QK@$-I!9F-C]AAW3]MA
M#K2S-^JQ+K0D#29@!L3@9[_$=!?"":9R==ZL# R@ T37-?[  <K2 ^;@"@ !
M<P%A"SQH)': /?H,#.*@ PP #N8,#*@W+N'2)GXD,4+P_7Q,+!IA'[@J HBH
M=A'"D8;O2]  <PU (OWU)Y30=0W@<MW''(/T*K,R 3B28Z.7)E(..J#S4C(S
M12$G*\XS+OX$#<P7$#2A$$) UQ:R!8*@'N W"&JO7:V.-F4R 5XS"%P7#K[
M ZA@"PA@96WW1P(3/3RN/>$/(;%--M^W@N=SW$)  J!  TJ.(3I.0';-'O,M
M $06B0LR&@$@!8[R"O87?O_GLR%8X!?<C04F10S,;#Q=CW8# (99X#U>UEXC
MH0B"@(=582Y4H"P#8(^!+0"$DB9Y@(/K014*Y$!7<"QOZLW$E).#XHB/V  J
MT$ 18C1"($N[LD$EU2P0$E(<!03>+ZD"9%\5M63CXD0YM6!#Z"<4@#84XPTF
M+G0KV VG>%U[[D4'%SV"&>(>V 5!) %"90Y"P3P2(.S&KB&L(2;^#HR%P6B@
M)4AZ!"C41#P#5R$.@PVD )&Q0!/*59/,#I$4*>TT239, @_4XC73QD_PX $J
MC5+@I(YC8A#&@0*P;CZL8LYD ILK+G7#UF?_E!&2@* K0 EN($0F90,38B10
M]*;_] !")*(?TBTD^NQ4AD0=G=?_O*4'K$ ![- B5$+,@"\-. %>T0 J2Q4S
M4#7*8$PFS%!+9 )L7U4*8E4FV*!APP=7S^?Y$H >[#,D-$$)2@4(+N'G7*.A
M;X;=3 *@GU4FVC3*F'E5J< !UNV>$\).:C(!J!,.Y,!NF]IN-Y/Q6';6^B(
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M@/880!+_);,=8+#*B2@F(J$ 1CY?#H+Q]O@%<A15.Z4,;#='">*T0P #_J$
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MB21PR$&*S=6;>&"U&  5!<D10'_M[5 C1(BH 5T$B/3!B Y$99&A(HC5B$@
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M6#UN"R(DH1&=5)Z=SK2;$OD48*WJFKO P0]L-76C 2!6G$7$J2#@U*?9MQ!
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MDO=XD1<!CQMP"?D&CQ,PCW/1 P6YDMZD"?>(DR8GDSQY 1H0CYGP< .Y ?O
M3LZ&D%+5 TZ98#Z)CTD <"X6C_=HCU;I$X PE5O9E/A( 4D =U Q#OEXD/:X
M/S)YEE4I+0.YE.P!"U'I'W.I'U")D%P'(8# !05Y!=T$D;=$$%%0D D)E6AY
MC_L@<7<!CQ'9CT<@&"ZICZ[$"5R0E6<)9C$IEAH@5;ACD/GHERZ&EF<)"EK'
M!V9I_X]LN0]Q@#L?YS@I0 &GD919^9*&('EW^7&X$9$BQ@<$F021:0=:L99A
M.4=W*9H(V0!0:0BED@)MF9O[D"()P)L,F9>0T9%B29:+>9C[\ A-2)<SV1,O
MP 6)>1']N)H$R6(QJ9$P>!>P()I+216X0YC>>!>=*8\(0P#"B99@]IJ-V9#P
MV9MV( R!^ +]:"T%RA&=()KVF%[XN:".PYBUB1J6B97^*&IU:9K^:)JH&9%*
MJ9AXPP<1"9JYR99XZ8M\:(A"MXV[>'21Z#5*4%!5  09,B;PE@&KTF>Y$0*3
M04J$\A[6PVY&  2< A:M,2=&T C"U!)5,"QXXQ$YP@<5%_\ (8 !)G!&OO$'
M"8 4-',7E4%KX25E%D%SA0!S0,!.-"<#,M(8@S"D4^4;,^)K*3"FO;6F0?9A
M%P11@S('*0(#HX 6EX$@ K*DY[-%6C9Q:C GD= $G>%3!M4$UK("+]I;0CHM
M[-8(]*0(;C8GEY%!<W(#D3 "QE%M&_$5@D4N#Q$93[!Q#. '$A!?&, #<'0!
M*X !!64#DYIHV^,L+N$R '!><P)4CT4HD=!</_I31=!1'V5=2/,/;#6E7&42
MSP4<-N!>+!"MP/%07R$H'U4X^1,NU 99N-0RA(*M7P%0H/(07XHN?O%1B01;
MM?4 <M*C#Q!>;;,H!%<DIC(##W7_ 3%P9JX:0671 TO0K!B@ PAS =:*%C:@
M7.^#%D\@5=+Q.5=4.!VA-@ZD!O?#*_&*%C>  =K!'<P:7P50I1"1 F@JJ8K!
MJ1\E!K0U)SN0"4S!!2$; $>ZDH@CL:O%"#"+/!\5+RIK9(:QJ[Z4(-M:(TB6
M,RH$& _T49EB<M6  ;\1"8/PF 0A'4:* <+TB,M88*0H8 3VB!% %%6  2=0
M &<&(/1P B>@#T^5!6H["%) /CZ'/O*5 '@&$FI[ B,A&J=2 'G[5&4B%D,R
MI6JK#V?&0E"1 UL5$0KR(@+S$06@#P7@/(:C49:! #,#4EPJ7C)1!7Y;N)/Z
M:49 MO]P_V:@)#:$:[A%X:%-$@(?D&3;1K:J>SKOQ%Z,,"5_@Q9@X);MTA6
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M(2X6OCC1Q!$26,"D%@/ (Q/.$CI$CAE!")"!'(S_( .I"$(4XZ +*M$Q04:
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MM -]SLM>(]BCN/"A*0N@>**O$ 4?( 8 !*(84 IFT"6NY$B'"AG5IG# (A_
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MDQQ@$C.H0CUOX^E[!-2#FL Q_R%Y)%-9&OF]/\1!I+[#*E<X8:(%994D"9A
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M:K,VWDE WV$]N<F$(.B %5@M64(L$4&(W#*=: J!E5@1C3" (#  +#   T"
M&#$:XH.)2/_I"AA(C"L(@GH !%@0@4T1CQD(E'K @FTZ#F@) 2"X @-X@3.)
M-R<A%KKJ('JHE0#8+"W9@2.H04 P@'I(C:_H!QXP@ Y( 1V)LWUBA"2HP2C0
MD>H;GB7P &9H.V$@ #.TF@&D(!XP04TXPV*! <I2J 2),P2:@P9 C"I  P>P
M!@>X .$ @38SKGA#+AHXK[S*FYR+ 0] NE&9@1VP@P[@A!5H!R.8EPA8 P6
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M.> 514BG).@/;V6AC_Y6]<P1^$F NN62)JF<#]&\,K (YF"L7$N0YSP(D[$
M!A (3?B"(<QO#YNKD&"1.;"(1TB +O" K9L3&I@/Y-@4BPB)(Z"0SV!PB^A*
M'Z+0D\9P#; #B/*_+$@"B__8-'D9BAP)@11O<#N@8.*F\1JW\1LO$'N>U8+N
M9E4V"2K@BYT[B%=8BB)3S.G9C46!)=2:UUY9E>Y5E?!&B,9^[ ]HA/P2MLD0
M[ 3IWM;T.)DY'^V1F;#!@%IYB+X. !7[H=GVE\P!@XHEO3*@7>CEOP$<.]=>
M[P]:;ZX($8_N C<"F_S@5X6 1J;^R'2ZFDAEA/S#\49W]$>'='0. ,T\[GP>
M995M =NJ M94A!D8IY_=$Y&Z@'B(B2@Q[(1PPL*)&^&;<O+@E03[="[2$</@
MT"S8A!",@/?>$*:"BD+8#$=I@AKXD*(0SYD;E!WX3M< \'J9EP'9OX1P P]P
M4*;_,@+Z"*@I^C;->(W,(.]255-%'M.8%=(?0( 7P"](1_=T5_?@OFL'3&Y5
MCC00> #<6$.Q('()-Q(L^@-L[!7?FZO@&9[4*8."DG+B(P^#Z"(CP( 38/A:
MN4_C!0&C8H,' )[(.X1',0$1>"@M< $=^+0S[XE(8/@3T <@*!7<T(A*$$4'
M</-M;8@FF/'(0$P(5_B1SP$/,%AGE9N19WAG"9$L&/E_6+J$HE %*("17ZYY
M!]JSHI8&$+9&0/K?7O>II_JJ%V?C-BMF+H#/).4V&BC6UBC!CG5/LFX(2Y1
MQ'8^T(HU^0P]Q:>#;^B-&80 X="M"P,/* -:$3BFN@$3_R !&\B %;"!*_ 0
M3,);@YD-__,$B=!)DU$D6G.P$!&'L4"$&PC4$UGT49+4&=$+PBQ-#. !B"B:
M&=DZS4.W@>N-!L@1J(4FJW?]UX?]:-9QO,X=6RUE/=^!"9@ /7A):")R>1\+
M?>^T14& /!&XITJ=-<D:QEZ*QVZ'*H""79VO(A-["V#\)- ?O;CXCT.$#_!X
M/(B#(9B!A_#L/]B )*" ]#=:_XNSLJ""K'GS]OB0 <E3\>[$Z$=_/^A$V Z
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MU[-O[_X]_/CRY].O;_\^?IY0HU)0FF!"5!@ DM]+! 0R0R0G$**@/AXP\@
MKU!&$ #_!*2@Q&8,T, < !R,PLAU '0Q0Q9H( ! !'!8L1V$B*C!1A$%?1<
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MB$ZG";\VJ%B+!>L!,YBO('^R;#]X4!+&>M=91HC?=RN]Y"3$H:V@%H-R(;*
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M6LA/'X0 $(S@.)S$W*G/:L3A93!"C # 9<Q=POB (S+ 2<S!"'8"V#@=O-!
M%N2 &8;)QQS;"U:"&([<^V5!#CZ")M"&OV@8B:2B)IR$6'@+C03A..R>#YR%
MVA2&"';":G!(PH!+CW0&[HG"=!2&"^Y@"!0!:K5@X(0B(@K#G\U%M$5 "O1!
M%<1(@,U T8S,<EA>=<V Y$UB^(F@)B3?2.+C# P< JH<A3A!.U1AOE7!;6E
M_T5.B$M@03)N9 @, B]>07:H0885! ?4'>@I1PB4HRA>0;Y\@AJ$(!":(S,=
M M@((,J@8.34Q3_RHD &P!.<!7@\7 Q!!R-,I'7IX=?P2 O66(E\VR+NI1T\
M HB1XA^X( G<0!680 $IU5"94DVY#EG$6T%H)1Z@  NH!;VYU6742$RDP)X\
M@D'>8T0@!(5,7P'$2!G:(DT481_V&4A\P0[0@,,5$ =8P5#RX?,5!'B8 7!X
MP.95'!4@ .4)X#5!Q/M5(@!40@$D2\AQ1'(81W!!Q 5TPA$("L[98\ -H$S
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MGQY$&0#&PG6Q%%0OC:PKN6YJV68'QX3P"/<*(\0EHG1S'0/!<\V5&A@!*Y^
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M=8CH2_0?Z<($'P3@#CSZ0GQ?<1@!%&S QJ0N;*L!G>)&QPY=0:@>6 1ZA0<
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MS@"#XB"B/HR8M$M+ *5,K'=93&%D@B],A(?0LHSLD(.<+* Y6)QS!$ $&.U
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MA#%,%C"A%"7<H!%E],#/?F04,%RG:1&!&O6^"29%"":2@GQE<ZJ3!8[(*#)
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M * "@(%!99O<_?*##L@I$B[0DH5,@/0GV-W#3'# AV#EPP;RX;<+:&*$23#
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MYK[O_11->_0@WD;($!J YH#(X' N(18@"(8.L9!-DB0I'_"*\32!A PA^%C
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MMPF% !ZAHA,"M>W[OP'\+*%;"F4ZP W\P*>1N_M$I<L;P1W\P7%1O>V$ %*
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M.)* 0;4&$!4R??@UKMRY=.O:O8LWK]Z]?/M&Y,33Y\@(?"@8 I0/!42E##$
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M6DG;$'$P0I0>/UU]^.+WC+Q&*2011VX$ ++"UWY7.7[\\H>\>T=$;W)T 4"
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MW ::WF?&W3P(1S65I@$B^0=0O935LJ :T3;"#@Q.37.BY*?+?$4[0"#>MJQ
M 3ZX B#\$ (?)" "2#AH$G 0 P^ ( ,$B((2&E&$!D0@$!!%  -ZO0.G?R$
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M(Q55R$936T5;/V!N(> ^BM 'WP<15#<#J68 H<$B)Y6 &34#<S!K2' #8/
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M\&Z18% F-G8S('<FR9[_ / *5*4%?6 $$1JA&"!KU-2/'?&/Q920*TJ(*U
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7M6[KMX[KN:[KN\[KO>[KOP[L>!$0 #L!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
